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ABSTRACT
Mechanistic Analysis and Quantification of Gastrointestinal Motility: Physiological
Variability and Plasma Level Implications
by
Arjang Talattof
Chair: Gordon L. Amidon
The oral route of administration is still by far the most ubiquitous method of drug
delivery. Development in this area still faces many challenges due to the complex
inhomogeneity of the gastrointestinal environment. In particular, gastric emptying
and gastrointestinal motility is not predictable and so dosing occurs randomly with
respect to these physiological variables. The goal of this research is to present a
mass balance analysis that captures this variation, highlighting the effects of motil-
ity and exploring how it ultimately impacts plasma levels and the relationship to
bioequivalence.
A mechanistic analysis is first developed describing the underlying fasted state
cyclical motility and how the contents of the gastrointestinal tract are propelled. This
physiologically based approach allows the estimation of potential absorption ranges
based on uncontrolled variation. Validation of the simulations is based on reported
gastric emptying profiles and volumetric emptying as well as previous experimental
works on gastrointestinal transit times, and the bioequivalence implications of such
variation are also considered. Next, a dissolution model is presented to account for
xiv
the dynamics of physiological conditions along the gastrointestinal tract, including
small volumes and variable pH profiles. Predicting the extent of dissolution along
with transit profiles of dissolved and particulate content is crucial to approximating
absorption. Ibuprofen and phenol red are used as example cases.
Finally, a method for refining the gastrointestinal transit model is critical for en-
suring accuracy, and a methodology is presented for extracting relevant information
from intubation studies. Gastrointestinal manometry can be thought of as a stochastic
process in which the indeterminacy of state transition times belies absolute period-
icity of the system. To account for this inherent randomness, the use of statistical
computing can identify and characterize the different phases of the gastrointestinal
cycle. Specifically, a Gaussian process is used as a robust regression method to model
the time-dependent evolution of the signal. As further validation, using a pressure
peak detection method based on continuous wavelet transforms and subsequently a
kernel density estimator as a smoothing function, regression-based motility phase
classification corresponds expected pressure peak density estimates.
xv
CHAPTER I
Gastrointestinal Motility Variation and
Implications for Plasma Level Variations
1.1 Introduction
The human stomach can be divided into three distinct muscular components, each
contributing in part to emptying: the fundus (proximal stomach) that relaxes and
receives content; the antrum (distal stomach) that grinds and titrates large matter
into small particles; and the pylorus, a region of high pressure that prevents emp-
tying of solids during antral contractions1,2. The small intestine, comprised of the
duodenum, jejunum, and ileum, varies from 3.5-9.8m in length with an inner diame-
ter of 2.5-3 cm3,4. Gastrointestinal (GI) motility and the associated migrating motor
or myoelectric complex (MMC) play a crucial role in transporting ingested material
from the stomach through the intestines and into the colon by means of segmental
and peristaltic contractions5. The propagating wave of peristalsis is regulated by
hormones, paracrine signaling, and the autonomous nervous system, while segmenta-
tion is carried out by longitudinal muscle relaxation and circular muscle contraction
thereby mixing GI contents with digestive enzymes and ensuring composition uni-
formity and sufficient epithelial contact for absorption6. The gastric emptying rate
is controlled by gastric distention promoting emptying and intestinal stimuli slowing
1
emptying7. Contractile activity propels matter from the stomach into the small bowel
where segmental contractions beginning in the duodenum reach the terminal ileum
in approximately 2 hours8. The MMC is defined by three distinct phases: phase I is
an inert period with little activity; phase II features sporadic contractions gradually
ascending in magnitude but with little net forward movement of gastric contents; and
phase III is characterized by powerful, high frequency contractile bursts that promote
emptying of contents where peak flow rates are observed9. The lengths of the phases
can vary greatly, phase I lasting between 20-90 minutes, phase II between 35-135 min-
utes, and phase III between 2-15 minutes10. As the contractile activity propagates
it becomes less spatiotemporally organized resulting in slower propulsion rates in the
distal small bowel11. It is thus important to acknowledge these physiological effects
on oral drug products and their intestinal residence times, which can impact the ex-
tent of absorption in the fasted state. Such temporal variations must be taken into
account to explain frequent and irregular plasma concentration profiles that cannot
be accounted for using compartmental, first-order rate models12,13. Indeed, mecha-
nistic approaches have been previously employed to help explain variable absorption
and double-peak phenomena in pharmacokinetic profiles14,15. A compartment-based,
continuously stirred reactor tank mass balance system is presented here to analyze
high solubility compounds with both high and low permeability (BCS Classes I &
III) and elucidate the effects of GI motility on drug plasma profile variations dur-
ing the fasted state. Both the gastric emptying and the intestinal transit rates are
time-dependent functions reflecting the various phases of GI motility.
2
1.2 Methods
1.2.1 Fasted state GI transit variability
The process of human gastric emptying and intestinal transit are traditionally
represented by first-order approximations. For volumes of 240 to 800 mL, experi-
mental measurements of gastric emptying half-time varied from 8 to 18 minutes16–19.
Oberle et al. demonstrated the emptying half-time dependence on MMC phase for
50 and 200 mL volumes20. Various numbers of compartments have been employed
to model the GI tract using constant transit rates: a two-compartment model with
well-mixed tanks21; a single-compartment model used to account for dissolution rate-
limited absorption22; a four-compartment model incorporating bile secretion effects
23; and representing the intestinal tract from stomach to colon as nine consecutive
compartments24.
There are several physiological factors that cannot be captured using these clas-
sical approaches. Gastric emptying patterns are heavily dependent on the MMC
phases20. Volumetric emptying from the stomach was shown to be non first-order,
bi-phasic in 25% of subjects evaluated25. MMC propagation can also result in the
orad transit of GI content26–28 which, when coupled with the formation of small water
volume packets along the intestinal tract (as opposed to a continuous region of fluid)
25, raises the issue of segmental, back and forth mixing of contents and its impact
on GI transit times. Indeed, the small intestine water volumes themselves in fasted
humans ranged from 80 to 300 mL29–32. The propagation of MMCs along the small
bowel has profound effects on the intestinal residence times which vary greatly when
measured experimentally33.
To tackle some of these more complicated sources of variation, Higaki et al. pre-
sented a two-phase model incorporating lag time, demonstrating the value of a time-
dependent absorption coefficient in prediction nonlinear properties of transit and
3
absorption. Langguth et al. used a single compartment but with transit as a periodic
step function corresponding to the MMC phases34. Herein, a multi-compartment ap-
proach is used based on previously described, phase-dependent gastric emptying rates
20, with a continuous function describing the transition between MMC phase states
which propagate along the entire GI tract (i.e. across all compartments).
1.2.2 Developing a periodic function
The cyclical gastric emptying rate and lag time are described by a Fourier series
approximation (Equation 1.1) and a sigmoidal decay function (Equation 1.2), respec-
tively, illustrated in Figure 1.1. The parameters, described in Table 1.1, reflect the
experimentally measured gastric emptying rates and delay times for 50 mL and 200
mL volumes20 (Figure 1.2). The two equations are used to construct a periodic, time-
dependent mass balance analysis for high solubility (BCS Class I and III) compounds
(Figure 3.1). Dose time refers to the time of dosing relative to the phase cycle, i.e.
kge(t + t0) and tlag(t + t0) for some t0 ≥ 0. Two examples of dose time selection are









tlag(t) = c1 − c2
c3 + c4 exp(−c5Mod[t0, 120] + c6) (1.2)
The compartments are treated as continuous stirred-tank reactors (CSTRs), bal-
ancing the influx/outflux of mass or concentration. Drug-containing volume enters
the stomach at dose time t0 and empties, according to the cyclical, time-dependent
emptying rate into a series of intestinal compartments with two outflows each–an
effective permeation rate into the plasma compartment and an intestinal transit rate
(equal to a phase shifting of the gastric emptying rate, i.e. kintN (t) = kge(t + τ) for
some time offset τ). This is equivalent to a contractile wave propagating along the
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GI tract. A 3-dimensional plot in Figure 1.5a shows the percent emptied from the
stomach compartment versus time t and dose time t0.
Plasma elimination half-lives of7, 14, 30, 60, and 240 minutes are used. The
multiple intestinal compartments reflect the different regions on the small intestine.
Yu et al. previously described GI transit using a 7-compartment model which best
reflected the average intestinal transit time of 199 minutes35–37. Similarly, here each
intestinal compartment is assigned transit rate kintN (t), an effective permeation rate
permN , and a back-mixing rate QN(t) for each of the 3 pairs after the first intestinal
compartment to reflect segmental contractions that can move luminal content in the
orad direction26–28. Permeation rates can vary in different compartments, thus allow-
ing consideration of location-dependent intestinal absorption as yet another factor in
plasma level variation.
1.2.3 Intra- and inter-patient variation and bioequivalence
Bioequivalence (BE) is defined as the mean 90% confidence interval (CI) of a test
product falling within the 80-125% range about the mean of the reference product. To
account for variability between simulated BE trials, 24 virtual patients are generated
from a uniformly distributed range of ±10% about the parameter values used in
generating the functions. For each virtual patient, a simulation is carried out over
a 2-hour range of dose time t0. Resultant plasma profiles and the BE metrics of
maximum plasma concentration Cmax, time of maximum plasma concentration Tmax,
and bioavailability AUC are considered versus dose time, highlighting the effects of
inter- and intra-patient variation. The population reference means and medians are
calculated from a sample of 10,000 values while the 6-, 12-, and 24-subject test values
are randomly selected from within that sample.
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1.2.4 Model validation
1.2.4.1 Gastric emptying patterns
Using non-disintegrating dosage forms during the fasted state, Weitschies et al.
demonstrated a broad time range of 1 to 185 minutes for gastric emptying time
with median and mean of 21 minutes and 37 minutes, respectively38. Simulations
are done over a range of dose times from t0 = 0 min (initial phase I) until t0 =
120 min (terminal phase III). The causatum range of gastric emptying patterns of
the three phases and stomach emptying half-times are in accordance with reported
gastric emptying patterns (Figures 1.5b, 1.6, 1.7)20.
Mudie et al. noninvasively measured emptying of 240 mL water in fasted healthy
humans using magnetic resonance imaging (MRI). They quantified the distribution
of water volumes into packets along the intestinal tract and showed that baseline
(resting) volumes varied greatly among different subjects during the fasted state25.
Normalizing to resting volumes, Figure 1.8 shows the emptying patterns overlayed
on the range of simulated predictions. In the study by Mudie et al., 75% of the sub-
jects displayed first-order emptying patterns while 25% had non-first order, biphasic
emptying. These ratios are similar in the simulations (80% and 20%, respectively).
Mean simulated gastric emptying time is comparable to that of reported 100 mL solu-
tions containing non-absorbable diethylenetriaminepentaacetic acid (DTPA) labeled
with technetium 99m administered to test subjects and monitored via scintigraphy36
(Figure 1.9, p = 0.79).
1.2.4.2 Intestinal transit
The simulated intestinal transit time is also similar to reported values (Figure 1.9,
p = 0.62). Davis et al. measured labeled solution transit times by imaging anterior
and posterior abdomen sites and quantifying radioactivity of labeled solution36. In
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the simulations, a non-absorbable (permeation rates peff = 0) dose administered at
a given dose time t0 empties from the stomach; entrance of the solution into the first
compartment (when the concentration exceeds 1%) marks the starting time while
exit from the final compartment (when concentration reaches below 1%) marks the
endpoint, the difference between the two being the intestinal transit time. Back-
mixing is optimized to reflect measured intestinal transit times. A 120-minute range
of dose times is used for each simulation of intestinal transit using different back-
mixing values, either constant for all three such that Q(t) = 0.02 min−1 (equaling
the slow, phase I forward rate); or proportional to the intestinal transit rate functions
(Equation 1.3).
QN(t) = α kint(2N−1)(t) for N ∈ {1, 2, 3} and α ∈ [0.01, 0.5] (1.3)
The distributions of simulated intestinal transit rates is optimized to reflect the
reported distributions via a Mann-Whitney test comparing the mean simulated and
experimental times, yielding a backflow parameter of α = 15%. The simulated and
experimental intestinal residence time distributions are shown in Figure 1.9 and agree
with previous results33,35–37,39–47. The experimental distribution includes both inter-
and intra-patient variation since it is an agglomeration of over 400 human studies,
while the simulated distribution captures only intra-patient variation (i.e. that due
to gastric emptying and motility phase). A comparison of small intestine residence
time predictions to the compartmental model proposed by Yu et al.35 is shown in
Figure 1.10. The advantage of this method is the ability to capture variations due
to motility phases: the previous model yields, for any particular formulation dosing,
a single residence time irrespective of how many simulations are carried out. The
current model yields instead a prediction range that reflects the effect of dose time
and evolving gastric emptying rate–as well as the related MMC propagation along the
GI tract–and still generates a mean residence time in accordance with experimental
7
values.
1.3 Results and Discussion
1.3.1 Dose time dependence and plasma levels
Previously, Kaus et al. showed in simulations that Cmax was susceptible to changes
in gastric emptying for high permeability compounds48. Here the effective permeabil-
ity rates for all intestinal compartments are on the order of 10-3 cm/s for BCS Class
I simulations. Thus the rapid absorption means the plasma elimination half-life is
the rate-limiting step even in very short half-life scenarios. A slow but constant per-
meation on the order of 10-5 cm/s is used for BCS Class III simulations where the
volumetric effect is less pronounced and variation in the plasma profile versus dose
time is mitigated. Restricting the slow permeation to initial intestinal compartments
(no permeation thereafter), however, results in slow absorption only in the first three
intestinal compartments, thus gastric emptying also plays a significant role in how
quickly the contents are presented and surpass the sites of absorption. The 50 mL
volume is more susceptible to plasma level variations as a function of dose time in
the BCS Class I simulations while in the BCS Class III simulations both the 50 mL
and 200 mL volumes are affected (Figures 1.11,1.12,1.13).
1.3.2 Example cases
Three compounds with relatively short plasma elimination half-lives are presented
as example cases (Table 1.2).
1.3.2.1 Fluvastatin
Fluvastatin, used for treatment of hypercholesterolemia and cardiovascular dis-
ease, has a reported plasma elimination half-life of 1-3 hours and is highly soluble (33
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mg/ml) and permeable (cLogP = 4)49–52. In the study by Tse et al., 24 healthy male
subjects received single doses of fluvastatin which were rapidly absorbed from the
GI tract though showed low bioavailability due to high first-pass metabolism52. The
experimental results and standard deviations are shown in red in Figure 1.14a. After
correcting for volume of distribution, the simulation using a short plasma elimination
half-life yields the mean predicted plasma profile (dashed green line) and upper/lower
bounds for the plasma levels (shaded region) consistent with the inter-subject varia-
tions reported by in the clinical study, illustrating the potential to reproduce accurate
variations in a population.
1.3.2.2 Fluorouracil
Fluorouracil is a BCS Class III compound (reported solubility of 11,000 mg/mL,
cLogP = -0.66) with a very short, 7-16 minute plasma elimination half-life used to
treat breast, ovary, and GI tract cancers53–57. Phillips et al. dosed the compound
intravenously and then orally in patients55. Accounting for bioavailability and volume
of distribution, Figure 1.14b shows the reported plasma concentrations (red) overlayed
on top of the simulated envelope of maximal and minimal plasma levels (shaded
region). In addition to capturing the variation of the study population, the dose time
is approximated to individual plasma profiles.
1.3.2.3 Diethylcarbamazine
Used for treatment of filariasis, diethylcarbamazine (DEC) is an anthelmintic BCS
Class III compound (reported solubility of 750 mg/mL, cLogP = 1.62) with a plasma
elimination half-life of 8 hours58–61. In a small study of 12 healthy volunteers, Bolla
et al. gave single doses to the subjects in a crossover study at either 0600h or 1800h58.
They reported statistically significant differences in plasma levels between the two co-
horts, consistent with previous studies highlighting circadian effects on motility62–64.
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Figure 1.14c shows both the 0600h and 1800h groups in red and blue, respectively,
superimposed over the predicted envelope of maximal and minimal plasma levels us-
ing the a 480-minute plasma elimination half-life. The predicted range (light green)
spans the variation of both groups, and the mean simulated plasma curve (dashed
green line) transects the mean reported values.
1.3.3 Bioequivalence implications
1.3.3.1 BCS Class I
By perturbing the physiological parameters over a ±10% uniformly distributed
range about the means, considerable variation is seen in the resultant BE simulations.
Figures 1.15, 1.16, and 1.17 illustrates the effect of increasing plasma elimination half-
life and volume of co-administered liquid for simulations of BCS Class I, BCS Class III
with constant permeation, and BCS Class III with regional permeation, respectively.
With very short, 7-minute elimination half-life, 25% of BCS Class I BE studies are
expected to fail when considering the mean test Cmax 90% CI versus the reference
80-125% range. With a 50 mL volume, gastric emptying accounts for 59% of the
80-125% interval for 7-minute plasma elimination half-life drugs, and this decreases
to 5% for 240-minute plasma elimination half-life drugs. Similarly, with a 200 mL
volume, the percent of the 80-125% range covered decreases from 22% to 3% for 7- to
240-minute plasma elimination half-lives. Thus longer plasma elimination half-lives
and increased volumes mitigate variation caused by gastric emptying. Using the test
Cmax medians rather than the means, it is expected that 98% of BCS Class I BE
studies will fail for short elimination half-life drugs in 50 mL volumes, and even with
200 mL volumes 10% will still fail. The percent of the 80-125% range attributed
to gastric emptying variation increases dramatically as well: 8-134% for 50 mL and
5-32% for 200 mL volumes. The results are summarized in Table 1.3.
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1.3.3.2 BCS Class III
In the case of BCS Class III simulations with constant and low effective permeation
in the intestinal compartments, the variations are far less extreme. No BE trials are
expected to fail, while only 4-13% (50 mL volume) and 3-14% (200 mL volume) of
the 80-125% reference range are attributable to gastric emptying variation. These
rates do not increase significantly when the median 90% CIs are instead considered
(Table 1.4).
Perhaps counterintuitively, however, for BCS Class III simulations with locational
permeation, increases in volume and plasma elimination half-life yield greater vari-
ation. For 240 min plasma elimination half-lives, 4% and 14% of the BE trials are
expected to fail using 50 mL and 200 mL volumes, respectively. Furthermore, 14-38%
(50 mL volume) and 27-57% (200 mL volume) of the reference 80-125% range are due
to variations in gastric emptying. These rise to 16-47% and 42-113% for 50 mL and
200 mL volumes, respectively, when the median CIs are used rather than the means
(Table 1.5). This reversal in trend is likely due to the change in the rate-limiting step:
BCS Class I compounds are readily absorbed along the entire intestinal tract and thus
the longer half-lives exempt gastric emptying as a source of variation. That is, no
matter how quickly or slowly the drug solution reaches the site of absorption, up-
take occurs rapidly enough and the comparatively longer elimination half-lives allow
sufficient time to achieve the same maximum concentration and bioavailability. Con-
versely, BCS Class III absorption profiles can depend heavily on intestinal location.
Thus with short plasma elimination half-lives, the drug is quickly cleared from the
system and so variation remains low (as absorption is the rate-limiting step). How-
ever, as plasma-elimination half-life increases and becomes the rate-limiting step, the
effect of gastric emptying is now emphasized to a greater degree: slowly emptying and
transiting content has time to be absorbed while faster moving drug concentrations
necessarily miss, at least in part, the site of absorption. Since the 50 mL volume is
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more concentrated, enough drug may be absorbed and available systemically, while
the 200 mL is more dilute and thus the potential to only partially absorb or miss
entirely is reflected even more severely in the Cmax variations.
1.3.3.3 Extending parameter variation and plasma elimination half-life
The current model assumes a uniform ±10% variation about the mean physiolog-
ical parameters, underpredicting the extent of experimental variation especially for
phase I lag times and phase III gastric emptying rates20. The results are also thus
far relevant to only short plasma-elimination half-lives. Therefore further simulations
are run with extended plasma elimination half-lives up to 24 hours and incrementally
increased parameter variations from ±10% to ±75%. The coefficient of variation
(CV) for bioavailability increases both with greater parameter variation as well as
longer plasma elimination half-life in the BCS Class I simulations, however, it is not
as dramatic in the BCS Class III simulations where CV is constant or indeed decreas-
ing with greater parameter variation (Figure 1.19). BCS Class I Cmax CV increases
with increased parameter variation however decreases as plasma elimination half-life
is increased, while BCS Class III Cmax CV increases with both greater parameter
variation as well as greater plasma elimination half-life (Figure 1.20). Only for a
very short, 7-minute plasma elimination half-life is there a significant expected rate
of BE failure in the BCS Class I simulations. However, for a 200 mL volume in the
BCS Class III model, longer plasma elimination half-life and greater parameter vari-
ation both contribute to increased expected BE failures, consistent with the previous
explanation (Figure 1.21).
1.3.3.4 Statistical considerations
The distribution of pharmacokinetic parameters is generally assumed to be log-
normal65–73. While gastric emptying is but one of a multitude of factors influencing
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plasma levels, its contribution in isolation appears to be asymmetrically -biased (i.e.
an extreme value distribution). For the BCS Class I and III simulations (with both
constant and locational absorption), the log-transformed population Cmax values do
not display normality whether using a 50 mL or 200 mL volume. The population
histograms are overlayed with normal (red) and either Gumbel or Weibull (blue)
approximations (Figures 1.22, 1.23, 1.24). It is perhaps reasonable to consider non-
parametric tests where applicable and to employ both the mean and median, at the
very least, when seeking to determine BE since the mean is more impervious to so-
called fat tailed distributions while the median accounts for these outliers.
1.4 Conclusion
GI motility is an important physiological process that has not been evaluated
regarding fasted-state oral absorption kinetics and BE implications. The results of
this study indicate that, for short elimination half-life drugs with fast absorption,
failures of BE are expected based on gastric emptying variation alone, and that for
low absorption drugs, failures may continue with even extended plasma elimination
half-lives. The framework for a mechanistic, bottom-up analysis is presented here.
Further studies are needed on GI motility to better determine the statistics of gastric
emptying in fasted and fed states and the corresponding implications for BE trial
design and refinement of the 80-125% range.
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1.5 Tables and figures
Table 1.1: Mass balance parameters
Parameter Description
ρ1 Length and amplitude of phase I
ρ2 Length and amplitude of phase II relative to phase I
ρ3 Length and amplitude of phase III
N Number of sine functions
φ Half the cycle frequency
s Initial phase I rate of gastric empting
ci Constants from experimental averages
20
Figure 1.1: Plots illustrating the continuous gastric emptying rate function (top) and
the phase-associated lag time function (bottom).
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Figure 1.2: Experimentally determined20 emptying rates (top) and lag times (bottom)
at the begging of the three phases.
Figure 1.3: Schematic of the GI tract with a pulsatile, time-dependent emptying rate
from the stomach compartment into the intestinal compartments. Intestinal transit
rates are phase-shifted such that the pulse initiating in the stomach travels through
the GI tract over a two-hour time period8.
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Figure 1.4: Effect of dose time t0. Left: early dosing, that corresponds to phase I, with
a low gastric emptying rate and long lag time; the volumetric lag time dependence
results in a considerable difference in the emptying and appearance in plasma. Right:
late dosing in phase III where the gastric emptying rate has increased considerably
and the lag time is nearly zero; there is a negligible difference between the 50 mL and
200 mL volumes since all gastric content is emptying rapidly and immediately.
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(a) Percent emptied from stomach compartment with respect to time t and dose time
t0 for 50 mL (left) and 200 mL (right) liquids, illustrating a volume dependence.
(b) Gastric emptying patterns corresponding to measured rates20 for 50 mL (left) and
200 mL (right) volumes.
Figure 1.5: Dependence of gastric emptying on volume and dose time (i.e. phase).
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Figure 1.6: A comparison of simulated (green) and experimentally determined20 (red)
gastric emptying rates and lag times for 50 mL (left) and 200 mL (right) volumes.
Figure 1.7: Simulated emptying half-times t50 (green dots) compared to measured
citepOberle1990 t50 of 50 mL (blue) and 200 mL (yellow) volumes.
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Figure 1.8: Left, the predicted gastric emptying results for a 120-minute range of dose
time t0 (green shaded region, mean prediction as dashed green line) with superimposed
volumetric emptying data from subjects measured by MRI25. Emptying patterns
show both first-order (center, 75%) and non-first order (right, 25%) corresponding to
the distribution of simulated emptying patterns.
Figure 1.9: Accordance of experimental36 and simulated gastric emptying and in-
testinal transit time ranges. The black diamonds represent the 95% CI about the
means, the white bars within the colored regions are the medians; the colored regions
represent the 25-75 percentiles; and the whiskers span the entire range. The differ-
ence between the means is not statistically significant (Mann-Whitney p = 0.79 and
p = 0.62 for gastric emptying and intestinal transit times, respectively).
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Figure 1.10: Left: probability density of simulated (green) and experimental36 in-
testinal transit times for solutions and dosage forms. Right: small intestinal transit
flow using previously reported compartmental model35 (red) and the current model
(mean as dashed line; predicted range as green shaded region).
Table 1.2: Properties of example compounds with short plasma elimination half-lives
used for simulation validations.
Name Solubility cLogP Structure
Fluvastatin 33 mg/ml 4.00
Fluorouracil 11,000 mg/ml -0.66
Diethylcarbamazine 750 mg/ml 1.62
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(a) Continuous high effective permeability
across the intestinal compartments.
(b) Volumetric effect on plasma level vari-
ation. The 50 mL volume (above) is much
more susceptible to different phases while it
is less pronounced an effect in the 200 mL
volume (below).
Figure 1.11: BCS Class I with high peff showing volumetric effect on plasma levels.
(a) Constant low effective permeability
along the intestinal compartments.
(b) Plasma level variation is mitigated when
there is continuous but slow permeation
across the intestinal compartments.
Figure 1.12: BCS Class III constant peff and volumetric effect on plasma levels.
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(a) Low effective permeability in the early
compartments followed by no absorption in
the latter regions.
(b) Plasma level variation is recaptured
with location-dependent permeation for
both 50 mL (above) and 200 mL (below)
volumes.
Figure 1.13: BCS Class III location-dependent peff and volumetric effect on plasma
levels.
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(a) Experimental52 fluvastatin plasma levels (red) overlayed on top of mean
prediction (dashed green line) and envelope function (green shaded region)
showing upper and lower bounds of predicted range.
(b) Plasma level variations of oral fluorouracil (dose- and weight-adjusted)55.
Above, the shaded regions represent the bounds of plasma level predictions.
Below, individual plasma level predictions can be reproduced as a function of
dose time t0.
(c) DEC plasma levels58 dosed in the morning (red) and evening (blue) over-
layed on top of the mean prediction (dashed green line) and the envelope
function (green shaded region) showing upper and lower bounds of predicted
range.
Figure 1.14: Examples of predicting plasma level variation for short plasma elimina-
tion half-life compounds.
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Figure 1.15: Simulated BCS Class I BE trials. The black horizontal bars represent
the reference 80-125% range. The vertical bars are individual BE simulations with
24 virtual subjects each, indicating the Cmax mean 90% CI. In the left column, the
mean Cmax is used while the median is considered in the right column.
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Figure 1.16: Simulated BCS Class III BE trials using constant permeation. The
vertical bars are individual BE simulations with 24 virtual subjects each, indicating
the Cmax mean 90% CI. In the left column, the mean Cmax is used while the median
is considered in the right column.
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Figure 1.17: Simulated BCS Class III BE trials using location-dependent permeation.
The vertical bars are individual BE simulations with 24 virtual subjects each, indi-
cating the Cmax mean 90% CI. In the left column, the mean Cmax is used while the
median is considered in the right column.
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(a) (b) (c)
Figure 1.18: Variations in bioavailability for BCS Class I (a), BCS Class III with
constant permeation (b), and BCS Class III with locational permeation (b). Bioavail-
ability as a function of dose time t0 (green) based on mean emptying rates and lag
times compared to a population with varied emptying rates and lag times (dotted
red) for each of the three simulations.
Table 1.3: Variation in BCS Class I simulations
50 mL
Elim. % Fail (mean) % Fail (median) % 80-125 (mean) % 80-125 (median)
7 min 24 98 59.41 134.11
14 min 0 66 39.65 85.02
30 min 0 0 23.32 49.07
60 min 0 0 14.29 27.22
240 min 0 0 5.54 8.03
200 mL
Elim. % Fail (mean) % Fail (median) % 80-125 (mean) % 80-125 (median)
7 min 0 10 22.37 32.00
14 min 0 2 16.45 24.49
30 min 0 0 11.51 19.16
60 min 0 0 7.76 12.18
240 min 0 0 3.07 5.47
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Table 1.4: Variation in BCS Class III (cont. abs.) simulations
50 mL
Elim. % Fail (mean) % Fail (median) % 80-125 (mean) % 80-125 (median)
7 min 0 0 4.20 2.89
14 min 0 0 5.85 6.01
30 min 0 0 11.21 9.53
60 min 0 2 15.81 12.57
240 min 0 0 12.82 11.40
200 mL
Elim. % Fail (mean) % Fail (median) % 80-125 (mean) % 80-125 (median)
7 min 0 0 3.51 2.73
14 min 0 0 8.91 12.60
30 min 8 0 15.50 28.95
60 min 0 0 18.83 38.85
240 min 0 0 14.39 25.64
Table 1.5: Variation in BCS Class III (loc. abs.) simulations
50 mL
Elim. % Fail (mean) % Fail (median) % 80-125 (mean) % 80-125 (median)
7 min 0 0 13.82 15.97
14 min 0 2 22.45 28.55
30 min 0 22 30.79 44.66
60 min 0 30 35.98 48.62
240 min 4 32 37.63 47.44
200 mL
Elim. % Fail (mean) % Fail (median) % 80-125 (mean) % 80-125 (median)
7 min 0 10 27.24 41.99
14 min 0 30 39.13 65.72
30 min 8 82 50.30 95.98
60 min 10 88 55.14 104.78




Figure 1.19: Bioavailability CV for BCS Class I (a) and BCS Class III with locational
permeation (a) simulations with respect to plasma elimination half-life and parameter




Figure 1.20: Cmax CV for BCS Class I (a) and BCS Class III with locational per-
meation (b) simulations with respect to plasma elimination half-life and parameter




Figure 1.21: Expected failure rate for BCS Class I (a) and BCS Class III with lo-
cational permeation (b) simulations with respect to plasma elimination half-life and
parameter variation (as % of mean).
31
Figure 1.22: Simulated BCS Class I half-life dependence of Tmax and Cmax distri-
butions for 50 mL and 200 mL volumes. Overlayed on the Cmax plots are various
distributions, highlighting the lack of normality following a log transformation.
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Figure 1.23: Simulated BCS Class III half-life dependence of Tmax and Cmax distri-
butions for 50 mL and 200 mL volumes using constant permeation. Overlayed on the
Cmax plots are various distributions, highlighting the lack of normality following a log
transformation.
33
Figure 1.24: Simulated half-life dependence of Tmax and Cmax distributions for 50
mL and 200 mL volumes using location-dependent permeation. Overlayed on the
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CHAPTER II
Fasted State Dissolution and Transit of Ibuprofen
2.1 Introduction
Solid oral dosage forms must dissolve in the GI fluids prior to being absorbed and
reaching systemic circulation. The rate and extent of this process depends not only on
the physiochemical properties of the dosage form–including lipophilicity, chemical or
enzymatic stability, solubility, particle size, density, diffusivity, pKa, and crystal form–
but also the physiological environment1. Buffer species, bile salts, gastric emptying,
intestinal motility and hydrodynamics, and pH all play significant roles in this process
2.
Several mass balance approaches have been previously described3–7. Ozturk et al.
presented dissolution kinetics of ionizable drugs assuming the process to be diffusion-
limited with instantaneous and reversible reactions8. However, many of these analysis
do not take into account the dynamics of the GI tract, for example locational perme-
ability profiles, environmental changes altering dissolution such as pH fluctuations;
pancreatic and biliary secretions; large inter-individual differences in gastric empty-
ing onset & rate; dynamic intestinal transit; and the effects these have on dissolution
kinetics9–14. Indeed this is due to the complexity of underlying mechanisms as well
as the difficulty in estimating adsorption from systemic availability9.
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2.1.1 Physiological properties of the gastrointestinal tract
Much of the dynamism in along the GI tract during the fasted state is due to cycli-
cal fluctuations referred to as the migrating motor complex (MMC) which includes
three distinct phases: the quiescent phase of little to no activity (phase I); a period of
more frequent and gradually increasing amplitudinal contractions that allow for much
back and forth but little net forward movement (phase II); and a short-lasting but
high-frequency period of activity that propels content aborally (phase III)15. How-
ever, many other factors contribute to the mutable activeness of the GI tract. A
summary of literature ranges for GI fluid composition, fluid volumes, and geometries
can be found in Table 2.1.
2.1.1.1 Fluid composition and volumes
GI fluid is composed of many ingredients that change over time, including saliva,
secretory fluids, and refluxed duodenal fluid. Among these, bicarbonate is one of
the major intestinal buffer species maintaining a pH gradient along the GI tract and
protecting the gastric mucosal layer against acid and proteolytic digestion by pepsin
16–18. Bicarbonate concentration in the human small intestine ranges from 6-20 mM
implying a buffer capacity of 2.5-2.8 per pH19–23. Crucial to drug product dissolution,
the pH is highly variable both locally and along the entire GI tract. During the fasted
state, the gastric pH can vary between 1 and 8 with the mean generally in the range
of 1 to 221,24–26, while small bowel pH has been shown to vary between 4 and 8
with a typical mean around 6.5 in the proximal regions21,22,27–31 and 6.5-8 in the
distal regions32,33. Closely linked to gastric acid secretion is the activity of pepsin
which can affect protein and peptide stability. Once activated at low pH, it aids in
proteolytic breakdown of dietary proteins, and it is deactivated at pH above 434–36.
Lipase is pertinent especially for lipid-based formulations and crucial in the absorption
of dietary fats and may not contribute significantly in the fasted state due to its
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low concentrations37–39. In addition, mucus production and secretion help prevent
physical injury; oxyntic and pyloric glands of the stomach produce gastric juices to
further aid in digestion; bile produced from the liver solubilizes fats; pancreatic juice
released into the duodenum neutralizes acidic contents entering from the stomach;
and the endogenous bacterial populations release enzymes promoting metabolism40.
Liquid volumes along the GI have an unequivocal influence on drug dissolution.
Indeed, the extent to which this occurs and thus the capacity for absorption and sys-
temic availability is largely affected by both inter- and intra-patient variability37. The
fasted stomach resting volume has been measured between 18-54 mL41,42. Following
ingestion of a 240 mL liquid volume and subsequent gastric emptying, Mudie et al.
showed, using magnetic resonance imaging, that subjects returned to approximately
their initial resting volumes43, driven presumably by the contribution of increased
gastric secretion to compensate for the augmented emptying. The reported range of
liquid volume in the fasted small intestine spans an order of magnitude, from of 30-
420 mL, while several studies showed it was around 100 mL on average44,45. Perhaps
most importantly for drug dissolution, Schiller et al. and Mudie et al. reported that
that fluid in the GI is not evenly distributed but rather in discrete packets of varying
volumes43,45. It is not hard to imagine how this might impact a transiting dosage
form: variable gastric emptying and random fluid pocket formations can lead to rad-
ically different local environments in terms of volume, hydrogen ion concentration,
and fluid composition.
2.1.1.2 Geometry
Absorption is in large part controlled by the GI surface area to which it is ex-
posed, with a larger surface area potentiating greater absorption. The extent of drug
absorption in the stomach is generally negligible as compared to the small intestine,
presumably due to the much larger surface area and longer residence times46. How-
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ever, the stomach and its associated hydrodynamics is important in the disintegration
and dissolution process for many oral dosage formulations. Using ultrasonography to
map the stomach in 3D, Liao et al. measured the luminal volume and inner surface
area for the whole stomach as 277.6 cm3 and 196.3 cm2, respectively, and 181.6 cm3
and 125.3 cm2, respectively, for the gastric antrum47. In contrast to the stomach, the
radius of the human small intestine is 4 cm at its junction with the stomach whence
it narrows progressively–thereby also altering the surface-to-area ratio–to 1-2 cm at
the ileocecal valve48–50. The lengths of the duodenum, jejunum, and ileum are 21,
105, and 156 cm, respectively, totaling a living physiological length of 282 cm. The
complex geometry in the small intestine, with villi extending from the surface each
containing their own smaller microvilli extensions, expands the surface area between
104 - 2 x 106 cm2 as compared to the smooth surface of a flat tube with the same
length and diameter50. This 3800-fold increase in small intestinal surface area rela-
tive to that of the stomach elucidates preferential absorption in the small intestine40,
however the unstirred water layer of the mucosal surface still presents resistance even
for highly permeable drugs51 (although this might be overestimated and resistance
may rather be membrane controlled irrespective of transport mechanism52).
2.2 Methods
Herein is presented a dissolution and disintegration mass balance analysis. In-
corporating this with the GI transit analysis from Chapter I, in vivo distribution of
drug concentrations along the GI tract is predicted based on motility phase and drug
product physiochemical properties. Ibuprofen as well as the tracer dye phenol red are
used as example cases.
Chemical properties of drug products dictate their dissolution and disintegration
performances under varying physiological conditions. Figure 2.1 illustrates the a
schematic for synthesizing disintegration, dissolution, and motility. A drug is dosed
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orally with a volume of liquid (here the FDA-required 240 mL) and begins disinte-
grating and, depending on its physiochemical properties, dissolving in the stomach.
Horizontal arrows to the right represent disintegration and dissolution. The dissolv-
ing particles and fluid transit along the GI tract, represented here by the vertical
arrows pointing downward. Several assumptions are made:
• A disintegrating formulation separates into identical, monodispersed particles
with starting radius r0.
• Gastric secretion is driven solely by the resting volume, current stomach volume,
and emptying rate.
• The pH, buffering capacity, and effective permeation can vary between com-
partments, however they remain constant (i.e. unaffected by dissolving drug).
• The system is well-buffered and stirred but with non-sink conditions (non-
negligible bulk concentration of dissolved drug).
• Larger particles are emptied more slowly from the stomach compartment53,54,
illustrated in Figure 2.1 as the light green arrow showing size-dependent transit
of the solid drug into the intestinal compartments.
2.2.1 Fluid and particle transit
The cyclical, time-dependent transit model described in Equations 1.1 and 1.2 are
used for the flow of fluid and particles suspension between compartments. Briefly, a
Fourier series approximation is used to represent the cyclical gastric emptying rate
function and lag time is described by a sigmoidal decay function, with 7 intesti-
nal compartments, each a continuously-stirred reactor tank where influx and outflux
are balanced. Drug and fluid enter the stomach at dose time t0 and empty accord-
ing to the cyclical, time-dependent emptying rate function, into sequential intestinal
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compartments with two outflows each–an effective permeation rate into the plasma
compartment and an intestinal transit rate (equal to a phase shifting of the gastric
emptying rate, i.e. kintN (t) = kge(t+ τ) for some time offset τ in intestinal compart-
ment N). This is equivalent to a contractile wave of the MMC propagating along the
GI tract.
2.2.1.1 Gastric secretion
To account for resting volumes in the stomach and small intestines, gastric fluid





When the current volume in the stomach is greater than the resting volume
(vg > vr), the gastric secretion rate is less than the gastric emptying rate (kgs < kge)
resulting in net outflow of fluid. Conversely, when the current volume is less than the
resting volume (vg < vr) the gastric fluid is replenished with greater gastric secretion
than emptying (kgs > kge). The relationship between gastric secretion, emptying, and
volume is illustrated in Figure 2.2.
2.2.1.2 Particle size effect on gastric emptying
Experimental results suggest particles larger than 2 mm in diameter tend to be
retained longer in the stomach, allowing for peristaltic back-and-forth mixing to fur-
ther break them down53. Almost all content, however, transits out of the stomach
during the powerful contractions of phase III. A dampening of the gastric emptying
rate function is used to reflect the size dependence, described by a logistic func-
tion(Figure 2.3).
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2.2.1.3 Effective boundary layer
The effective boundary layer for dissolving particles is determined by a given crit-
ical radius rc, described by Wang and Flanagan (Equation 2.2)
55. Previously, Hintz
and Johnson suggested a critical radius of 30 µm based on rotating disk experiments,
and below this they treated the effective boundary layer linearly with respect to
particle radius. Here, the effective boundary layer is equal to its radius for small par-
ticles, however for larger particles where r ≥ rc, the effective boundary layer remains







2.2.2 Disintegration and dissolution mass balance
Flux from the particle surface depends on the product solubility ST , particle radius
r, diffusion coefficient in water D, bulk concentration Cb and pH, as described by the




(ST,pH − Cb) (2.3)
The mass release rate across a surface is thus related by the flux and the surface area
A, dM/dx = A · J . While the pH and thus predicted solubility in a compartment
remain constant, the bulk concentration Cb determines the extent of dissolution and
indeed potential precipitation.
2.2.3 Ibuprofen and phenol red
Physiochemical properties of ibuprofen and phenol red are summarized in Ta-
bles 2.2 & 2.3, respectively. Phenol red is a non-absorbable dye that can be used to
monitor the net concentration change along the GI tract, revealing information about
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volumetric flow. Ibuprofen is a well-characterized, weakly acidic BCS Class II non-
steroidal anti-inflammatory drug that is poorly soluble and readily absorbable58. It
is here used as an example case for the analysis. Ibuprofen dissolution is determined
based on intrinsic solubility, its pKa, and the environmental pH. Potthast et al., Levis
et al., and Shaw et al. reported the pH-dependent solubility of ibuprofen (Figure 2.6),
and while three experimental points deviate toward a plateau (potentially due to the
salt effect where dissolution is driven by the solubility product Ksp
61) , this study
bases solubility prediction on the experimental results of Shaw et al.58–60.
The stomach resting volume is fixed at 30 mL, while the small intestine has a
total of 70 mL divided between the 7 compartments. This reflects the low reported
intestinal volumes43. Disintegration for ibuprofen, treated as a first order process, is
extremely rapid (90% within 3 minutes), and the initial particle radius once disinte-
gration has commenced is 400 µm. Permeation is constant at 8.0 x 10-4 cm2/s along
the entire small intestine (all compartments have same peff ). The plasma elimination
half-life is 2.25 hours. The initial dose is either 200, 400, or 800 mg for ibuprofen and
65 mg for phenol red.
2.3 Results and discussion
The phenol red is introduced at dose time t0 (relative to the motility state) into
the stomach compartment as a fully dissolved solution (65 mg in 240 mL) and thus
there is no disintegration or dissolution taking place. The solution transits inter-
compartmentally based on the contractile activity influencing the rates kge(t) and
kintN (t). Figure 2.7 illustrates the effect of motility phase on the distribution of the
phenol red marker along the GI tract. During phase I, there is a transit-related lag
from when the solution is introduced in the stomach until it appears in the first
intestinal compartment, as well as a lag until it first arrives in the final intestinal
compartment. Progressing through phase II and III, these lags are shortened as the
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gastric emptying rate increases and phenol red solution appears almost immediately
in the first intestinal compartment and transits quickly until the end. However, in
late phase III, there is an initial quick release from the stomach but the emptying
rate is soon reduced as the contractile pattern cycles back to phase I, thereby re-
introducing a lag. This latency results in even longer total transit time and it is
not until nearly an hour and half post dose that the solution appears in the distal
intestinal compartments.
Applying the GI transit analysis and dissolution mass balance to the specific case
of ibuprofen, the plasma profiles show clear dependence on motility phase for 200,
400, and 800 mg doses (Figure 2.8). Later dose times with respect to motility result
in faster transit and thus earlier absorption, shifting the Tmax earlier. However, a
late phase III dose time causes a delay of up to 50 minutes in the Tmax. Ibupro-
fen transit along the intestinal GI tract shows detectable concentrations transiting
into the last compartments and even undissolved particles in the distal region (Fig-
ure 2.9). Initially, simulations were done using larger intestinal volumes and particle
dissolution occurred almost entirely in the first intestinal compartments, resulting in
much earlier Tmax predictions. However, reflecting findings that showed much lower
intestinal volumes43, dissolution is predicted to be a rate-limiting step in the systemic
appearance of ibuprofen. Similar to the phenol red transit, early dosing in the cycle
has a longer lag time before appearance in the intestines while later dosing results in
shortening of the lag time. However, dosing in late phase III results in longer gastric
residence time and slower transit through the intestinal compartments. This allows
for a greater extent of dissolution, and so fewer particles are seen distally. The rate of
absorption is also faster here than transit, and so the distal ibuprofen concentration
is predicted to be less than when dosed earlier in the cycle.
As further valuation, the distribution of predicted bioequivalence metrics is con-
sidered for ibuprofen with 200, 400, and 800 mg doses. Using the dissolution and
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transit model, each simulation is carried out with the given dose administered with
a 240 mL fluid volume in accordance with FDA guidelines. The dose time is varied
to reflect the random nature of the underlying MMC. Resultant maximum plasma
concentrations Cmax, peak plasma concentration times Tmax, and bioavailability AUC
are predicted in accordance with reported values (Figure 2.10)62. Literature values
encompass a very broad range of subjects who differ greatly in weight, age, and in-
herent physiological parameters. This accounts for greater variation, in particular for
bioavailability, in the experimental results whereas the variation in predicted results
is due solely to simulating over the possible range of dose times relating to motility
phase and assuming a 70 kg subject with a fixed volume of distribution.
2.4 Conclusion
Over the course of several decades, researchers have worked toward developing
mechanistic absorption models for oral drug products. Such prediction relies on the
ability to determine a drug’s fate in the GI tract. The coupling of a pH-dependent,
non-sink condition dissolution model with the cyclical, motility-driven gastrointestinal
transit model is an important step toward a more accurate physiological analysis
of oral drug products. Using the non-absorbable phenol red dye, transit based on
fluid flow is simulated showing a decidedly motility-dependent lag in distal intestinal
appearance of fluid. Ibuprofen is used as an example case, showing strong accord with
reported pharmacokinetics values. There remains a testable hypothesis of prolonged
particulate matter transiting through much of the small intestine due to the small
reported fluid volumes.
Applying these methods to current and future pharmaceutical products should
lead to successful prediction of in vivo pharmacokinetic profiles thereby simplifying
tests and regulatory burdens‘ as well as allow industry to incorporate product changes
in a timelier manner. While there remains much to refine based on forthcoming
48
experimental work, the compartmental transit model has been at the foundation of
in vivo predictive dissolution and absorption of oral drug products and will continue
to be at the forefront of mechanistic drug product development and evaluation of
bioequivalence standards.
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2.5 Tables and figures
Figure 2.1: Incorporating dissolution mass balance into the GI transit system. A solid
dose is administered with a liquid volume. Gastric emptying drives fluid and solid
out of the stomach. Fluid is replenished via gastric secretion. Disintegration and
dissolution take place in all compartments based on the physiological environment


















































































































































































































































































































































































































































































































































































































































































Table 2.2: Ibuprofen physiochemical properties
Molecular mass 206.3 g/mol
Diffusion coefficient in water 7.5E-6 cm2/s




Plasma elimination half-life 1.3-3 hrs
Disintegration 90% in 2 min
Table 2.3: Phenol red physiochemical properties
Molecular mass 354.38 g/mol





Figure 2.2: Visualizing gastric secretion rate relative to stomach volume and gastric
emptying rate.
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Figure 2.3: The effect of particle size on emptying rate.
Figure 2.4: Effective boundary layer thickness heff (Equation 2.2).
Figure 2.5: Ibuprofen dissolution under different conditions.
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Figure 2.6: Reported58–60 and calculated ibuprofen solubility.
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(a) Early Phase I
(b) Phase II
(c) Early Phase III
(d) Late Phase III
Figure 2.7: Phenol red solution transit through GI tract when dosed during (a) early
phase I; (b) phase II; (c) early phase III; and (d) late phase III.
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Figure 2.8: Ibuprofen plasma profiles for early phase I (blue), phase II (red), early
phase III (purple), and late phase III (green) showing the variation in Cmax and
especially Tmax.
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(a) Early Phase I
(b) Phase II
(c) Early Phase III
(d) Late Phase III
Figure 2.9: Ibuprofen particulate and solution transit through GI tract when dosed
during (a) early phase I; (b) phase II; (c) early phase III; and (d) late phase III.
57
Figure 2.10: Predicted (green) and experimental (orange) values for Cmax (top), Tmax
(middle), and AUC (bottom) for 200, 400, and 800mg doses of ibuprofen. The
colored boxes represent the 25-75 percentiles, the whiskers span the entire range, and
the fuchsia circles are outliers.
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CHAPTER III
Methodology for Statistical Analysis of
Antroduodenal Manometry Signals
“On no subject in physiology do we meet with so many discrepancies of fact and
opinion as in that of the physiology of the intestinal movements. Among factors con-
tributing to such divergences must doubtless be included the varying behavior of the
gut in different animals, the varying conditions of the animal with regard to feeding or
conditions of experiment, such as exposure and cooling of the intestines.”1
3.1 Introduction
The migrating motor or myoelectric complex (MMC) occurs in most mammals to
ensure proper mixing, transport, digestion and absorption of luminal content, as well
as facilitate blood flow and clear accumulated secretory fluids and overpopulating
bacteria2,3. Typically, a cycle of the MMC–seemingly controlled by enteric neural
mechanisms that are modulated by the central nervous system and circulating en-
dogenous substances–includes a quiescent state (phase I) followed by progressively
increasing contractional frequency (phase II) and finally the most active state of high
amplitude contractions (phase III)3. During the fasted state, the MMC is character-
ized by cyclical transitions between three states: phase I, lasting 20-90 minutes, is a
period of little activity where few contractions over 10 mmHg are seen; phase II is
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characterized by an increase in frequency for a period of 35-135 minutes during which
irregular contractions over 10 mmHg occur but below a frequency of 10 contractions
per minute; and phase III, or the active phase, shows regular contractions (≥ 10 per
minute) for 2 to 15 minutes4–8 and the coefficient of variation of contraction forces is
much greater in this phase9.
Through quantitative analysis of radiological and manometric studies, Vantrappen
et al. demonstrated the similarities of the MMC in canines and humans10. Using
fasted dogs, Sarna et al.12 sought to correlate contractile activity with plasma levels
of motilin–thought to be one of the most important factors in controlling the MMC
13. Morphine is known to act on opioid receptors and initiate phase III activities11,
and they found that both spontaneous (i.e. natural) and morphine-induced phase
III patterns correlated with high levels of motilin in the plasma which subsequently
declined during phase I. Furthermore, it was shown that, in fasted dogs, bands of
action potential activity migrated caudally with new bands starting in the stomach
or duodenum as earlier ones reached the ileum14–17. Indeed, the propagation of the
MMC seemed to decline aborally, with the steepest decrease occurring in the distal
jejunum, while contraction frequencies of phase III remained constant in the upper
small bowel18.
It is therefore unsurprising that characterization of normal gastrointestinal (GI)
functions of many regions of the gut is still an ongoing endeavor that has led to
advances in many techniques. GI motility in particular has been the subject of in-
tense and growing research for some time. Gastric contractions have been evaluated
by Fourier analysis of condensed images of gastric scintigraphy studies19. Other
technologies include: high resolution manometry to study motor patterns with de-
tailed spatiotemporal mapping; magnetic resonance imaging (MRI) and ultrasound
measuring dynamic flow and morphological change without the need for radiation;
wireless capsules that transit along the entire gut yielding concurrent measures of
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contractions and transit times along with other physiological data such as changes
in pH; and slow wave mapping and magnetometry reporting GI electrical activity
20–28. Veritably, a recent study regarding colonic motility described the necessity for
high resolution manometry by demonstrating the high incidence of misinterpretation
of both frequency and polarity of propagating sequences when sensors were too far
apart29. Further complexification arises from the large variability in site of origin,
cycle length, and migration velocity of the MMC in humans, both healthy and dis-
eased8. Nevertheless, there remains a need for an objective and automated means
of classifying motility signals and determining the statistics of phase durations, cycle
lengths, and MMC wave propagation.
3.2 Methods
3.2.1 Data acquisition
As of this writing, a current study funded by the FDA is under way to analyze
manometric data based on triplicate sampling in the stomach, duodenum, jejunum,
and, if possible, the ileum (Figure 3.1). The three manometry ports are spaced 5cm
apart at each site, sufficient for proper identification of MMC polarity29. For the
development of a statistical-based classification scheme here, Medical Measurement
Systems (MMS) provided multi-channel antroduodenal manometry data sampled at
a frequency of 10Hz for approximately 250 minutes (Figure 3.2).
It is reasonable to assume, given the periodic nature of MMCs, that a first ap-
proach would involve a Fourier transform analysis of the signal to detect cycle fre-
quency. Due to noise and lack of absolute regularity, however, this proves a much
more complicated task. Figure 3.3 illustrates the signal, a histogram of pressure oc-
currences heavily skewed toward low baseline values, and a Fourier transformation of
the signal wherein no apparent frequency stands out. Previous classification attempts
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included the wavelet transformation of signal data followed by a principal component
analysis to determine if wavelet coefficients sufficed in differentiating regions of ac-
tivity from inactivity; and the optimization a Poisson process to best represent the
stochastic evolution of signal data. Neither of these methods proved able classifiers
due to the underlying noise as well as the pseudo-deterministic cycle (i.e. the neces-
sarily ordered transition from phase I to II to III back to I). Herein, two orthogonal
methods are discussed which complement each other’s results when applied to the
test data set.
3.2.2 Wavelet transformations
Manometry signals are generally characterized by sharp peaks entrenched in noisy
data, thus requiring a careful approach when determining what constitutes pressure
activity of interest. Due to the semi-periodic nature of GI motility, Fourier trans-
forms cannot be relied upon to extract information on cyclicality of phase transitions.
Rather, the analogous continuous wavelet transform (CWT) approach is more robust
due to the time-frequency representation of a signal offering frequency localization.
CWT-based peak detection methods have been used to characterize various types of
spectra with low signal-to-noise ratios including x-ray diffraction, mass spectrometry,
atmospheric patterns of convection, and complex geological processes30–33. A CWT
is a function ψ ∈ L2(R) such that ∫R ψ(t)dt = 0, normalized so ||ψ||2 = 1. This
function is called the mother wavelet, from which a family of time-scale waveforms
can be obtained for scale a > 0 and translational value b (Equation 3.1). Given a
time-dependent signal f(t) ∈ L2(R), the CWT is defined as its projection on that the













The signal is first de-trended (using scipy.signal.detrend) and thresholded such
that pressures below 50 mmHg are discounted. Du et al. developed a peak detection
method based on the CWT of a one-dimensional signal. The algorithm is as fol-
lows: a series of widths are chosen corresponding to the expected widths of the signal
peaks; the signal is convolved with a wavelet of each defined width; the maxima that
are maintained across all widths–forming “ridges” across each row that corresponds
to the convolution with that particular width–are thus defined as peaks; there can
be allowances for the maximum distance between ridge connections (in this case, a
temporal shift in either direction); a gap threshold defining potential discontinuities
across rows, the minimum length a ridge must be; the noise floor which is the per-
centile of data examined below which to consider noise; and the signal-to-noise ratio
(the signal is the value of the CWT matrix at the shortest length scale). Abramovich
et al., Antoniadis, and Silverman provide comprehensive reviews of the statistical
applications of wavelet analysis34–36.
3.2.3 Kernel density estimators
GI manometry can be treated as a spike train sampled from a stochastic process.
Shimazaki and Shinomoto developed a kernel smoother for estimating the instan-
taneous rate of spike occurrences37. The array of time points associated with the
CWT-detected peaks, xt, is convolved with the kernel, k(s), to obtain the kernel den-
sity estimate (KDE) such that
∫
k(s)ds = 1 (Equation 3.3). The most frequently-used
kernel is the Gaussian density function (Equation 3.4), where w2 =
∫
s2k(s)ds < ∞
















Assuming the spike train to be an inhomogeneous Poisson point process, the
estimate λˆt is optimized to best reflect the unknown underlying rate λt using the mean
integrated square error (MISE) as a goodness-of-fit of the estimate (Equation 3.5)




E(λˆt − λt)2dt (3.5)
Shimazaki and Shinomoto further expand on determination of a fixed bandwidth
that best evinces the underlying rate λt (equations not reproduced here). Briefly, for
an interval of interest [a, b], the cost function Cn(w) of a kernel kw is expressed as a
function of the associated bandwidth w (Equation 3.6). Thus there is a bandwidth
w∗ that minimizes the cost function Cn(w). Assuming the underlying data of size
n being estimated is Gaussian with standard deviation σˆ, an approximation for the

















5 ≈ 1.06σˆn−1/5 (3.7)
3.2.4 Gaussian processes
As functions are continuous over time, there are an infinite number of points over
which they are defined. For a given range of time, an uncountably infinite number of
possible functions that may exist. Therefore there exists a seemingly impossible task
of computing such possibilities in finite time. However, Gaussian probability distri-
butions can be extended from random variables to random functions with associated
values for particular inputs. Despite the apparent na¨ıvety of such an approach, it has
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been employed with tremendous success in many different applications.
Since this is simply an extension of multivariate distributions, there thus exist
mean functions and covariances. Observations, in this case the manometry data, are
related via the covariance function k(x, x′) for two inputs x and x′. A popular choice
is the squared exponential:





The maximum covariance is defined as σf , when x ≈ x′. Conversely, if the inputs
are far apart, then k(x, x′) ≈ 0. The separation of x and x′ is reflected in the
parameter l. Thus, given n observations of the signal y, the objective is to predict
the value y∗ rather than the actual function f∗ whose expectations are equivalent but
differ in terms variance according to observational noise (see Rasmussen and Williams
for further discussion39).
Using this approach, an expected pressure and whether that pressure is above or
below certain thresholds (75th or 25th percentile, respectively) can be determined
for a given time point. A continuous region above the threshold lasting 5 minutes or
longer is defined as phase III. If, on the other hand, there is a region of extensive low-
pressure activity below the threshold with peaks spaced more than 10 minutes apart,
this is phase I. Phase II is the intermittent regions where expected pressure oscillates
between high and low but is not sustained for a sufficient period–the 5 minute time
span corresponding to phase III.
3.3 Results and discussion
3.3.1 Peak detection
The method of CWT-based peak detection is successful in determining a time-
variant peak density distribution in the test data. Two duodenal and one antral
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port are analyzed with considerably differing patterns to test the potential extreme
scenarios (dense regions of pressure peaks and sparsely distributed ones with large
intermittent regions of inactivity). The detected peaks and their corresponding his-
togram plots are presented in Figure 3.4. It is important to note the dependence
of histogram presentation on the arbitrary bin width when plotting, an issue that
motivates non-parametric smoothing of the data.
3.3.2 Kernel smoothing
Detected peaks from the duodenal channel (Figure 3.2) are plotted showing the
evolution of spike activity over time (Figure 3.5). There is an apparent cluster of high
activity centered around ∼75 minutes and ∼225 minutes. Treating each peak (dark
red bar) as the mean of a Gaussian distribution results in N basis functions where N
is the number of detected peaks (Figure 3.6).
Two important factors in KDE are the bandwidth parameter and the kernel func-
tion. The effect of using different bandwidths is illustrated in Figure 3.7. Applying
Silverman’s rule (Equation 3.7) based on assumed normality, the bandwidth is 7.17.
An alternative to this assumption is evaluation of the bandwidth hyperparameter
using cross-validation as follows:
• The data is split into k sets
• The KDE is evaluated for a range of bandwidths using k − 1 sets as training
data
• The resultant model is validated on the remaining part where a performance
measure is computed to produce the maximum likelihood
Employing this empirical method, the optimum bandwidth is 8.64. The effects of us-
ing different bandwidths can lead to both over-smoothing and under-smoothing, how-
ever both the estimated Silverman bandwidth and the computed empirical bandwidth
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produce very similar results (Figure 3.7). KDE can be accomplished with a variety of
kernel functions, the most common being the Gaussian kernel. The kernel function
does not have as great an impact on the resultant density as the bandwidth esti-
mation does. Several other common kernel functions include the quartic/bi-weight,
cosine, Epanechnikov, triangular, and tri-weight (Figure 3.8). Wand and Jones pro-
vide extensive discussion of common kernel functions40. Summing the Gaussian basis
functions used with the estimated bandwidth, regions of high peak density are de-
tected (Figure 3.9). These are potentially regions of phase III activity, and low peak
densities thus corresponds to phase I.
3.3.3 Regression
Applying a Gaussian process regression, the large amplitudinal differences between
baseline and peak pressures are minimized and smoothed resulting in identifiable
regions of high, moderate, and low expected pressure activity (Figure 3.10). Therefore
regions of high activity can be clustered into contiguous timespans and so too can
regions of low activity. Oscillations between high and low predicted ranges are thus
periods of moderate activity.
3.3.3.1 Determination of motility states
Figure 3.11 illustrates the classification of the phases based on this approach.
The phase durations of the sample data correspond to physiological ranges that have
previously been reported4, and this method will be used to analyze the manometry
signals acquired from the volunteer subjects in the forthcoming FDA study. The
annotated regions are shown with the detected peaks (plotted as notches along the




The use of CWT-based peak detection allows for a robust method of detecting true
pressure-related activity engulfed in noisy data. This allows treatment of manometric
data as a stochastic process, using a kernel density estimator which has the benefit
of being smooth and independent of the endpoints unlike histograms, and it has
a tunable bandwidth parameter that can be analytically or empirically solved to
best represent the underlying stochastic rate. Employing GPs, the time-dependent
pressure values can be estimated and used to identify the different regions of the
signal based on thresholding. The accordance of the two approaches suggests the
high likelihood of an accurate, unsupervised signal classification scheme.
Beyond distinguishing different phases, a pattern of interest is seen in the sig-
nals. Phase III peaks appear to be preceded by smaller spikes of activity not quite
reaching the same amplitudes. However, the regions of phases I & II do not display
such pre-spikes. Figure 3.12 illustrates examples from each phase. Higher temporal
resolution in future studies will aide to substantiate the integrity of this pattern and




Figure 3.1: Schematic of tube placement with motility channels in the stomach (4),
duodenum (3), proximal jejunum (2), and distal jejunum (1).
Figure 3.2: Manometry signal from a single duodenal channel.
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Figure 3.3: Left: original manometry tracing from Figure 3.2. Center: Histogram of
pressure (mmHg) occurrences in the signal. Right: Fourier transform of the signal in
Figure 3.2 showing lack of identifiable periodicity.
Figure 3.4: CWT-based peak detection results for three different antroduodenal
manometry channels. The detected peaks are shown as red dots overplayed on top of
the signals. Horizontally adjacent are histogram plots showing detected peak densities
along the time axis.
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Figure 3.5: Temporal distribution of detected peaks (red ticks) represented as a
histogram plot.
Figure 3.6: Each detected peak (red bar) is associated with a Gaussian basis function
(gray curve).
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Figure 3.7: Kernel density estimations using different smoothing bandwidths.
Figure 3.8: Using different kernel functions to estimate peak density: quartic/bi-
weight, cosine, Epanechnikov, Gaussian, triangular, and tri-weight
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Figure 3.9: The distribution of detected peaks is estimated (green curve) by summing
the basis functions (and normalizing so the functions integrates to 1 as a proper
densities). The red tick marks are the time positions of peaks and the grey histogram
shows their temporal distribution.
Figure 3.10: Prediction of average pressure function as determined by the Gaussian
process regressions. Regions of low (black), medium (blue), and high (red) expected
pressures are overplayed on the original signal (light blue).
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Figure 3.11: Top: overlay of the original signal with identified regions corresponding
to the different phases (I in green, II in blue, and III in red). The durations are
labeled above. Center: a transition plot, with the detected peaks plotted in red
below. Bottom: the kernel density estimation (light red) of detected peak times (red
tick marks).
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Figure 3.12: Phase III pressure peaks are preceded by short spikes that are not seen
in either phases I or II. Top row contains 40-minute spans of signals in phases I-III.
Middle row shows the boxed regions from top row in greater detail. The black arrows
correspond to pressure peaks in the respective regions while the red arrows indicate
the pre-spikes. Bottow row is further enlargement of a 1-minute period that shows
pre-spikes occurring only in phase III.
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Motility of the gastrointestinal (GI) tract is without doubt a great source of vari-
ability for oral drug products both within individuals and across populations, yet
its tremendous complexity has thus far encumbered many attempts at mechanistic
analysis. Here, a continuous, time-dependent function is developed to model cyclical
motility of the human GI tract during the fasted state and elucidate the effects of
physiological variation on plasma levels. Results show that fast absorption and short
plasma elimination half-lives profoundly affect bioequivalence testing. Plasma level
variation is further compounded by a volumetric effect, calling into question patient
compliance during self-administration. For oral drug products whose absorption pro-
files vary locationally, longer plasma elimination half-lives are still subject to great
variation in systemic availability. The non log-normality of resultant Cmax simulations
also suggests the need for re-evaluating current metrics and the potential application
of non-parametric methods in determining bioequivalence.
Predicting drug dissolution and transit along the GI tract relies on the ability
to account for dynamic physiological conditions: locational pH changes, small fluid
volumes, and the cyclical motility that drives contents, among others. A transit
model is developed, using as examples the non-absorbable phenol red marker of net
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fluid change and ibuprofen, a weakly-acidic BCS Class II compound. Indeed, re-
sults suggest dissolution is not immediately completed and still occurs even in the
mid-jejunum. Assuming non-sink conditions (i.e. measurable bulk concentrations of
dissolving drug) leads to accurate predictions of reported Cmax, Tmax, and AUC. Val-
idation and future refinement of this model will allow for successful in vivo predictions
of drug product performances based on physiochemical properties.
Future refinement also relies on estimating the statistics pertaining to motility at
the individual and population levels. It is then essential to have an objective quantifi-
cation of motility, and treating manometric data as a stochastic process invites many
applications of statistical computing to extract cycle and phase information. Kernel
density estimation enables a non-parametric method of smoothing peak density along
the time axis. A tunable bandwidth parameter is optimized thereby best representing
the stochastic nature of peak occurrences and identifying regions of high-frequency
pressure peaks. Orthogonal to kernel density estimation, a Gaussian process is used
as a robust regression method based on thresholding. Time-dependent expected pres-
sure values and their associated confidence intervals allow identification via relative
differences in regions of the signal being analyzed. The accordance of the two meth-
ods therefore validates this unsupervised classification scheme. This can be extended
to a multi-channel analysis where it becomes a two-dimensional problem, correlating
signal patterns across space (location in the GI tract).
4.2 Future considerations
4.2.1 Mass balance analysis
A more robust model for diffusion-controlled dissolution can be employed by in-
corporating factors such as hydrodynamic influences, degree of confinement affecting
bulk concentration, dissolving particle geometries, and [de]aggregation of particles
85
due to inter-particle forces and shear stress1. The dissolution mass balance analysis
presented in this dissertation has dealt with immediate release oral products. How-
ever, there is the potential to incorporate modified release and degradation. Indeed,
the model can account for first-order degradation kinetics. Bulk degradation of poly-
mers and release kinetics of modified formulations–taking into account erosion, drug
dissolution, pore percolation, and matching multi-phasic release profiles–are certainly
within reach2,3, and this should be further explored for developing a more general and
widely-applicable model of oral product performance along the GI tract.
4.2.2 Motility signal processing
Since a sub-pattern is seen in the signals during Phase III where small pressure
spikes precede the larger peaks, alternative classification methods may be used in
concert with those presented here to infer phase transitions and durations. Indeed,
since the phase state is not directly observable but the dependent outputs (pressure
signals) are, each state can be defined with a probability distribution over the output.
The signal evolution then reveals information about the states. Since the sequence
of the phases measured cannot be known directly (assuming sequential transitions–
phase I to II to III back to I–but with random initial phase at the time of dosing), a
Hidden Markov model can be employed to recover the initial state and thus the full
sequence transition. A similar approach has previously been used, simultaneously
recording intraluminal pressure and gut diameter in the isolated rabbit colon and
relating changes in pressure to those in diameter along the length of the gut section
4.
Another approach involves exploring other generalized regression models. The
Gaussian process approach is suitable because it reduces the noisy data to a smoothed
signal and the associated posterior estimate can help identify regions of dramatic
change (where a phase III begins). However, more a more robust approach would be,
86
for example, a trained learning method employing Artificial Neural Networks with
physician-annotated data sets that can estimate an unknown function best represent-
ing the manometry signal.
4.2.3 Physiological studies
High spatiotemporal resolution has provided insight in GI function from the per-
spective of the oral dosage form subject to the influences of the gut: magnetic marker
monitoring has been used to quantitate in vivo drug release and transit based on
magnetic dipole labeling of the solid dosage form5. MRI is also being explored as an
alternative, non-invasive method with recent success in small bowel flow rate and vol-
umetric emptying studies6,7. Direction of the migrating motor complex (MMC) prop-
agation is also of great importance. High temporal resolution studies of both colonic
and duodenal manometry revealed a large majority of pressure wave sequences were
indeed retrograde8,9. This calls into question the assumptions underlying many tran-
sit models that account for net forward movement but not the shearing and turbulent
effects of segmental back-mixing and aboral movement of GI contents. However, these
are still examinations of GI motility’s consequences rather than causes.
Slow wave propagation is potentially an underlying phenomenon driving motility
but whose exact relationships with the MMC remain yet unknown. Magnetic mea-
surements have been used to characterize what is thought to control smooth muscle
activity along the small bowel10. Recently, gastric contractions in humans were cor-
related to gastric slow waves using high-resolution MRI11. Contrastingly, a study of
tubular and sheet segments of feline duodenum showed the electrical activity of slow
waves propagating as broad wave fronts, similar to electrical wave fronts recorded
during peristaltic contractions, however at different velocities and with spontaneous
interruptions in conduction during peristalsis, something not seen in slow wave prop-
agations12. Furthermore, generation and directional propagation of the MMC in
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isolated mouse small intestines appeared independent of slow wave activity which is
seemingly an intrinsic capability of the enteric nervous system13. However, tremen-
dous advances in technologies allow for non-invasive and more sensitive detection
methods of slow wave frequencies in the small bowel, including biomagnetic signa-
tures assessment using magnetometer measurements in healthy humans14,15.
Beyond quantification of the MMC and potential underlying electrical activity
is the biochemistry controlling motility phases. Morphine is known to act on opioid
receptors and initiate phase III activities16. It was shown in fasted dogs that as bands
of action potential activity migrating caudally reached the ileum new bands began in
the stomach or duodenum17–20. While contractile frequencies of phase III remained
constant in the upper small intestines, the propagation of the MMC declined aborally
and most steeply in the distal jejunum21. Sarna et al. correlated plasma levels of
motilin–thought to be one of the most important factors controlling motility23–with
contractile activity in fasted dogs. They found that both spontaneous (i.e. natural)
and morphine-induced phase III patterns were associated with high levels of plasma
motilin which subsequently declined during phase I22 Furthermore, polymorphisms
of endogenous factors have been reported previously and implicated in certain GI
disorders24–28. To be certain, characterization of normal GI function is still an ongoing
endeavor and will continue to be the focus of many interdisciplinary studies to come.
As new technologies continue to develop, a better understanding of these various
components of motility will ultimately enhance the ability to predict the fate of oral
drug products with greater confidence and accuracy.
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Sample Python Code for Motility, Dissolution, and
Signal Analyses
A.1 Gastrointestinal motility transit
A.1.1 Mass balance Framework
1 # Import required libraries
import numpy as np
3 from scipy.integrate import odeint
from sympy.functions.special.delta_functions import Heaviside
5 import time
7 # Define custom Heaviside function
def u(t):
9 t = np.asarray(t)
is_scalar = False if t.ndim > 0 else True
11 t.shape = (1,)*(1-t.ndim) + t.shape
unit_step = np.arange(t.shape [0])
13 lcv = np.arange(t.shape [0])
for place in lcv:
15 if t[place] == 0:
unit_step[place] = .5
17 elif t[place] > 0:
unit_step[place] = 1
19 elif t[place] < 0:
unit_step[place] = 0
21 return (unit_step if not is_scalar else (unit_step [0] if
unit_step else Heaviside(t)))
92
23 # System of equations
class massBalance:
25
def __init__(self , t, to , Kpel , PermRates , KgeParams , LagParams ,
vol , M0 , title):
27 self.title = title
29 self.vol = vol





# Gastric emptying parameters
37 self.p150 ,self.p1200 = KgeParams [0], KgeParams [6]
self.p250 , self.p2200 = KgeParams [1], KgeParams [7]
39 self.p350 , self.p3200 = KgeParams [2], KgeParams [8]
self.theta50 , self.theta200 = KgeParams [3], KgeParams [9]
41 self.tau50 , self.tau200 = KgeParams [4], KgeParams [10]
self.s50 , self.s200 = KgeParams [5], KgeParams [11]
43
# Delay parameters
45 self.a50 ,self.a200 = LagParams [0], LagParams [7]
self.b50 ,self.b200 = LagParams [1], LagParams [8]
47 self.c50 ,self.c200 = LagParams [2], LagParams [9]
self.d50 ,self.d200 = LagParams [3], LagParams [10]
49 self.e50 ,self.e200 = LagParams [4], LagParams [11]
self.f50 ,self.f200 = LagParams [5], LagParams [12]
51 self.g50 ,self.g200 = LagParams [6], LagParams [13]
53 # Effective permeation rates
self.PermRates = PermRates
55 self.perm0 ,self.perm1 ,self.perm2 ,self.perm3 ,self.perm4 ,self.
perm5 ,self.perm6 = self.PermRates
57 # MMC decreases as it propagates along GI tract
self.KIntFactors = np.array ([0.77 , 0.76, 0.75, 0.74, 0.73,
0.72, 0.7], float)
59
# Plasma elimination half -life
61 self.Kpel = Kpel
63 # Gastric emptying functions for 50mL and 200mL volumes
def kge50ml(self ,t):
65 sum = 0.0
for k in range (1,26):
67 sum += (( -1.0)**k*np.sin(-self.theta50*np.pi*k*(t-self.tau50
)))/k+self.p150
return self.p250*sum**self.p350+self.s50
69 def kge200ml(self ,t):
sum = 0.0
71 for k in range (1,26):
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sum += (( -1.0)**k*np.sin(-self.theta200*np.pi*k*(t-self.
tau200)))/k+self.p1200
73 return self.p2200*sum**self.p3200+self.s200
75 # Delay functions for 50mL and 200mL volumes
def tlag50ml(self ,t):
77 return (self.a50 - self.b50/(self.c50+self.d50*np.exp(-self.
e50*np.mod(t ,2.0/ self.theta50)+self.f50)))*self.g50
def tlag200ml(self ,t):
79 return (self.a200 - self.b200/(self.c200+self.d200*np.exp(-
self.e200*np.mod(t ,2.0/ self.theta200)+self.f200)))*self.g200
81 # Gastroretentitive effect reducing rate of emptying function
# for small particules and solutions
83 def Kge(self ,t,to):
T = np.mod(t+to ,120)




# Intestinal transit functions
89 def KInt0(self ,t,to):
return self.KIntFactors [0]*(u(np.mod(t+to ,120)-self.tlag50ml(t
+to))*self.kge50ml(t+to))
91 def KInt1(self ,t,to):
return self.KIntFactors [1]*(u(np.mod(t+to ,120)-self.tlag50ml(t
+to))*self.kge50ml(t+to))
93 def KInt2(self ,t,to):
return self.KIntFactors [2]*(u(np.mod(t+to ,120)-self.tlag50ml(t
+to))*self.kge50ml(t+to))
95 def KInt3(self ,t,to):
return self.KIntFactors [3]*(u(np.mod(t+to ,120)-self.tlag50ml(t
+to))*self.kge50ml(t+to))
97 def KInt4(self ,t,to):
return self.KIntFactors [4]*(u(np.mod(t+to ,120)-self.tlag50ml(t
+to))*self.kge50ml(t+to))
99 def KInt5(self ,t,to):
return self.KIntFactors [5]*(u(np.mod(t+to ,120)-self.tlag50ml(t
+to))*self.kge50ml(t+to))
101 def Kie(self ,t,to):




105 def Q1(self ,t,to):
return .15*self.KInt1(t,to)
107 def Q2(self ,t,to):
return .15*self.KInt3(t,to)
109 def Q3(self ,t,to):
return .15*self.KInt5(t,to)
111
# System of equations
113 def dF(self ,F,t):
self.F = F
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115 self.t = t
DSolns , DSolnInt0 , DSolnInt1 , DSolnInt2 , DSolnInt3 , DSolnInt4 ,
DSolnInt5 , DSolnInt6 , DSolnPlasma = F[0:9]
117 self.Mnew = np.array([-DSolns*self.Kge(t,self.to), \
DSolns*self.Kge(t,self.to) - DSolnInt0*(self.KInt0(t,self.to
) + self.perm0), \
119 DSolnInt0*self.KInt0(t,self.to) - DSolnInt1*(self.KInt1(t,
self.to) + self.perm1) + DSolnInt2*self.Q1(t,self.to), \
DSolnInt1*self.KInt1(t,self.to) - DSolnInt2*(self.KInt2(t,
self.to) + self.Q1(t,self.to) + self.perm2), \
121 DSolnInt2*self.KInt2(t,self.to) - DSolnInt3*(self.KInt3(t,
self.to) + self.perm3) + DSolnInt4*self.Q2(t,self.to), \
DSolnInt3*self.KInt3(t,self.to) - DSolnInt4*(self.KInt4(t,
self.to) + self.Q2(t,self.to) + self.perm4), \
123 DSolnInt4*self.KInt4(t,self.to) - DSolnInt5*(self.KInt5(t,
self.to) + self.perm5) + DSolnInt6*self.Q3(t,self.to), \
DSolnInt5*self.KInt5(t,self.to) - DSolnInt6*(self.Kie(t,self
.to) + self.Q3(t,self.to) + self.perm6), \
125 DSolnInt6*self.Kie(t,self.to)],dtype=’float ’)
# DSolnInt0*self.perm0 + DSolnInt1*self.perm1 + DSolnInt2*
self.perm2 + DSolnInt3*self.perm3 + DSolnInt4*self.perm4 +
DSolnInt5*self.perm5 + DSolnInt6*self.perm6 - DSolnPlasma*self
.Kpel],dtype=’float ’)
127 return self.Mnew
# Jacobian of matrix F defined above (right now this is not used
)
129 def Fjac(self ,F,t):
self.t = t
131 Fmat = np.array ([[ self.Kge(t,self.to)
,0.0 ,0.0 ,0.0 ,0.0 ,0.0 ,0.0 ,0.0 ,0.0] , \
[self.Kge(t,self.to), -(self.KInt0(t,self.to) + self.perm0)
,0.0 ,0.0 ,0.0 ,0.0 ,0.0 ,0.0 ,0.0] , \
133 [0.0, self.KInt0(t,self.to), -(self.KInt1(t,self.to) + self.
perm1), self.Q1(t,self.to) ,0.0 ,0.0 ,0.0 ,0.0 ,0.0] , \
[0.0 ,0.0 , self.KInt1(t,self.to), -(self.KInt2(t,self.to) +
self.Q1(t,self.to) + self.perm2) ,0.0 ,0.0 ,0.0 ,0.0 ,0.0] , \
135 [0.0 ,0.0 ,0.0 , self.KInt2(t,self.to), -(self.KInt3(t,self.to)
+ self.perm3), self.Q2(t,self.to) ,0.0,0.0,0.0], \
[0.0 ,0.0 ,0.0 ,0.0 , self.KInt3(t,self.to), -(self.KInt4(t,self.
to) + self.Q2(t,self.to) + self.perm4) ,0.0,0.0,0.0], \
137 [0.0 ,0.0 ,0.0 ,0.0 ,0.0 , self.KInt4(t,self.to), -(self.KInt5(t,
self.to) + self.perm5), self.Q3(t,self.to) ,0.0], \
[0.0 ,0.0 ,0.0 ,0.0 ,0.0 ,0.0 , self.KInt5(t,self.to), -(self.Kie(t
,self.to) + self.Q3(t,self.to) + self.perm6) ,0.0], \
139 [0.0 ,0.0 ,0.0 ,0.0 ,0.0 ,0.0 , self.Kie(t,self.to) ,0]],’float ’)
# np.concatenate (([0.0] , self.PermRates ,[self.Kpel]))],’float
’)
141 return Fmat
# Method call to solve the system of equations
143 # relative and absolute tolerances set to 10^-3
def solveSys(self ,t):
145 self.t = t
# Solve system of equations
147 start_time = time.time()
95
result = odeint(self.dF ,self.M0 ,t,rtol=1e-3, atol=1e-3) #
mxstep =500, hmax =100, Dfun=self.Fjac ,full_output=True ,




A.1.2 BCS Class I 50 mL Volume Model
1 # Import required libraries
import numpy as np
3 from scipy.integrate import odeint , simps
from sympy.functions.special.delta_functions import Heaviside
5 import time , sys
from massBalanceBE import *










17 Define functions for saving/opening multiple files from/into large
array
’’’
19 def mySaveFile(title ,data):
# Write the array to disk
21 with file(title , ’w’) as outfile:
# I’m writing a header here just for the sake of readability
23 # Any line starting with "#" will be ignored by numpy.loadtxt
outfile.write(’# Array shape: {0}\n’. format(np.shape(data)))
25
# Iterating through a ndimensional array produces slices along
27 # the last axis. This is equivalent to data[i,:,:] in this
case
for data_slice in data:
29
# The formatting string indicates that I’m writing out
31 # the values in left -justified columns 7 characters in width
# with 2 decimal places.
33 np.savetxt(outfile , data_slice , fmt=’%-7.2f’)





39 # Read the array from disk
new_data = np.loadtxt(fname)
41
# Note that this returned a 2D array!
43 print new_data.shapest
45 # Gastric emptying parameters
p150 ,p1200 = 0.15, .14
47 p250 , p2200 = .285/( np.pi*15000) , .16/(np.pi*3900000)
p350 , p3200 = 6.65, 10.4
49 theta50 , theta200 = 1/60.0 , 1/60.0
tau50 , tau200 = 59.4, 60
51 s50 , s200 = 0.0001 , 0.1
KgeParams = np.array ([p150 ,p250 ,p350 ,theta50 ,tau50 ,s50 ,p1200 ,p2200
,p3200 ,theta200 ,tau200 ,s200],float)
53
# Delay parameters
55 a50 ,a200 = 2190/50. ,2591/100.
b50 ,b200 = 481/10. , 141/10.
57 c50 ,c200 = 27/25. , 11/20.
d50 ,d200 = 531/25. ,138/5.
59 e50 ,e200 = 13/200. ,6/25.
f50 ,f200 = 41/100. , -59/50.
61 LagParams = np.array ([a50 ,b50 ,c50 ,d50 ,e50 ,f50 ,a200 ,b200 ,c200 ,d200 ,
e200 ,f200],float)
63 # Randomly generate parameters for 23 more virtual subjects
randKgeParam = []
65 randKgeParam.append(KgeParams*np.transpose ([np.concatenate (([1.0] ,
np.array ((10-np.random.uniform (-1,1,23))/10, float)))]))
randKgeParam = randKgeParam [0]
67 randLagParam = []
randLagParam.append(LagParams*np.transpose ([np.concatenate (([1.0] ,
np.array ((10-np.random.uniform (-1,1,23))/10, float)))]))
69 randLagParam = randLagParam [0]
71 dose = 100.0 # Initial doses
vol = 50 # Initial volume
73
# 7, 14, 30, 60, and 120 minute plasma elimination half -lives
75 KpelVals = np.array ([0.1 , .05, .0231 , .011552 , .002888] , float)
77 # 4000- minute time range
t = np.arange (0 ,4000 ,1)
79
title = ’BCS I Slow $50mL$ ’
81
# Constant permeation rate along all compartments
83 perm0 ,perm1 ,perm2 ,perm3 ,perm4 ,perm5 ,perm6 = np.ones (7)*.5
PermRates = [perm0 ,perm1 ,perm2 ,perm3 ,perm4 ,perm5 ,perm6]
85
# Initial vector. Only stomach has content = dose
87 M0 = np.array([dose ,0,0,0,0,0,0,0,0], float)
97
89 # Simulate over t0 = 0 to 120 min
inputs = range (121)
91
# Determine number of available cores for processing
93 num_cores = multiprocessing.cpu_count ()
95 # Set up function calls to solve each iteration
# Determine concentration profiles in different compartments
97 # Calculate Cmax , Tmax , and AUC
def solve_to(i):
99 to = i
x = massBalance( t, to, Kpel , PermRates , patientKgeParams ,
patientLagParams , vol , M0,title)









# Store all results in matrices
111 MresultList50 , cMaxList50 , tMaxList50 , AUCList50 = [],[],[],[]
start_time = time.time()
113 totIts = len(KpelVals)*len(range (24))
bar_length = 20
115 for j in range (5):
Kpel = KpelVals[j]
117 for k in range (24):
patientKgeParams = randKgeParam[k]
119 patientLagParams = randLagParam[k]
result = Parallel(n_jobs=num_cores)(delayed(solve_to)(i) for i
in inputs)
121 cMax = Parallel(n_jobs=num_cores)(delayed(c_max)(result[i])
for i in inputs)
tMax = Parallel(n_jobs=num_cores)(delayed(t_max)(result[i])
for i in inputs)






129 percent = float (((j)*24.+(k+1))/totIts)
hashes = ’#’ * int(round(percent * bar_length))
131 spaces = ’ ’ * (bar_length - len(hashes))
runtime = round(time.time()-start_time ,2)
133 sys.stdout.write("\rPercent: [{0}] {1}% completed in {2}









139 print("--- Name: %s ---" % title)
print("--- Data sizes: ---")






147 Save files for conc profiles , cmax , tmax , and auc
’’’
149
fname = title.replace(" ","").replace(’$’,’’).replace(’_’,’’).
replace(’$’,’’).replace(’{’,’’).replace(’}’,’’).replace(’in ’,’
_’)
151 fnameConc ,fnamecMax ,fnametMax ,fnameAUC = fname+’_conc ’,fname+’
_cMax ’,fname+’_tMax ’,fname+’_AUC ’
153 print("--- Saving resutls: %s ---" % fname)
start_time = time.time()
155 totIts = len(KpelVals)*len(range (24))
bar_length = 20
157 for j in range (5):
for k in range (24):
159 np.savetxt(fnameConc + ’_Elim ’ + repr(j+1) + ’_P_ ’ + repr(k+1)
+ ’.csv ’, MresultList50 [(j)*24+k], delimiter=’,’)
np.savetxt(fnamecMax + ’_Elim ’ + repr(j+1) + ’_P_ ’ + repr(k+1)
+ ’.csv ’, cMaxList50 [(j)*24+k], delimiter=’,’)
161 np.savetxt(fnametMax + ’_Elim ’ + repr(j+1) + ’_P_ ’ + repr(k+1)
+ ’.csv ’, tMaxList50 [(j)*24+k], delimiter=’,’)
np.savetxt(fnameAUC + ’_Elim ’ + repr(j+1) + ’_P_ ’ + repr(k+1)
+ ’.csv ’, AUCList50 [(j)*24+k], delimiter=’,’)
163
percent = float (((j)*24.+(k+1))/totIts)
165 hashes = ’#’ * int(round(percent * bar_length))
spaces = ’ ’ * (bar_length - len(hashes))
167 runtime = round(time.time()-start_time ,2)
sys.stdout.write("\rPercent: [{0}] {1}% completed in {2}
seconds".format(hashes + spaces , int(round(percent * 100)),
runtime))
169 sys.stdout.flush()




A.2 Dissolution mass balance analysis
A.2.1 Mass Balance Framework
# Import required libraries
2 import ipybell
import json , matplotlib





8 from IPython.core.pylabtools import figsize
import numpy as np
10 from scipy.integrate import odeint , simps
from sympy.functions.special.delta_functions import Heaviside
12 import matplotlib.pyplot as plt
from matplotlib.pyplot import figure , show , axes , sci
14 from matplotlib import cm , colors
from matplotlib.font_manager import FontProperties
16 from numpy import amin , amax , ravel
import seaborn as sns
18
import time , sys
20 from Ibuprofen_massBalance import *




# Permeation rates , cm^2*s^-1 / 1.143
26 perm0 ,perm1 ,perm2 ,perm3 ,perm4 ,perm5 ,perm6 = np.ones (7)*8e-4 # 2.0e
-3
PermRates = [perm0 ,perm1 ,perm2 ,perm3 ,perm4 ,perm5 ,perm6]
28
Kpel = 8.557e-5 # 2.25 hr plasma elimination half -life
30 # Kpel = 7.7016e-5 # 2.5hr plasma elimination half -life
# Kpel = 9.627e-5 # 2hr plasma elimination half -life
32 Kdiss = 46.8/60/60 # Fast disintegration (90% in 3 min)
34 # Resting volumes (mL)
Grest = 30.0
36 Irest = 10.0 # 40.0
RestVol = [Grest ,Irest]
38
vol0 = 240.0 # Liquid volume
40 dose = 200.0 # Initial dose (mg)
ro = 400.0 # Initial particulate radius (um)
42
# Initial condition matrix








50 t = np.linspace (0 ,800*60 ,800*60*2)
# Index of time equaling 4 plasma elimination half -lives
52 tindex = min(range(len(t)), key=lambda i: np.abs(t[i]-4*np.log (2)/
Kpel))
54 #to_vals = np.array ([0.0*60,30*60 ,75.0*60 ,100.0*60 ,115.0*60],dtype
=’float ’)
to_vals = np.arange (0 ,121 ,10)*60.0
56 dose_vals = np.array ([200 ,400 ,800] , dtype=’float ’)
phase_names = [’Early Phase I’,’Mid Phase I’,’Phase II’,’Early
Phase III ’, ’Late Phase III ’]
58 lbls = ["Stom","Int0","Int1","Int2","Int3","Int4","Int5","Int6"]





62 MresultsMatrix = np.empty((len(t) ,33,len(to_vals)))







70 totIts = len(dose_vals)*len(to_vals)
bar_length = 20
72 # for D in range(len(dose_vals)):
for D in range (3):
74 for To in range(len(to_vals)):
percent = float (((1.0*D)*len(to_vals)+(To))/totIts)
76 hashes = ’#’ * int(round(percent * bar_length))
spaces = ’ ’ * (bar_length - len(hashes))
78 runtime = round(time.time()-start_time ,2)
sys.stdout.write("\rPercent: [{0}] {1}% completed in {2}
seconds".format(hashes + spaces , int(round(percent * 100)),
runtime))
80 sys.stdout.flush()
82 # print(’--- Dose: %.2f\t\tTo: %.2f ---’ % (dose_vals[D],
to_vals[To ]/60.0))
to = to_vals[To]
84 M0[8] = dose_vals[D]
x = massBalance(t,to,Kpel ,Kdiss ,ro,RestVol ,PermRates ,M0,title)
86 Mresult = x.solveSys(t)
MresultsMatrix [:,:,To] = np.copy(Mresult)
88 tMax = np.copy(t[np.argmax(Mresult [:,-1]) ]/60)
cMax = np.copy(np.max(Mresult [:,-1])/(.1*70))
90 AUC= np.copy(np.trapz(Mresult [: , -1]/(.1*70),t/60.0) /60)
conc_results[D,To ,:] = np.copy(Mresult [:,-1])
101
92 cMax_results[D,To] = np.copy(cMax)
tMax_results[D,To] = np.copy(tMax)
94 AUC_results[D,To] = np.copy(AUC)




98 Phenol red 65mg dosed
as solution in 240mL liquid volume
100 Treat as instantaneous dissintegration
and dissolution (on order fo 1e3)
102 ’’’
%%bell
104 start_time = time.time()
totIts = len(dose_vals)
106 for D in range (1):
for To in range(len(to_vals)):
108 print(’--- Dose: %.2f\t\tTo: %.2f ---’ % (65, to_vals[To ]/60.0)
)
to = to_vals[To]
110 M0[8] = 65
x = massBalance(t,to,Kpel ,Kdiss*1e3,ro,RestVol ,PermRates*np.
zeros (7),M0,title)
112 x.C0 = 1e3
Mresult = x.solveSys(t)
114 MresultsMatrix [:,:,To] = np.copy(Mresult)
tMax = np.copy(t[np.argmax(Mresult [:,-1]) ]/60)
116 cMax = np.copy(np.max(Mresult [:,-1])/(.1*70))
AUC= np.copy(np.trapz(Mresult [: , -1]/(.1*70),t/60.0) /60)
118 conc_results[D,To ,:] = np.copy(Mresult [:,-1])
cMax_results[D,To] = np.copy(cMax)
120 tMax_results[D,To] = np.copy(tMax)
AUC_results[D,To] = np.copy(AUC)
122 print(’--- Executiton time: %.4f ---’ % float(time.time()-
start_time))
124 ’’’
mass / (Vd * Wt)
126 mg / (L/kg * kg)
’’’
128
cMax_results2 = np.concatenate (([ Ibu200_cMax ],[ Ibu400_cMax ],[
Ibu800_cMax ]))
130 tMax_results2 = np.concatenate (([ Ibu200_tMax ],[ Ibu400_tMax ],[
Ibu800_tMax ]))/60.0
conc_results2 = np.concatenate (([ Ibu200_conc ],[ Ibu400_conc ],[
Ibu800_conc ]))/(.14*70)
132 # cMax_results2 ,tMax_results2 , conc_results2 = cMax_results ,
tMax_results ,conc_results
134 # Plot results
pI,pII ,pIIIe ,pIIIl = 0 ,70 ,100 ,119
136 figsize (8.5 ,6)
102




140 for i in range (3):
ax[i]. fill_between(t/60, np.min(conc_results2[i,:],axis =0),
142 np.max(conc_results2[i,:],axis =0), facecolor =’#444444’, alpha
=0.15)
ax[i].plot(t/60, conc_results2[i,pI],label=r’Early Phase I’)
144 ax[i].plot(t/60, conc_results2[i,pII],label=r’Phase II ’)
ax[i].plot(t/60, conc_results2[i,pIIIe],label=r’Early Phase III ’)





if i==2: ax[i]. set_xlabel(’time ($min$)’)
152 if i==0: ax[i]. set_title(’Ibuprofen Phase -Dependent\nPlasma
Profile ’)
if i==1: ax[i]. set_ylabel(’Conc. ($mg/L$)’)
154 props = dict(boxstyle=’round ’, facecolor=’white ’, alpha =0.5)
ax[0]. text (240 ,80 ,’200mg ’,size=12, verticalalignment=’top ’,
horizontalalignment=’left ’,bbox=props)
156 ax[1]. text (240 ,80 ,’400mg ’,size=12, verticalalignment=’top ’,
horizontalalignment=’left ’,bbox=props)
ax[2]. text (240 ,80 ,’800mg ’,size=12, verticalalignment=’top ’,
horizontalalignment=’left ’,bbox=props)
158 # place a text box in upper left in axes coords
if i==2: leg = ax[i]. legend(bbox_to_anchor =(0.25 , -.7, 1., .102)
, loc=3,ncol=2, borderaxespad =0.)
160 plt.ylim (0 ,100)
plt.xlim (0 ,500)





# Function for visualizaton
168 def plot_results(Mresult ,title):
# Plot results
170 tindex = min(range(len(t)), key=lambda i: np.abs(t[i]-4*np.log
(2)/Kpel))





axes [0]. set_title(title + ’\nDelayed Gastric Emptying ’)
176 for i in range (8):
c=next(color)
178 axes [0]. plot(t[0: tindex ]/60, Mresult [0: tindex ,i],c=c,label=lbls
[i])
axes [0]. set_ylabel(’Vol ($mL$)’)
180 axes [0]. set_ylim(-5,Grest+vol0 +5)
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182 # Solid drug
color=iter(cm.rainbow(np.linspace (0,1,n)))
184 for i in range (8):
c=next(color)
186 axes [1]. plot(t[0: tindex ]/60, Mresult [0: tindex ,i+8],c=c,label=
lbls[i])
axes [1]. set_ylabel(’Solid Drug ($mg$)’)
188 axes [1]. set_ylim(-5,dose +5)
color=iter(cm.rainbow(np.linspace (0,1,n)))
190 for i in range (8):
c=next(color)
192 axes [2]. plot(t[0: tindex ]/60, Mresult [0: tindex ,i+16],c=c,label=
lbls[i])
axes [2]. set_ylabel(’Drug Particulate ($mg$)’)




198 for i in range (8):
c=next(color)
200 axes [3]. plot(t[0: tindex ]/60, Mresult [0: tindex ,i+24]*1000/
Mresult [0: tindex ,i],c=c,label=lbls[i])
maxConc = np.ceil(np.max([ Mresult [0: tindex ,i+24]*1000 for i in
range (8)])/10)*10
202 axes [3]. set_xlabel(’time ($min$)’)
axes [3]. set_ylabel(’Dissolved Drug ($\mu g/mL$)’)
204 axes [3]. set_ylim (1e-4,maxConc)
axes [3]. set_yscale(’log ’)
206 leg = axes [3]. legend(bbox_to_anchor =(0.0 , -.95, 1., .102), loc
=3,
ncol=3, mode="expand", borderaxespad =0.)
208 plt.tight_layout ()
# plt.savefig(title ,bbox_inches=’tight ’,bbox_extra_artist =[leg],
dpi =300)
210 plt.show()
212 def plot_cmax(Mresult ,title):
plt.figure(dpi =300)
214 # fig = plt.figure(figsize =(6,4), dpi=80, facecolor=’w’,
edgecolor=’k’)
tMax ,cMax = t[np.argmax(Mresult [:,-1])],np.max(Mresult
[: , -1]/(.14*70))
216 plt.bone()
plt.plot(t/60, Mresult [: , -1]/(.14*70))
218 plt.plot(tMax/60,cMax ,’ro ’)
plt.xlabel(’time ($min$)’)
220 plt.ylabel(’Drug ($mg/mL$)’)
plt.title(title + ’\nPlasma Profile ’)
222 # plt.text(tMax+3,cMax+2, r’$C_{max}$’, fontsize =12)
# plt.ylim (0 ,100)
224 # place a text box in upper left in axes coords
# props = dict(boxstyle=’round ’, facecolor=’wheat ’, alpha =0.5)
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226 # textstr = ’$C_{max }=%.2f mg$\n$T_{max }=%.2f min$\
nDisintegration HL=$%.2f min$ ’%(cMax , tMax ,np.log(2)/Kdiss)
# plt.text(t[-100], 95, textstr , fontsize=9,
228 # verticalalignment=’top ’, horizontalalignment=’right ’,bbox=
props)
plt.tight_layout ()





234 tt = np.linspace (0,800*60,800*60*2)
236 ’’’
Various functions that help visualize distributions of content
along
238 the GI tract (compartments)
Take as input the result concentration profiles from solutions to
sys of eq above ,
240 title , color map , and whether to save and under what title
242 plotIntConcs shows intestinal contents of dissolved solutions
plotIntSolids shows intestinal contents of solid particles




248 ’update image in response to changes in clim or cmap on
another image ’
def __init__(self , follower):
250 self.follower = follower




def plotIntConcs(Mresult ,figtitle ,cmap=plt.cm.bone ,savePlt=0,
saveName=’’):
256 Nr = 1
Nc = 8
258
fig = figure(dpi =300)
260




cax = fig.add_axes ([0.95 , 0.2, 0.05, 0.45])
266 h = 0.5
w = 0.1
268 ax = []
images = []
270 vmin = 1e40
vmax = -1e40
272 for i in range(Nr):
105
for j in range(Nc):




278 if j == 0:
a.set_yticks(np.linspace (0 ,50000 ,6))
280 a.set_yticklabels ([np.round (10*k)/10 for k in np.linspace
(0,tt [50000]/60.0 ,6) ])
a.set_ylabel(’Time (min) ’)
282 else: a.set_yticklabels ([])
a.set_title(lbls[j])
284 # Make some fake data with a range that varies
# somewhat from one plot to the next.
286 data = np.tile(Mresult [0: tindex ,j+24]*1000/ Mresult [0: tindex ,
j],(5e1 ,1)).T
dd = ravel(data)
288 # Manually find the min and max of all colors for
# use in setting the color scale.
290 vmin = min(vmin , amin(dd))
vmax = max(vmax , amax(dd))
292 images.append(a.imshow(data , aspect="auto",interpolation="
none",cmap=cmap))
294 ax.append(a)
296 # Set the first image as the master , with all the others
# observing it for changes in cmap or norm.
298
norm = colors.Normalize(vmin=vmin , vmax=vmax)
300 for i, im in enumerate(images):
im.set_norm(norm)
302 if i > 0:
images [0]. callbacksSM.connect(’changed ’, ImageFollower(im))
304
# The colorbar is also based on this master image.
306 cbar = fig.colorbar(images [0], cax=cax , orientation=’vertical ’)
cbar.ax.set_ylabel(’Conc. ($\mu g/mL$)’)
308 # We need the following only if we want to run this
interactively and
# modify the colormap:
310
axes(ax[0]) # Return the current axes to the first one ,
312 sci(images [0]) # because the current image must be in current
axes.





def plotIntSolids(Mresult ,figtitle ,cmap=plt.cm.bone ,savePlt=0,
saveName=’’):




fig = figure(dpi=300, figsize =(8.5 ,4.5))
322




cax = fig.add_axes ([0.85 , 0.2, 0.05, 0.45])
328 h = 0.5
w = 0.1
330 ax = []
images = []
332 vmin = 1e40
vmax = -1e40
334 for i in range(Nr):
for j in range(Nc):




340 if j == 0:
a.set_yticks(np.linspace (0 ,50000 ,6))
342 a.set_yticklabels ([np.round (10*k)/10 for k in np.linspace
(0,tt [50000]/60.0 ,6) ])
a.set_ylabel(’Time (min) ’)
344 else: a.set_yticklabels ([])
a.set_title(lbls[j])
346 # Make some fake data with a range that varies
# somewhat from one plot to the next.
348 data = np.tile(Mresult [0: tindex ,j+16]*1000/ Mresult [0: tindex ,
j],(5e1 ,1)).T
dd = ravel(data)
350 # Manually find the min and max of all colors for
# use in setting the color scale.
352 vmin = min(vmin , amin(dd))
vmax = max(vmax , amax(dd))
354 images.append(a.imshow(data , aspect="auto",interpolation="
none",cmap=cmap))
356 ax.append(a)
358 # Set the first image as the master , with all the others
# observing it for changes in cmap or norm.
360
norm = colors.Normalize(vmin=vmin , vmax=vmax)
362 for i, im in enumerate(images):
im.set_norm(norm)
364 if i > 0:
images [0]. callbacksSM.connect(’changed ’, ImageFollower(im))
366
# The colorbar is also based on this master image.
368 cbar = fig.colorbar(images [0], cax=cax , orientation=’vertical ’)
cbar.ax.set_ylabel(’Conc. ($\mu g/mL$)’)
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370 # We need the following only if we want to run this
interactively and
# modify the colormap:
372
axes(ax[0]) # Return the current axes to the first one ,
374 sci(images [0]) # because the current image must be in current
axes.






def plotIntDissSolids(Mresult ,figtitle ,savePlt=0,saveName=’’,
thresh=False ,threshMax1 =200.0 , threshMax2 =35.0):
382 Nr = 1
Nc = 8
384
fig = figure(dpi=300, figsize =(9.5 ,5))
386





392 cmap2 = plt.cm.GnBu
ax_cb1 = fig.add_axes ((0.62 , 0.2, 0.05, 0.45))
394 ax_cb2 = fig.add_axes ((0.77 , 0.2, 0.05, 0.45))
396 h = 0.5
w = 0.03
398 ax = []
images1 ,images2 = [],[]
400 vmin1 = 1e40
vmax1 = -1e40
402 vmin2 = 1e40
vmax2 = -1e40
404 for i in range(Nr):
for j in range(Nc):
406 pos1 = [0.075 + j*1.1*w*2, 0.18 + i*1.2*h, w, h]
pos2 = [0.075 +w + j*1.1*w*2, 0.18 + i*1.2*h, w, h]







if j == 0:
416 a1.set_yticks(np.linspace (0 ,50000 ,6))
a1.set_yticklabels ([np.round (10*k)/10 for k in np.linspace
(0,tt [50000]/60.0 ,6) ])
418 a1.set_ylabel(’Time (min)’)
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# a2.set_yticks(np.linspace (0 ,50000 ,6))
420 # a2.set_yticklabels ([np.round (10*k)/10 for k in np.
linspace(0,tt [50000]/60.0 ,6) ])






# Make some fake data with a range that varies
428 # somewhat from one plot to the next.
data1 = np.tile(Mresult [0:tindex ,j+16]*1000/ Mresult [0:tindex
,j],(5e1 ,1)).T
430 dd1 = ravel(data1)
data2 = np.tile(Mresult [0:tindex ,j+24]*1000/ Mresult [0:tindex
,j],(5e1 ,1)).T
432 dd2 = ravel(data2)
# Manually find the min and max of all colors for
434 # use in setting the color scale.
vmin1 = min(vmin1 , amin(dd1))
436 vmax1 = max(vmax1 , amax(dd1))
vmin2 = min(vmin2 , amin(dd2))
438 vmax2 = max(vmax2 , amax(dd2))
images1.append(a1.imshow(data1 , aspect="auto",interpolation=
"none",cmap=cmap1 ,alpha =0.5))





# Set the first image as the master , with all the others
446 # observing it for changes in cmap or norm.
if thresh ==True: vmax1=threshMax1
448 norm1 = colors.Normalize(vmin=vmin1 , vmax=vmax1)
for i, im in enumerate(images1):
450 im.set_norm(norm1)
if i > 0:
452 images1 [0]. callbacksSM.connect(’changed ’, ImageFollower(im))
if thresh ==True: vmax2=threshMax2
454 norm2 = colors.Normalize(vmin=vmin2 , vmax=vmax2)
for i, im in enumerate(images2):
456 im.set_norm(norm2)
if i > 0:
458 images2 [0]. callbacksSM.connect(’changed ’, ImageFollower(im))
460 # The colorbar is also based on this master image.
cbar1 = fig.colorbar(images1 [0], cax=ax_cb1 , orientation=’
vertical ’)
462 cbar2 = fig.colorbar(images2 [0], cax=ax_cb2 , orientation=’
vertical ’)
if thresh ==True:
464 cbar1.set_ticks(np.arange(0, threshMax1*1.1, threshMax1 /10.0))
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cbar1.ax.set_yticklabels(np.concatenate (([str(i) for i in np.
arange(0,threshMax1 ,threshMax1 /10.0)],[str(threshMax1)+’$\leq$
’])))
466 if thresh ==True:
cbar2.set_ticks(np.arange(0, threshMax2*1.1, threshMax2 /10.0))
468 cbar2.ax.set_yticklabels(np.concatenate (([str(i) for i in np.
arange(0,threshMax2 ,threshMax2 /10.0)],[str(threshMax2)+’$\leq$
’])))
cbar1.ax.set_ylabel(’Particulate Conc. ($\mu g/mL$)’, labelpad
=-1)
470 cbar2.ax.set_ylabel(’Dissolved Conc. ($\mu g/mL$)’, labelpad =-1)
# We need the following only if we want to run this
interactively and
472 # modify the colormap:
474 axes(ax[0]) # Return the current axes to the first one ,
sci(images1 [0]) # because the current image must be in current
axes.
476 # sci(images2 [0]) # because the current image must be in
current axes.





482 # Look at the spread along GI tract during different phases
pI,pII ,pIIIe ,pIIIl = 0,7,10,12
484 tindex = min(range(len(t)), key=lambda i: np.abs(t[i]-4*np.log (2)/
Kpel))
plotIntConcs(MresultsMatrix [:,:,pI],’Early Phase I’,cmap=plt.cm.
Reds ,savePlt=True ,saveName=’PhenolRed_PhaseIEarly ’)
486 plotIntConcs(MresultsMatrix [:,:,pII],’Phase II ’,cmap=plt.cm.Reds ,
savePlt=True ,saveName=’PhenolRed_PhaseII ’)
plotIntConcs(MresultsMatrix [:,:,pIIIe],’Early Phase III ’,cmap=plt.
cm.Reds ,savePlt=True ,saveName=’PhenolRed_PhaseIIIEarly ’)
488 plotIntConcs(MresultsMatrix [:,:,pIIIl],’Late Phase III ’,cmap=plt.
cm.Reds ,savePlt=True ,saveName=’PhenolRed_PhaseIIILate ’)
490 pI,pII ,pIIIe ,pIIIl = 0,7,10,12
tindex = np.array ([np.abs(t[i]/60 - 250.0) for i in range(len(t))
]).argmin () # Only plot until 250 min
492 plotIntDissSolids(MresultsMatrix [:,:,pI],’Early Phase I’,savePlt=
True ,saveName=’Ibu_PhaseIEarly ’,thresh=True ,threshMax1 =1000,
threshMax2 =1000)
plotIntDissSolids(MresultsMatrix [:,:,pII],’Phase II’,savePlt=True ,
saveName=’Ibu_PhaseII ’,thresh=True ,threshMax1 =1000, threshMax2
=1000)
494 plotIntDissSolids(MresultsMatrix [:,:,pIIIe],’Early Phase III ’,
savePlt=True ,saveName=’Ibu_PhaseIIIEarly ’,thresh=True ,
threshMax1 =1000 , threshMax2 =1000)
plotIntDissSolids(MresultsMatrix [:,:,pIIIl],’Late Phase III ’,
savePlt=True ,saveName=’Ibu_PhaseIIILate ’,thresh=True ,




Compare predicted Cmax , Tmax , and AUC to reported values from
Davies paper




exp_200 = np.array ([[22.0 , 1.5, np.NAN], [21.8, 1.0, np.NAN],
504 [27.0 , 1.375 , 76.0] , [19.0 , 1.95, 63.0] , [14.94 , 2.605 ,
58.37] ,
[20.96 , 1.737 , 78.41] , [25.79 , 1.694 , 106.2] , [24.46 , 1.858 ,
106.2] ,
506 [23.24 , 2.028 , 122.8] , [23.43 , 2.126 , 109.8] , [16.3 , 1.5,
246.78] ,
[19.6 , 1.59, 60.3] , [19.2 , 1.06, 58.8]] , dtype=’float ’)
508 exp_400 = np.array ([[27.92 ,1.1 ,np.NAN ] ,[30.15 ,1.165 ,np.NAN],
[23.6 ,2.0 ,np.NAN] ,[26.8 ,2.0 ,np.NAN
] ,[27.6 ,1.17 ,319.8] ,[22.0 ,1.5 ,79.2] ,
510
[21.1 ,2.6 ,100.0] ,[27.9 ,1.9 ,103.0] ,[37.7 ,1.3 ,122] ,[25.6 ,2.48 ,113.6] ,
[36.4 ,2.07 ,128.8] ,[32.5 ,1.0 ,np.NAN
] ,[56 ,1.38 ,203] ,[32.3 ,1.5 ,113.2] ,
512
[35.3 ,1.28 ,127.53] ,[29 ,2.13 ,105.0] ,[32.4 ,1.5 ,173] ,[43.0 ,1.06 ,429.66] ,
[26.7 ,1.1 ,114] ,[42.28 ,0.93 ,120.08] ,[42.55 ,0.97 ,118.32] ,[44.7 ,0.53 ,100.87]] ,
dtype=’float ’)
514 exp_800 = np.array ([[60.2 ,1.5 ,np.NAN
] ,[55.6 ,1.59 ,217.78] ,[61 ,1.6 ,98] ,
[54.7 ,1.67 ,214.3] ,[45.23 ,2.56 ,213.66] ,[ np.NAN ,np.NAN ,239.7] ,[
np.NAN ,np.NAN ,286.8]] , dtype=’float ’)
516
’’’
518 Import saved results





MresultsMatrix = np.empty((3,len(t) ,33,len(to_vals)))
524
for i in range (3):
526 AUC_results[i,:] = np.loadtxt(’IbuprofenData/Abs1e -3 _Irest40/
Ibuprofen200400800_AUC_dose ’ + str(i+1) +
’.csv ’,delimiter=’,’)
528 cMax_results[i,:] = np.loadtxt(’IbuprofenData/Abs1e -3 _Irest40/
Ibuprofen200400800_cMax_dose ’ + str(i+1) +
’.csv ’,delimiter=’,’)
111
530 tMax_results[i,:] = np.loadtxt(’IbuprofenData/Abs1e -3 _Irest40/
Ibuprofen200400800_tMax_dose ’ + str(i+1) +
’.csv ’,delimiter=’,’)
532 conc_results[i,:,:] = np.loadtxt(’IbuprofenData/Abs1e -3 _Irest40/
Ibuprofen200400800_conc_dose ’ + str(i+1) +
’.csv ’,delimiter=’,’)
534 # MresultsMatrix[i,:,:] = np.loadtxt(’IbuprofenData/Abs1e -3
_Irest40/Ibuprofen200400800_result_dose ’ + str(i+1) +
’.csv ’,delimiter=’,’)
536 ’’’
538 # filebase = ’IbuprofenData/Abs1e -3 _Irest40/Ibuprofen200400800_ ’
filebase = ’IbuprofenData/Ibuprofen200400800_ ’
540
Ibu200_cMax = np.genfromtxt(filebase + ’cMax_dose1.csv ’,
delimiter=’,’)
542 Ibu200_tMax = np.genfromtxt(filebase + ’tMax_dose1.csv ’,
delimiter=’,’)
Ibu200_AUC = np.genfromtxt(filebase + ’AUC_dose1.csv ’, delimiter
=’,’)
544 Ibu400_cMax = np.genfromtxt(filebase + ’cMax_dose2.csv ’,
delimiter=’,’)
Ibu400_tMax = np.genfromtxt(filebase + ’tMax_dose2.csv ’,
delimiter=’,’)
546 Ibu400_AUC = np.genfromtxt(filebase + ’AUC_dose2.csv ’, delimiter
=’,’)
Ibu800_cMax = np.genfromtxt(filebase + ’cMax_dose3.csv ’,
delimiter=’,’)
548 Ibu800_tMax = np.genfromtxt(filebase + ’tMax_dose3.csv ’,
delimiter=’,’)
Ibu800_AUC = np.genfromtxt(filebase + ’AUC_dose3.csv ’, delimiter
=’,’)
550 Ibu200_conc = np.genfromtxt(filebase + ’conc_dose1.csv ’,
delimiter=’,’)
Ibu400_conc = np.genfromtxt(filebase + ’conc_dose2.csv ’,
delimiter=’,’)
552 Ibu800_conc = np.genfromtxt(filebase + ’conc_dose3.csv ’,
delimiter=’,’)
554
ibu_200 = np.array([ Ibu200_cMax ,Ibu200_tMax /60.0/60.0 , Ibu200_AUC ])
.T
556 ibu_400 = np.array([ Ibu400_cMax ,Ibu400_tMax /60.0/60.0 , Ibu400_AUC ])
.T
ibu_800 = np.array([ Ibu800_cMax ,Ibu800_tMax /60.0/60.0 , Ibu800_AUC ])
.T
558
# ibu_200 = np.array ([[ cMax_results [0,i],tMax_results [0,i]/60,
AUC_results [0,i]] for i in range (13)])
560 # ibu_400 = np.array ([[ cMax_results [1,i],tMax_results [1,i]/60,
AUC_results [1,i]] for i in range (13)])
# ibu_800 = np.array ([[ cMax_results [2,i],tMax_results [2,i]/60,
AUC_results [2,i]] for i in range (13)])
562
112
data_cMax = [ibu_200 [:,0], exp_200 [:,0], ibu_400 [:,0], exp_400
[:,0], ibu_800 [:,0], exp_800 [:,0]]
564 data_tMax = [ibu_200 [:,1], exp_200 [:,1], ibu_400 [:,1], exp_400
[:,1], ibu_800 [:,1], exp_800 [:,1]]
data_AUC = [ibu_200 [:,2], exp_200 [:,2], ibu_400 [:,2], exp_400
[:,2], ibu_800 [:,2], exp_800 [:,2]]
566
# Boxplot of predicted and experimental cMax , tMax , and AUC for
200, 400, and 800 mg doses of ibuprofen
568
numDists = 6
570 randomDists = [’200mg’,’ 400mg’, ’800mg ’]
572 c1, c2, c3 = sns.color_palette("Set1", 3)
574 fig , ax = plt.subplots(figsize =(5.5 ,9), nrows=3, ncols=1, dpi=300,
sharex=True , sharey=False)
#fig.canvas.set_window_title(’A Boxplot Example ’)
576 plt.subplots_adjust(left =0.075 , right =0.95 , top=0.9, bottom =0.25)
578 bp0 = ax[0]. boxplot(data_cMax , notch=0, sym=’+’, vert=1, whis =1.5,
widths =0.3)
bp1 = ax[1]. boxplot(data_tMax , notch=0, sym=’+’, vert=1, whis =1.5,
widths =0.3)
580 bp2 = ax[2]. boxplot(data_AUC , notch=0, sym=’+’, vert=1, whis =1.5,
widths =0.3)
plt.setp(bp0[’boxes ’], color=’black ’)
582 plt.setp(bp0[’whiskers ’], color=’black ’, linestyle=’solid ’,
linewidth =0.5)
plt.setp(bp0[’fliers ’], marker=’o’, color=’#e7298a ’, alpha =0.5)
584 # plt.setp(bp0[’caps ’], color=’none ’)
plt.setp(bp1[’boxes ’], color=’black ’)
586 plt.setp(bp1[’whiskers ’], color=’black ’, linestyle=’solid ’,
linewidth =0.5)
plt.setp(bp1[’fliers ’], marker=’o’, color=’#e7298a ’, alpha =0.5)
588 # plt.setp(bp1[’caps ’], color=’none ’)
plt.setp(bp2[’boxes ’], color=’black ’)
590 plt.setp(bp2[’whiskers ’], color=’black ’, linestyle=’solid ’,
linewidth =0.5)
plt.setp(bp2[’fliers ’], marker=’o’, color=’#e7298a ’, alpha =0.5)
592 # plt.setp(bp2[’caps ’], color=’none ’)
594 ax[0]. spines[’left ’]. _linewidth = 0.5
ax[1]. spines[’left ’]. _linewidth = 0.5
596 ax[2]. spines[’left ’]. _linewidth = 0.5




602 ax[0]. set_ylabel(’Conc. ($mg\cdot mL^{-1}$)’)
ax[1]. set_ylabel(’Time ($hr$)’)
604 ax[2]. set_ylabel(’Bioavail. ($mg\cdot mL^{-1}\ cdot hr}$)’)
113
606 # Now fill the boxes with desired colors
boxColors = [’#1b9e77 ’,’#FF8000 ’]
608 numBoxes = 6
medians0 ,medians1 ,medians2 = range(numBoxes),range(numBoxes),range
(numBoxes)
610 for i in range(numBoxes):
box0 ,box1 ,box2 = bp0[’boxes ’][i],bp1[’boxes ’][i],bp2[’boxes ’][i]
612 boxX0 ,boxX1 ,boxX2 = [],[],[]
boxY0 ,boxY1 ,boxY2 = [],[],[]







boxCoords0 ,boxCoords1 ,boxCoords2 = zip(boxX0 ,boxY0),zip(boxX1 ,
boxY1),zip(boxX2 ,boxY2)
622 # Alternate between Dark Khaki and Royal Blue
k = i % 2






628 # Now draw the median lines back over what we just filled in
med0 ,med1 ,med2 = bp0[’medians ’][i],bp1[’medians ’][i],bp2[’
medians ’][i]
630 medianX0 ,medianX1 ,medianX2 = [],[],[]
medianY0 ,medianY1 ,medianY2 = [],[],[]
632 for j in range (2):
medianX0.append(med0.get_xdata ()[j])
634 medianY0.append(med0.get_ydata ()[j])
ax[0]. plot(medianX0 , medianY0 , ’k’)
636 medians0[i] = medianY0 [0]
638 medianX1.append(med1.get_xdata ()[j])
medianY1.append(med1.get_ydata ()[j])
640 ax[1]. plot(medianX1 , medianY1 , ’k’)




ax[2]. plot(medianX2 , medianY2 , ’k’)
646 medians2[i] = medianY2 [0]
# Finally , overplot the sample averages , with horizontal
alignment
648 # in the center of each box
ax[0]. plot([np.average(med0.get_xdata ())], [np.average(data_cMax
[i][~np.isnan(data_cMax[i])])],
650 color=c2 , marker=’*’, markeredgecolor=’k’)
ax[1]. plot([np.average(med1.get_xdata ())], [np.average(data_tMax
[i][~np.isnan(data_tMax[i])])],
114
652 color=c2 , marker=’*’, markeredgecolor=’k’)
ax[2]. plot([np.average(med2.get_xdata ())], [np.average(data_AUC[
i][~np.isnan(data_AUC[i])])],
654 color=c2 , marker=’*’, markeredgecolor=’k’)
656 # Set the axes ranges and axes labels
ax[0]. set_xlim (0.5, numBoxes +0.5)
658 ax[1]. set_xlim (0.5, numBoxes +0.5)
ax[2]. set_xlim (0.5, numBoxes +0.5)
660
ax[0]. set_ylim(0, 80)
662 ax[1]. set_ylim (.25, 4)
ax[2]. set_ylim (20, 500)
664 xtickNames = plt.setp(ax[2], xticklabels=np.repeat(randomDists , 2)
)
plt.setp(xtickNames , rotation =45, fontsize =12)
666
# Due to the Y-axis scale being different across samples , it can
be
668 # hard to compare differences in medians across the samples. Add
upper
# X-axis tick labels with the sample medians to aid in comparison
670 # (just use two decimal places of precision)
pos = np.arange(numBoxes)+1
672 upperLabels0 ,upperLabels1 ,upperLabels2 = [str(np.round(s, 2)) for
s in medians0],[str(np.round(s, 2)) for s in medians1],[str(np
.round(s, 2)) for s in medians2]
weights = [’bold ’, ’semibold ’]
674 for tick ,label in zip(range(numBoxes),ax[0]. get_xticklabels ()):
k = tick % 2
676 ax[0]. text(pos[tick], 80-(80*0.1), upperLabels0[tick],
horizontalalignment=’center ’, size=’medium ’, weight=weights[k
],
678 color=boxColors[k])
ax[1]. text(pos[tick], 4-(4*0.1), upperLabels1[tick],
680 horizontalalignment=’center ’, size=’medium ’, weight=weights[k
],
color=boxColors[k])
682 ax[2]. text(pos[tick], 500 -(500*0.1), upperLabels2[tick],
horizontalalignment=’center ’, size=’medium ’, weight=weights[k
],
684 color=boxColors[k])
686 # Finally , add a basic legend
plt.figtext (0.75, 0.15, ’Predicted ’ ,
688 backgroundcolor=boxColors [0], color=’black ’, weight=’roman
’,
size=’medium ’)
690 plt.figtext (0.75, 0.12, ’Davies , 1998’,
backgroundcolor=boxColors [1], color=’white ’, weight=’roman
’,
692 size=’medium ’)
plt.figtext (0.75, 0.09, ’*’, color=c2 , backgroundcolor=’white ’,
694 weight=’roman ’, fontsize =15)# size=’extralarge ’)
115
plt.figtext (0.765 , 0.095 , ’ Average Value ’, color=’black ’, weight
=’roman ’,
696 size=’medium ’)
698 plt.savefig(’IbupPK.png ’,bbox_inches=’tight ’,dpi =300)
plt.show()
./AppendixA/Ibuprofen gastric fluid.py
A.2.2 Ibuprofen 800 mg Model
1 # Import required libraries
import json , matplotlib




from IPython.core.pylabtools import figsize
7 import numpy as np
from scipy.integrate import odeint
9 from sympy.functions.special.delta_functions import Heaviside
import matplotlib.pyplot as plt
11 import matplotlib.cm as cm
import time
13
# Define custom Heaviside function
15 def u(t):
t = np.asarray(t)
17 is_scalar = False if t.ndim > 0 else True
t.shape = (1,)*(1-t.ndim) + t.shape
19 unit_step = np.arange(t.shape [0])
lcv = np.arange(t.shape [0])
21 for place in lcv:
if t[place] == 0:
23 unit_step[place] = .5
elif t[place] > 0:
25 unit_step[place] = 1
elif t[place] < 0:
27 unit_step[place] = 0
return (unit_step if not is_scalar else (unit_step [0] if
unit_step else Heaviside(t)))
29
# Gastric emptying parameters
31 p150 ,p1200 = 0.15, .14
p250 , p2200 = .285/( np.pi*15000) /60.0, .16/(np.pi*3900000) /60.0
33 p350 , p3200 = 6.65 -1/np.log (60.0) , 10.4 -1/np.log (60.0)
theta50 , theta200 = 1/60.0 , 1/60.0
35 tau50 , tau200 = 59.4*60, 60*60.0
s50 , s200 = 0.0001/60.0 , 0.1/60.0
37
116
# Gastric emptying functions for 50mL and 200mL volumes
39 def kge50ml(t):
sum = 0.0
41 for k in range (1,26):




45 sum = 0.0
for k in range (1,26):





51 a50 ,a200 = 2190/(50/60.0) ,2591/(100.0/60.0)
b50 ,b200 = 481/10*60.0, 141/10.*60.0
53 c50 ,c200 = 27/25. , 11/20.
d50 ,d200 = 531/25. ,138/5.
55 e50 ,e200 = 13/200./60.0 ,6/25./60.0
f50 ,f200 = 41/100./60.0 , -59/50./60.0
57
# Delay functions for 50mL and 200mL volumes
59 def tlag50ml(t):
return a50 - b50/(c50+d50*np.exp(-e50*np.mod(t,2/( theta50 /60.0))
+f50))
61 def tlag200ml(t):




65 Set up class for mass balance analysis
Take in time , dose time , plasma elimination rate , disintegration
rate ,
67 initial particle radius , resting volume vector , permeation rate
vector ,




def __init__(self , t, to , Kpel , Kdiss , ro , RestVol , PermRates ,
M0, title):
73 self.t = t
self.to = to
75 self.Kpel = Kpel
self.Kdiss = Kdiss
77 self.M0 = M0
self.title = title
79 self.perm0 ,self.perm1 ,self.perm2 ,self.perm3 ,self.perm4 ,self.
perm5 ,self.perm6 = PermRates
self.Grest ,self.Irest = RestVol
81 self.KIntFactors = np.array ([0.77 , 0.76, 0.75, 0.74, 0.73,
0.72, 0.7], float)
117
self.KIntShifts = np.array ([450*i for i in np.arange
(0 ,.3 ,.3/7)],float)*0.0
83
self.vol = M0[0] # Volume , mL
85 self.molwt = 206.3 # Molecular weight , g/mol
self.MT = M0[8] # Initial dose , mg
87 self.ro = ro # particle radius , um
self.Vpo = (4.0/3)*np.pi*(self.ro*1.0e-4)**3 # Particle
volume , cm^3
89 self.Pp = 1.1e3 # Particle density , mg/cm^3
self.N = (self.MT)/(self.Vpo*self.Pp) # Number of
particles
91 self.C0 = .066 # Intrinsic solubility at 37C,
g/L
self.pKa = 4.4 # Logarithmic acid
dissociation constant
93 self.Ka = 10.0**(-self.pKa) # Acid dissociation
constant
self.krel = 27.63/60/60 # Release rate from solid
dosage ( sec ^ -1)
95 self.peff = 1.413*5.84**-4 # Peff (cm/sec)
self.kel = 0.0001925 # Plasma elimination rate (
sec ^ -1)
97 self.DHA = 7.5e-6 # diffusivity , cm^2/s
self.heff = 30e-4 # effective boundary layer , cm
99
self.pHS ,self.pHInt0 ,self.pHInt1 ,self.pHInt2 ,self.pHInt3 ,self.
pHInt4 ,self.pHInt5 ,self.pHInt6 = np.array
([2 ,5 ,5.5 ,6 ,6.63 ,7.41 ,7.49 ,7.5] , dtype=’float ’)
101 self.rS,self.rInt0 ,self.rInt1 ,self.rInt2 ,self.rInt3 ,self.rInt4
,self.rInt5 ,self.rInt6 = np.ones (8)*self.ro*1.0e-4
103 # Emptying rate factor as function of particle radius
def kge_mod(self ,r):
105 return 1.01 -.99/(1.0+10.0*np.exp(-r*25+2.47))
107 # Delayed gastric emptying function for small particules and
solutions
def Kge(self ,t,to):
109 self.t = t
self.to = to
111 T = np.mod(t+to ,120.0*60.0)
if (t+to <120.0*60.0): return u(T-tlag200ml(t+to))*kge200ml(t+
to)
113 else: return u(T-tlag50ml(t+to))*kge50ml(t+to)
115 # Intestinal transit functions
def KInt0(self ,t,to):
117 return self.KIntFactors [0]*self.Kge(t-self.KIntShifts [0],to)
def KInt1(self ,t,to):
119 return self.KIntFactors [1]*self.Kge(t-self.KIntShifts [1],to)
def KInt2(self ,t,to):
121 return self.KIntFactors [2]*self.Kge(t-self.KIntShifts [2],to)
def KInt3(self ,t,to):
118
123 return self.KIntFactors [3]*self.Kge(t-self.KIntShifts [3],to)
def KInt4(self ,t,to):
125 return self.KIntFactors [4]*self.Kge(t-self.KIntShifts [4],to)
def KInt5(self ,t,to):
127 return self.KIntFactors [5]*self.Kge(t-self.KIntShifts [5],to)
def Kie(self ,t,to):
129 return self.KIntFactors [6]*self.Kge(t-self.KIntShifts [6],to)







139 # Gastric secretion function
def Kgs(self ,VS ,t,to):
141 return 2*self.Grest*self.Kge(t,to)/(VS+self.Grest)
143 # Take as input the pH and particulate mass
# Determine solubility , number of particles , individual radius ,
145 # effective boundary layer and surface area
def part_props(self ,pH , Mp):
147 S = self.C0*(1+(10**-self.pKa)/(10**-pH))
N = Mp/(self.Vpo*self.Pp)
149 if N<=1e-9: r = 0
# ((wt/no. particles) / (density))^1/3 = (mg/(mg/cm^3))^1/3 =
cm
151 else: r = (3*(Mp/N)/(self.Pp*4.0*np.pi))**(1./3)
if (r <= 1e-9 or np.isnan(r)):
153 r = 0
heff = 1e22
155 A = 0.0
else:
157 heff = 1/(1/r+1/.003)
A = 4.0*np.pi*r**2*N
159 return [S,r,heff ,A]
161 # Calculate radius based on mass remaining
def solid_rad(self ,Dmass):
163 if Dmass <=1e-6: return 0.0
else: return (Dmass /(self.Pp /1000.0) /(4*np.pi /3.0))**(1/3.)
165
# System of equations
167 def dM(self ,M,t):
self.M = M
169 self.t = t
171 VS , VInt0 , VInt1 , VInt2 , VInt3 , VInt4 , VInt5 , VInt6 = M[0:8]
DSolids , DSolidInt0 , DSolidInt1 , DSolidInt2 , DSolidInt3 ,
DSolidInt4 , DSolidInt5 , DSolidInt6 = M[8:16]
173 DParts , DPartInt0 , DPartInt1 , DPartInt2 , DPartInt3 , DPartInt4 ,
DPartInt5 , DPartInt6 = M[16:24]
119
DSolns , DSolnInt0 , DSolnInt1 , DSolnInt2 , DSolnInt3 , DSolnInt4 ,
DSolnInt5 , DSolnInt6 , DSolnPlasma = M[24:33]
175
SS ,rS ,hS ,AS = self.part_props(self.pHS ,DParts)
177 SInt0 ,rInt0 ,hInt0 ,AInt0 = self.part_props(self.pHInt0 ,
DPartInt0)
SInt1 ,rInt1 ,hInt1 ,AInt1 = self.part_props(self.pHInt1 ,
DPartInt1)
179 SInt2 ,rInt2 ,hInt2 ,AInt2 = self.part_props(self.pHInt2 ,
DPartInt2)
SInt3 ,rInt3 ,hInt3 ,AInt3 = self.part_props(self.pHInt3 ,
DPartInt3)
181 SInt4 ,rInt4 ,hInt4 ,AInt4 = self.part_props(self.pHInt4 ,
DPartInt4)
SInt5 ,rInt5 ,hInt5 ,AInt5 = self.part_props(self.pHInt5 ,
DPartInt5)
183 SInt6 ,rInt6 ,hInt6 ,AInt6 = self.part_props(self.pHInt6 ,
DPartInt6)
185 VS_ = VS*(self.Kgs(VS ,t,self.to)-self.Kge(t,self.to))
VInt0_ = VS*self.Kge(t,self.to) - VInt0*self.KInt0(t,self.to)
187 VInt1_ = VInt0*self.KInt0(t,self.to) - VInt1*self.KInt1(t,self
.to) + VInt2*self.Q1(t,self.to)
VInt2_ = VInt1*self.KInt1(t,self.to) - VInt2*(self.KInt2(t,
self.to) + self.Q1(t,self.to))
189 VInt3_ = VInt2*self.KInt2(t,self.to) - VInt3*self.KInt3(t,self
.to) + VInt4*self.Q2(t,self.to)
VInt4_ = VInt3*self.KInt3(t,self.to) - VInt4*(self.KInt4(t,
self.to)+self.Q2(t,self.to))
191 VInt5_ = VInt4*self.KInt4(t,self.to) - VInt5*self.KInt5(t,self
.to) + VInt6*self.Q3(t,self.to)
VInt6_ = VInt5*self.KInt5(t,self.to) - VInt6*(self.Kie(t,self.
to)+self.Q3(t,self.to))
193
# Solid drug undergoing disintegration
195 # amount(g) / (1.1 g/cm^3) = cm^3
# radius of solid = (vol/(4*pi/3))^(1/3) cm
197 DSolids_ = (-DSolids*(self.Kge(t,self.to)*self.kge_mod(self.
solid_rad(DSolids)) + self.Kdiss))
199 DSolidInt0_ =( DSolids*self.Kge(t,self.to)*self.kge_mod(self.
solid_rad(DSolids)) - DSolidInt0*(self.KInt0(t,self.to) + self
.Kdiss))
201 DSolidInt1_ = (DSolidInt0*self.KInt0(t,self.to) - DSolidInt1*(
self.KInt1(t,self.to) + self.Kdiss) + DSolidInt2*self.Q1(t,
self.to))
DSolidInt2_ = (DSolidInt1*self.KInt1(t,self.to) - DSolidInt2*(
self.KInt2(t,self.to) + self.Q1(t,self.to) + self.Kdiss))
203
DSolidInt3_ = (DSolidInt2*self.KInt2(t,self.to) - DSolidInt3*(
self.KInt3(t,self.to) + self.Kdiss) + DSolidInt4*self.Q2(t,
self.to))
120
205 DSolidInt4_ = (DSolidInt3*self.KInt3(t,self.to) - DSolidInt4*(
self.KInt4(t,self.to) + self.Q2(t,self.to) + self.Kdiss))
207 DSolidInt5_ = (DSolidInt4*self.KInt4(t,self.to) - DSolidInt5*(
self.KInt5(t,self.to) + self.Kdiss) + DSolidInt6*self.Q3(t,
self.to))
DSolidInt6_ = (DSolidInt5*self.KInt5(t,self.to) - DSolidInt6*(
self.Kie(t,self.to) + self.Q3(t,self.to) + self.Kdiss))
209
# Drug particulates in suspension
211 DParts_ = (-DParts*(self.Kge(t,self.to) + AS*self.DHA/hS*(SS -
DSolns/VS)) + self.Kdiss*DSolids)
213 DPartInt0_ = (DParts*self.Kge(t,self.to) - DPartInt0*(self.
KInt0(t,self.to)
+ (AInt0*self.DHA/hInt0*(SInt0 -DSolnInt0/VInt0))) + self.Kdiss
*DSolidInt0)
215
DPartInt1_ = (DPartInt0*self.KInt0(t,self.to) - DPartInt1*(
self.KInt1(t,self.to)
217 + (AInt1*self.DHA/hInt1*(SInt1 -DSolnInt1/VInt1))) + DPartInt2*
self.Q1(t,self.to) + self.Kdiss*DSolidInt1)
DPartInt2_ = (DPartInt1*self.KInt1(t,self.to) - DPartInt2*(
self.KInt2(t,self.to)
219 + (AInt2*self.DHA/hInt2*(SInt2 -DSolnInt2/VInt2))) + self.Kdiss
*DSolidInt2)
221 DPartInt3_ = (DPartInt2*self.KInt2(t,self.to) - DPartInt3*(
self.KInt3(t,self.to)
+ (AInt3*self.DHA/hInt3*(SInt3 -DSolnInt3/VInt3))) + DPartInt4*
self.Q2(t,self.to) + self.Kdiss*DSolidInt3)
223 DPartInt4_ = (DPartInt3*self.KInt3(t,self.to) - DPartInt4*(
self.KInt4(t,self.to)
+ (AInt4*self.DHA/hInt4*(SInt4 -DSolnInt4/VInt4))) + self.Kdiss
*DSolidInt4)
225
DPartInt5_ = (DPartInt4*self.KInt4(t,self.to) - DPartInt5*(
self.KInt5(t,self.to)
227 + (AInt5*self.DHA/hInt5*(SInt5 -DSolnInt5/VInt5))) + DPartInt6*
self.Q3(t,self.to) + self.Kdiss*DSolidInt5)
DPartInt6_ = (DPartInt5*self.KInt5(t,self.to) - DPartInt6*(
self.Kie(t,self.to)
229 + (AInt6*self.DHA/hInt6*(SInt6 -DSolnInt6/VInt6))) + self.Kdiss
*DSolidInt6)
231
# Solution of dissolved drug
233 DSolns_ = (-DSolns*self.Kge(t,self.to) + (AS*self.DHA/hS*(SS -
DSolns/VS))*DParts)




237 DSolnInt1_ = (DSolnInt0*self.KInt0(t,self.to) - DSolnInt1*(
self.KInt1(t,self.to) + self.perm1) + DSolnInt2*self.Q1(t,self
.to)
+ (AInt1*self.DHA/hInt0*(SInt1 -DSolnInt1/VInt1))*DPartInt1)
239 DSolnInt2_ = (DSolnInt1*self.KInt1(t,self.to) - DSolnInt2*(
self.KInt2(t,self.to) + self.Q1(t,self.to) + self.perm2)
+ (AInt2*self.DHA/hInt1*(SInt2 -DSolnInt2/VInt2))*DPartInt2)
241 DSolnInt3_ = (DSolnInt2*self.KInt2(t,self.to) - DSolnInt3*(
self.KInt3(t,self.to) + self.perm3) + DSolnInt4*self.Q2(t,self
.to)
+ (AInt3*self.DHA/hInt2*(SInt3 -DSolnInt3/VInt3))*DPartInt3)
243 DSolnInt4_ = (DSolnInt3*self.KInt3(t,self.to) - DSolnInt4*(
self.KInt4(t,self.to) + self.Q2(t,self.to) + self.perm4)
+ (AInt4*self.DHA/hInt3*(SInt4 -DSolnInt4/VInt4))*DPartInt4)
245 DSolnInt5_ = (DSolnInt4*self.KInt4(t,self.to) - DSolnInt5*(
self.KInt5(t,self.to) + self.perm5) + DSolnInt6*self.Q3(t,self
.to)
+ (AInt5*self.DHA/hInt4*(SInt5 -DSolnInt5/VInt5))*DPartInt5)
247 DSolnInt6_ = (DSolnInt5*self.KInt5(t,self.to) - DSolnInt6*(
self.Kie(t,self.to) + self.Q3(t,self.to) + self.perm6)
+ (AInt6*self.DHA/hInt5*(SInt6 -DSolnInt6/VInt6))*DPartInt6)
249 DSolnPlasma_ = (DSolnInt0*self.perm0 + DSolnInt1*self.perm1 +
DSolnInt2*self.perm2
+ DSolnInt3*self.perm3 + DSolnInt4*self.perm4 + DSolnInt5*
self.perm5
251 + DSolnInt6*self.perm6 - DSolnPlasma*self.Kpel)
253 Mnew = np.array ([VS_ ,VInt0_ ,VInt1_ ,VInt2_ ,VInt3_ ,VInt4_ ,VInt5_
,VInt6_ ,
DSolids_ ,DSolidInt0_ ,DSolidInt1_ ,DSolidInt2_ ,DSolidInt3_ ,
DSolidInt4_ ,DSolidInt5_ ,DSolidInt6_ ,
255 DParts_ ,DPartInt0_ ,DPartInt1_ ,DPartInt2_ ,DPartInt3_ ,
DPartInt4_ ,DPartInt5_ ,DPartInt6_ ,
DSolns_ ,DSolnInt0_ ,DSolnInt1_ ,DSolnInt2_ ,DSolnInt3_ ,
DSolnInt4_ ,DSolnInt5_ ,DSolnInt6_ ,DSolnPlasma_],dtype=’float ’)
257 return Mnew
259 # Call for solving system of equations
def solveSys(self ,t):
261 self.t = t
# Solve system of equations
263 start_time = time.time()
Mresult = odeint(self.dM ,self.M0 ,t,rtol=1e-6, atol=1e-6)#
mxstep =500, hmax =50)





A.3 Manometry signal analsysis
A.3.1 Kernel Density Estimation
1 # Import required libraries
import json , matplotlib





7 from IPython.core.pylabtools import figsize
import numpy as np
9 from matplotlib import pyplot as plt
import matplotlib.patches as patches
11 import seaborn as sns
from sklearn.gaussian_process import GaussianProcess
13 from scipy.signal import detrend
from scipy.signal import medfilt
15 import time , sys
from joblib import Parallel , delayed
17 import multiprocessing
19 # Determine number of cores
num_cores = multiprocessing.cpu_count ()
21
# Loads the data to be analysed.
23 data1 = np.loadtxt ( ’00540301 _01.csv ’)
data2 = np.loadtxt ( ’00540301 _02.csv ’)
25 data3 = np.loadtxt ( ’00540301 _03.csv ’)
data4 = np.loadtxt ( ’00540301 _04.csv ’)
27 data5 = np.loadtxt ( ’00540301 _05.csv ’)
data6 = np.loadtxt ( ’00540301 _06.csv ’)
29 data7 = np.loadtxt ( ’00540301 _07.csv ’)
data8 = np.loadtxt ( ’00540301 _08.csv ’)
31 data9 = np.loadtxt ( ’00540301 _09.csv ’)
data10 = np.loadtxt ( ’00540301 _10.csv ’)
33 data11 = np.loadtxt ( ’00540301 _11.csv ’)
data12 = np.loadtxt ( ’00540301 _12.csv ’)
35 data13 = np.loadtxt ( ’00540301 _13.csv ’)
mydata = np.array ([data1 ,data2 ,data3 ,data4 ,data5 ,data6 ,data7 ,data8
,data9 ,data10 ,data11 ,data12 ,data13 ]).T
37 dataMat1 = np.array ([data1 ,data2 ,data3 ,data4 ]).T
dataMat2 = np.array ([data7 ,data8 ,data9 ,data10 ,data11 ,data12 ,data13
]).T
39
# Baseline correction via scipy.signal
41 mydata_corr = []
[mydata_corr.append(detrend(mydata[:,i])) for i in range(mydata.
shape [1])]
43 mydata_corr = np.squeeze(np.transpose(mydata_corr))
123
45 # sampling frequency: 10Hz
samp_freq = 10
47
# total time (minutes)
49 N = len(mydata)
T = N/samp_freq /60.0
51 ts = np.linspace(0,T,num=N)
53 min_snr , noise_perc = 1,2 # 1.0, 0.3, 2
widths = np.array ([2**i for i in range(0,np.mod(2**(samp_freq),
samp_freq) ,1)])
55 min_thres = 50.0










67 Pre -spike activity in phase III portion of signal that is not seen
in other regions
’’’
69 f, ax = plt.subplots(nrows=3,ncols=3,dpi=120, sharex=False ,sharey=
True ,figsize =(15.5 ,8))
plt.subplots_adjust(hspace =0.25 , wspace =0.1)
71 f.suptitle("Pre -spike Activity", fontsize =12)
ax[0,0]. set_title(’Phase I’)
73 ax[0,1]. set_title(’Phase II ’)
ax[0,2]. set_title(’Phase III ’)
75 ax[1,0]. set_ylabel(’Pressure (mmHg)’)
ax[2,1]. set_xlabel(’Time (min)’)
77
t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i]-50)),min(
range(len(ts)), key=lambda i: abs(ts[i]-90))
79 ax[0,2]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
ax[0,2]. set_xlim(ts[t0],ts[t1])
81 t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i]-64)),min(
range(len(ts)), key=lambda i: abs(ts[i]-70))
ax[1,2]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
83 ax[1,2]. set_xlim(ts[t0],ts[t1])
t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i] -64.5)),min(
range(len(ts)), key=lambda i: abs(ts[i] -65.5))
85 ax[2,2]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
ax[2,2]. set_xlim(ts[t0],ts[t1])
87
t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i] -120)),min(
range(len(ts)), key=lambda i: abs(ts[i] -160))
89 ax[0,1]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
ax[0,1]. set_xlim(ts[t0],ts[t1])
124
91 t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i] -135)),min(
range(len(ts)), key=lambda i: abs(ts[i] -141))
ax[1,1]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
93 ax[1,1]. set_xlim(ts[t0],ts[t1])
t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i] -140)),min(
range(len(ts)), key=lambda i: abs(ts[i] -141))
95 ax[2,1]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
#ax[2 ,1]. set_xlim(ts[0],ts[t1])
97
t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i]-90)),min(
range(len(ts)), key=lambda i: abs(ts[i] -130))
99 ax[0,0]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
ax[0,0]. set_xlim(ts[t0],ts[t1])
101 t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i]-92)),min(
range(len(ts)), key=lambda i: abs(ts[i]-99))
ax[1,0]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
103 ax[1,0]. set_xlim(ts[t0],ts[t1])
t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i]-94)),min(
range(len(ts)), key=lambda i: abs(ts[i]-95))
105 ax[2,0]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
ax[2,0]. set_xlim(ts[t0],ts[t1])
107
ax[0,2]. add_patch(patches.Rectangle ((64 ,0) ,6,180,fill=False ,
edgecolor="g",linewidth =5,alpha =.5))
109 ax[1,2]. arrow( 64.8, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
ax[1,2]. arrow( 64.95, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
111 ax[1,2]. arrow( 64.2, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
ax[1,2]. arrow( 64.3, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
113 ax[1,2]. arrow( 65.60, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
ax[1,2]. arrow( 65.70, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
115 ax[1,2]. arrow( 67.15, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
ax[1,2]. arrow( 67.25, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
117 ax[1,2]. arrow( 67.95, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
ax[1,2]. arrow( 68.10, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
119 ax[1,2]. arrow( 68.7, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
ax[1,2]. arrow( 68.9, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
121 ax[2,2]. arrow( 65.0, 175, 0, -60, fc="k", ec="k",head_width =0.05,
head_length =10)




ax[0,1]. add_patch(patches.Rectangle ((135 ,0) ,6,180,fill=False ,
edgecolor="g",linewidth =5,alpha =.5))
125 ax[1,1]. arrow( 131.75 , 175, 0, -60, fc="k", ec="k",head_width
=0.15, head_length =10)
ax[1,1]. arrow( 132.5, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
127 ax[1,1]. arrow( 135.75 , 175, 0, -60, fc="k", ec="k",head_width
=0.15, head_length =10)
ax[1,1]. arrow( 140.3, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
129 ax[2,1]. arrow( 140.25 , 175, 0, -60, fc="k", ec="k",head_width
=0.06, head_length =10)
131 ax[0,0]. add_patch(patches.Rectangle ((92 ,0) ,6,180,fill=False ,
edgecolor="g",linewidth =5,alpha =.5))
ax[1,0]. arrow( 94.55, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
133 ax[2,0]. arrow( 94.55, 175, 0, -60, fc="k", ec="k",head_width =0.05,
head_length =10)
plt.savefig(’pre_spike_activity.png ’, bbox_inches=’tight ’,dpi =300)
135
’’’
137 Set up class for Gaussian process analysis
Take in data vector , time vector , optionally the nugget , minimum
lengths for phases III and II ,





def __init__(self , data , ts , nugget =.2, p3_delta=4, p2_delta=2,
theta0 =5e-1, thetaL =1e-3, thetaU =1):
145 self.data = data
self.ts = ts
147 # Divide signal into <step > segments
self.M = self.data.shape [0]
149 self.delta = 30 # Fit data in increments of 30 time steps
self.step = np.int(self.M/self.delta*1.0)
151
# self.nugget_ = None
153 # if nugget ==None: self.nugget = (np.var(data)/data)**2
# else: self.nugget = nugget
155 self.nugget = nugget
157 self.X_, self.y_ ,self.sigma_ = [],[],[]
159 self.bar_length = 20
self.step_range = range(1,self.delta)
161









# Function to fit Gaussian process in increments
171 def fit_data(self):
start_time = time.time()
173 for i in self.step_range:
step_i = i
175
count_data = np.copy(self.data[(step_i -1)*self.step:step_i*
self.step])
177 # count_data[count_data <0] = 0
n_count_data = len(count_data)
179
X, y = ts[(step_i -1)*self.step:step_i*self.step][:,None],
count_data
181 # if len(self.nugget) >1: self.nugget_ = self.nugget [(step_i
-1)*self.step:step_i*self.step]
# else: self.nugget_ = self.nugget
183
# Estimate probable signal mean for segment using
185 # Gaussian process
self.G = GaussianProcess(corr=’squared_exponential ’,




# Calculate the predicted pressure and the mean squared
error
191 X_pred = np.linspace(X.min(), X.max())[:, None]
y_pred , MSE = self.G.predict(X_pred , eval_MSE=True)
193 sigma = np.sqrt(MSE)





# Just a simple progress bar visualization
201 percent = float(i-self.step_range [0]) / (self.step_range
[-1]-self.step_range [0])
hashes = ’#’ * int(round(percent * self.bar_length))
203 spaces = ’ ’ * (self.bar_length - len(hashes))
runtime = int(time.time()-start_time)
205 sys.stdout.write("\rPercent: [{0}] {1}% completed in {2}




self.y_pctiles = np.percentile(np.ravel(self.y_) ,(25,75))
209
def contiguous_regions(self ,cond):
211 self.cond = cond
127
"""Finds contiguous True regions of the boolean array "
condition". Returns
213 a 2D array where the first column is the start index of the
region and the
second column is the end index."""
215 # Find the indicies of changes in "condition"
d = np.diff(self.cond)
217 idx , = d.nonzero ()
# We need to start things after the change in "condition".
Therefore ,
219 # we ’ll shift the index by 1 to the right.
idx += 1
221 if self.cond [0]:
# If the start of condition is True prepend a 0
223 idx = np.r_[0, idx]
if self.cond [-1]:
225 # If the end of condition is True , append the length of the
array
idx = np.r_[idx , self.cond.size] # Edit
227 # Reshape the result into two columns
idx.shape = (-1,2)
229 return idx
231 # Return summary of findings
def summary(self):
233 y__ = np.ravel(self.y_)
X__ = np.ravel(self.X_)
235 self.condition = y__ > self.y_pctiles [-1]
# Print the start and stop indicies of each region where the
absolute
237 # values of x are below 1, and the min and max of each of
these regions
for start , stop in self.contiguous_regions(self.condition):
239 segment = y__[start:stop]
seg_time = X__[stop]-X__[start]
241 if seg_time >= self.p3_delta:
print("--- Continuous segment length: %.2f min [%.2f : %.2




# figsize (12.5 , 4)
247 for i in range(len(self.step_range)):
step_i = i+self.step_range [0]
249
X__ ,y__ ,sigma__ = self.X_[i],self.y_[i],self.sigma_[i]
251
plt.plot(ts[(step_i -1)*self.step:step_i*self.step], self.
data[(step_i -1)*self.step:step_i*self.step], color="#348 ABD",
alpha =.25)
253 plt.plot(self.X_[i],self.y_[i],’g:’)
plt.plot(X__[y__ <self.y_pctiles [0]], y__[y__ <self.y_pctiles
[0]], ’k.’, label=u’PI ’)
128
255 plt.plot(X__[(self.y_pctiles [0]<=y__) * (y__ <self.y_pctiles
[1])], y__[(self.y_pctiles [0]<=y__) * (y__ <self.y_pctiles [1])
], ’b.’, label=u’PII ’)
plt.plot(X__[y__ >=self.y_pctiles [1]], y__[y__ >=self.
y_pctiles [1]], ’r.’, label=u’PIII ’)
257 plt.fill(np.concatenate ([X__ , X__ [:: -1]]),
np.concatenate ([y__ - 1.9600 * sigma__ ,
259 (y__ + 1.9600 * sigma__)[:: -1]]),
alpha =.3, fc=’k’, ec=’None ’, label =’95% confidence
interval ’)
261 # plt.legend(loc=’upper left ’)
def plot_regions(self):
263 y__ = np.ravel(self.y_)
X__ = np.ravel(self.X_)
265 self.condition = y__ > self.y_pctiles [-1]
267 plt.plot(self.ts ,self.data ,alpha =.5)
plt.xlim((self.ts[0],self.ts[-1]))
269 for start , stop in self.contiguous_regions(self.condition):
seg_time = X__[stop]-X__[start]
271 [ts_start ,ts_stop] = [np.abs(self.ts - X__[start ]).argmin (),
np.abs(self.ts - X__[stop]).argmin ()]
if seg_time >= self.p3_delta: plt.plot(self.ts[ts_start:
ts_stop],self.data[ts_start:ts_stop],’g’,alpha =1)
273
# Return summary of findings
275 def summary ():
cond1 = X_classified ==1
277 # Print the start and stop indicies of each region where the
absolute
# values of x are below 1, and the min and max of each of these
regions
279 for start , stop in contiguous_regions(cond1):
segment = X_classified[start:stop]
281 seg_time = ts[stop]-ts[start]
if seg_time >= 1: print("--- Phase I: %.2f min [%.2f : %.2f]
---" % (ts[stop]-ts[start],ts[start], ts[stop]))
283 cond2 = X_classified ==2
# Print the start and stop indicies of each region where the
absolute
285 # values of x are below 1, and the min and max of each of these
regions
for start , stop in contiguous_regions(cond2):
287 segment = X_classified[start:stop]
seg_time = ts[stop]-ts[start]
289 if seg_time >= 1: print("--- Phase II: %.2f min [%.2f : %.2f]
---" % (ts[stop]-ts[start],ts[start], ts[stop]))
cond3 = X_classified ==3
291 # Print the start and stop indicies of each region where the
absolute
# values of x are below 1, and the min and max of each of these
regions
293 for start , stop in contiguous_regions(cond3):
segment = X_classified[start:stop]
129
295 seg_time = ts[stop]-ts[start]
if seg_time >= 1: print("--- Phase III: %.2f min [%.2f : %.2f]
---" % (ts[stop]-ts[start],ts[start], ts[stop]))
297
def contiguous_regions(cond):
299 """Finds contiguous True regions of the boolean array "condition
". Returns
a 2D array where the first column is the start index of the
region and the
301 second column is the end index."""
# Find the indicies of changes in "condition"
303 d = np.diff(cond)
idx , = d.nonzero ()
305 # We need to start things after the change in "condition".
Therefore ,
# we ’ll shift the index by 1 to the right.
307 idx += 1
if cond [0]:
309 # If the start of condition is True prepend a 0
idx = np.r_[0, idx]
311 if cond [-1]:
# If the end of condition is True , append the length of the
array
313 idx = np.r_[idx , cond.size] # Edit
# Reshape the result into two columns




319 Use the test data from MMS (loaded above)
’’’
321
323 # Signal from first channel
indeces = [0]
325 X = np.ndarray ((len(indeces) ,),dtype=np.object)
for ind in range(len(indeces)):
327 X[ind] = GP_analysis(mydata_corr [:,indeces[ind]],ts=ts)
329 start_time = time.time()
for i in range(len(indeces)):
331 print("\n--- Channel %d ---" % indeces[i])
X[i]. fit_data ()
333 print("--- Parallelized execution completed: %s seconds ---" %
float(time.time() - float(start_time)))




341 figsize (7.5 ,3)
fig = plt.figure(dpi =120)
130
343 plt.plot(ts ,X[0].data ,alpha =.95, label=’Signal ’)
plt.xlim(ts[0],ts[-1])
345 plt.title(’Original Signal ’)
plt.ylabel(’Pressure (mmHg)’)
347 plt.xlabel(’Time (min)’)
plt.savefig(’gaus_process_fig0 ’, bbox_inches=’tight ’,dpi =300)
349 plt.show()
351 y__ = np.ravel(X[0].y_)
X__ = np.ravel(X[0].X_)
353 sigma__ = np.ravel(X[0]. sigma_)
condition = y__ > X[0]. y_pctiles [-1]
355
figsize (7.5 ,3)
357 fig = plt.figure(dpi =120)
plt.plot(ts ,X[0].data ,alpha =.25, label=’Signal ’)
359 plt.xlim(ts[0],ts[-1])
plt.plot(X__[y__ <X[0]. y_pctiles [0]], y__[y__ <X[0]. y_pctiles [0]], ’
k.’, label=u’Low ’)
361 plt.plot(X__[(X[0]. y_pctiles [0]<=y__) * (y__ <X[0]. y_pctiles [1])],
y__[(X[0]. y_pctiles [0]<=y__) * (y__ <X[0]. y_pctiles [1])], ’b.’,
label=u’Medium ’)
plt.plot(X__[y__ >=X[0]. y_pctiles [1]], y__[y__ >=X[0]. y_pctiles [1]],
’r.’, label=u’High ’)
363 plt.fill(np.concatenate ([X__ , X__ [:: -1]]),
np.concatenate ([y__ - 1.9600 * sigma__ ,
365 (y__ + 1.9600 * sigma__)[:: -1]]),
alpha=.3, fc=’k’, ec=’None ’, label =’95% CI ’)
367 plt.title(’Predicting Average Pressures ’)
plt.ylabel(’Pressure (mmHg)’)
369 plt.xlabel(’Time (min)’)
plt.legend(bbox_to_anchor =(1.05 , 1), loc=2, borderaxespad =0.)
371 plt.savefig(’gaus_process_fig1 ’, bbox_inches=’tight ’,dpi =300)
plt.show()
373
375 y__ = np.ravel(X[0].y_)
X__ = np.ravel(X[0].X_)
377 X_labeled = np.empty_like(X__)
X_labeled[y__ <X[0]. y_pctiles [0]] = 1
379 X_labeled [(X[0]. y_pctiles [0]<=y__) * (y__ <X[0]. y_pctiles [1])] = 2
X_labeled[y__ >=X[0]. y_pctiles [1]] = 3
381 y_filt = medfilt(medfilt(X_labeled ,kernel_size =21),kernel_size =21)
383 X_class = np.zeros(np.shape(ts))
385 plt.plot(ts ,mydata_corr [:,0],’:k’,alpha =.5)
plt.xlim((ts[0],ts[-1]))
387
condition = y_filt > 2 # y__ > X[0]. y_pctiles [-1]
389 ind = 1
tmp_reg = contiguous_regions(condition)
391 for start , stop in contiguous_regions(condition):
seg_time = X__[stop]-X__[start]
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393 [ts_start ,ts_stop] = [np.abs(ts - X__[start ]).argmin (),np.abs(ts
- X__[stop]).argmin ()]
395 X_class[ts_start:ts_stop] = 3
397 if seg_time >= 5: plt.plot(ts[ts_start:ts_stop],mydata_corr[
ts_start:ts_stop ,0],’r’,alpha =1)
399 if ind <len(tmp_reg):
if (X__[tmp_reg[ind ][0]] - X__[stop]<= 10):
401 [ts_start ,ts_stop] = [np.abs(ts - X__[stop]).argmin (),np.abs





405 condition = (y_filt <= 2) * (y_filt > 1)
# (y__ <= X[0]. y_pctiles [-1])*(y__ > X[0]. y_pctiles [0])
407 ind = 1
tmp_reg = contiguous_regions(condition)
409 for start , stop in contiguous_regions(condition):
if stop <len(X__):
411 seg_time = X__[stop]-X__[start]
[ts_start ,ts_stop] = [np.abs(ts - X__[start ]).argmin (),np.abs(
ts - X__[stop]).argmin ()]
413 X_class[ts_start:ts_stop] = 2




417 if (X__[tmp_reg[ind ][0]] - X__[stop]<= 5):
[ts_start ,ts_stop] = [np.abs(ts - X__[stop]).argmin (),np
.abs(ts - X__[tmp_reg[ind ][1]]).argmin ()]
419 X_class[ts_start:ts_stop] = 2
plt.plot(ts[ts_start:ts_stop],mydata_corr[ts_start:
ts_stop ,0],’b’,alpha =.5)
421 ind += 1
condition = (y_filt == 1)
423
ind = 1
425 tmp_reg = contiguous_regions(condition)
for start , stop in contiguous_regions(condition):
427 if stop <len(X__):
seg_time = X__[stop]-X__[start]
429 [ts_start ,ts_stop] = [np.abs(ts - X__[start ]).argmin (),np.abs(
ts - X__[stop]).argmin ()]
X_class[ts_start:ts_stop] = 1
431 if seg_time >= 1:
if ind <len(tmp_reg):
433 if (X__[tmp_reg[ind ][0]] - X__[stop]<= 30):
[ts_start ,ts_stop] = [np.abs(ts - X__[stop]).argmin (),np
.abs(ts - X__[tmp_reg[ind ][1]]).argmin ()]




437 ind += 1
439 ’’’
Make sure the transitions are appropriate , else it is a false
positive detection
441
1 -> 2: -1
443 2 -> 3: -1
3 -> 1: 2
445
1 -> 3: -2
447 2 -> 1: 1





453 for i in range(len(X_class) -1):
if (X_classified[i]-X_classified[i+1]== -2): X_classified[i+1]
= X_classified[i]+1
455 elif (X_classified[i]-X_classified[i+1]==1): X_classified[i+1]
= X_classified[i]
457 figsize (7.5 ,7)
sns.set_style("whitegrid")
459 f, (ax2 ,ax0 ,ax1) = plt.subplots(nrows=3,ncols=1,dpi=120, sharex=
True ,sharey=False)
ax2.plot(ts ,mydata_corr [:,0],’:k’,alpha=.5, label=u’Signal ’)
461 ax2.set_xlim ((ts[0],ts[-1]))
ax2.set_ylim ((-5,250))
463 ax2.plot(ts[X_classified ==1], mydata_corr[X_classified ==1,0], ’.g
’, label=u’PI ’)
ax2.plot(ts[X_classified ==2], mydata_corr[X_classified ==2,0], ’.b
’, label=u’PII ’)




ax2.legend(loc=’upper center ’, bbox_to_anchor =(0.5 , 1.05),
469 ncol=4, fancybox=True , shadow=True)
ax2.text(10, 190, ’58.60 min ’, style=’normal ’,
471 bbox={’facecolor ’:’blue ’, ’alpha ’:0.25 , ’pad ’:10})
ax2.text(60, 190, ’24.80 min ’, style=’normal ’,
473 bbox={’facecolor ’:’red ’, ’alpha ’:0.25 , ’pad ’:10})
ax2.text (110, 190, ’71.33 min ’, style=’normal ’,
475 bbox={’facecolor ’:’green ’, ’alpha ’:0.25 , ’pad ’:10})
ax2.text (165, 190, ’55.42 min ’, style=’normal ’,
477 bbox={’facecolor ’:’blue ’, ’alpha ’:0.25 , ’pad ’:10})
ax2.text (210, 190, ’27.54 min ’, style=’normal ’,





majorticks = np.array ([1,2,3], dtype=’float ’)/3*.009
485 ax0.set_yticks(majorticks)
ax0.set_yticklabels ([’I’,’II ’,’III ’])
487 ax0.set_xlim ((ts[0],ts[-1]))
sns.rugplot(np.array(data), c=c1 , ax=ax0)
489
# Set up the plots
491 c1, c2 = sns.color_palette("husl", 3)[:2]
# Plot the summed basis functions
493 summed_kde = np.sum(kernels , axis =0)
# ax1.plot(xx, summed_kde , c=c1)
495 sns.kdeplot(np.array(data), bw=bandwidth , linewidth=1, shade=True ,
color=c1, label=r’Peak Density ’, ax=ax1)




plt.savefig(’gaus_process_fig2 ’, bbox_inches=’tight ’,dpi =300)
./AppendixA/gauss proc.py
A.3.2 Gaussian Process Regression
# Import required libraries
2 import json , matplotlib




from IPython.core.pylabtools import figsize
8 import numpy as np
from matplotlib import pyplot as plt
10 import matplotlib.patches as patches
import seaborn as sns
12 from sklearn.gaussian_process import GaussianProcess
from scipy.signal import detrend
14 from scipy.signal import medfilt
import time , sys
16 from joblib import Parallel , delayed
import multiprocessing
18
# Determine number of cores
20 num_cores = multiprocessing.cpu_count ()
22 # Loads the data to be analysed.
data1 = np.loadtxt ( ’00540301 _01.csv ’)
24 data2 = np.loadtxt ( ’00540301 _02.csv ’)
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data3 = np.loadtxt ( ’00540301 _03.csv ’)
26 data4 = np.loadtxt ( ’00540301 _04.csv ’)
data5 = np.loadtxt ( ’00540301 _05.csv ’)
28 data6 = np.loadtxt ( ’00540301 _06.csv ’)
data7 = np.loadtxt ( ’00540301 _07.csv ’)
30 data8 = np.loadtxt ( ’00540301 _08.csv ’)
data9 = np.loadtxt ( ’00540301 _09.csv ’)
32 data10 = np.loadtxt ( ’00540301 _10.csv ’)
data11 = np.loadtxt ( ’00540301 _11.csv ’)
34 data12 = np.loadtxt ( ’00540301 _12.csv ’)
data13 = np.loadtxt ( ’00540301 _13.csv ’)
36 mydata = np.array ([data1 ,data2 ,data3 ,data4 ,data5 ,data6 ,data7 ,data8
,data9 ,data10 ,data11 ,data12 ,data13 ]).T
dataMat1 = np.array ([data1 ,data2 ,data3 ,data4 ]).T
38 dataMat2 = np.array ([data7 ,data8 ,data9 ,data10 ,data11 ,data12 ,data13
]).T
40 # Baseline correction via scipy.signal
mydata_corr = []




# sampling frequency: 10Hz
46 samp_freq = 10
48 # total time (minutes)
N = len(mydata)
50 T = N/samp_freq /60.0
ts = np.linspace(0,T,num=N)
52
min_snr , noise_perc = 1,2 # 1.0, 0.3, 2




f = plt.figure(figsize =(8.5 ,4),dpi =120)






64 plt.savefig(’signal1.png ’,dpi =300)
66 ’’’
Pre -spike activity in phase III portion of signal that is not seen
in other regions
68 ’’’
f, ax = plt.subplots(nrows=3,ncols=3,dpi=120, sharex=False ,sharey=
True ,figsize =(15.5 ,8))
70 plt.subplots_adjust(hspace =0.25 , wspace =0.1)
f.suptitle("Pre -spike Activity", fontsize =12)
72 ax[0,0]. set_title(’Phase I’)
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ax[0,1]. set_title(’Phase II ’)
74 ax[0,2]. set_title(’Phase III ’)
ax[1,0]. set_ylabel(’Pressure (mmHg)’)
76 ax[2,1]. set_xlabel(’Time (min)’)
78 t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i]-50)),min(
range(len(ts)), key=lambda i: abs(ts[i]-90))
ax[0,2]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
80 ax[0,2]. set_xlim(ts[t0],ts[t1])
t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i]-64)),min(
range(len(ts)), key=lambda i: abs(ts[i]-70))
82 ax[1,2]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
ax[1,2]. set_xlim(ts[t0],ts[t1])
84 t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i] -64.5)),min(
range(len(ts)), key=lambda i: abs(ts[i] -65.5))
ax[2,2]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
86 ax[2,2]. set_xlim(ts[t0],ts[t1])
88 t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i] -120)),min(
range(len(ts)), key=lambda i: abs(ts[i] -160))
ax[0,1]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
90 ax[0,1]. set_xlim(ts[t0],ts[t1])
t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i] -135)),min(
range(len(ts)), key=lambda i: abs(ts[i] -141))
92 ax[1,1]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
ax[1,1]. set_xlim(ts[t0],ts[t1])
94 t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i] -140)),min(
range(len(ts)), key=lambda i: abs(ts[i] -141))
ax[2,1]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
96 #ax[2 ,1]. set_xlim(ts[0],ts[t1])
98 t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i]-90)),min(
range(len(ts)), key=lambda i: abs(ts[i] -130))
ax[0,0]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
100 ax[0,0]. set_xlim(ts[t0],ts[t1])
t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i]-92)),min(
range(len(ts)), key=lambda i: abs(ts[i]-99))
102 ax[1,0]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
ax[1,0]. set_xlim(ts[t0],ts[t1])
104 t0, t1 = min(range(len(ts)), key=lambda i: abs(ts[i]-94)),min(
range(len(ts)), key=lambda i: abs(ts[i]-95))
ax[2,0]. plot(ts[t0:t1],mydata_corr[t0:t1 ,0], alpha =.75)
106 ax[2,0]. set_xlim(ts[t0],ts[t1])
108 ax[0,2]. add_patch(patches.Rectangle ((64 ,0) ,6,180,fill=False ,
edgecolor="g",linewidth =5,alpha =.5))
ax[1,2]. arrow( 64.8, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
110 ax[1,2]. arrow( 64.95, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
ax[1,2]. arrow( 64.2, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
112 ax[1,2]. arrow( 64.3, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
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ax[1,2]. arrow( 65.60, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
114 ax[1,2]. arrow( 65.70, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
ax[1,2]. arrow( 67.15, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
116 ax[1,2]. arrow( 67.25, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
ax[1,2]. arrow( 67.95, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
118 ax[1,2]. arrow( 68.10, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
ax[1,2]. arrow( 68.7, 175, 0, -60, fc="r", ec="r",head_width =0.15,
head_length =10)
120 ax[1,2]. arrow( 68.9, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
ax[2,2]. arrow( 65.0, 175, 0, -60, fc="k", ec="k",head_width =0.05,
head_length =10)
122 ax[2,2]. arrow( 64.85, 175, 0, -60, fc="r", ec="r",head_width =0.05,
head_length =10)
124 ax[0,1]. add_patch(patches.Rectangle ((135 ,0) ,6,180,fill=False ,
edgecolor="g",linewidth =5,alpha =.5))
ax[1,1]. arrow( 131.75 , 175, 0, -60, fc="k", ec="k",head_width
=0.15, head_length =10)
126 ax[1,1]. arrow( 132.5, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
ax[1,1]. arrow( 135.75 , 175, 0, -60, fc="k", ec="k",head_width
=0.15, head_length =10)
128 ax[1,1]. arrow( 140.3, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
ax[2,1]. arrow( 140.25 , 175, 0, -60, fc="k", ec="k",head_width
=0.06, head_length =10)
130
ax[0,0]. add_patch(patches.Rectangle ((92 ,0) ,6,180,fill=False ,
edgecolor="g",linewidth =5,alpha =.5))
132 ax[1,0]. arrow( 94.55, 175, 0, -60, fc="k", ec="k",head_width =0.15,
head_length =10)
ax[2,0]. arrow( 94.55, 175, 0, -60, fc="k", ec="k",head_width =0.05,
head_length =10)
134 plt.savefig(’pre_spike_activity.png ’, bbox_inches=’tight ’,dpi =300)
136 ’’’
Set up class for Gaussian process analysis
138 Take in data vector , time vector , optionally the nugget , minimum
lengths for phases III and II ,
the theta value and ranges (see documentation)
140 ’’’
142 class GP_analysis:
144 def __init__(self , data , ts , nugget =.2, p3_delta=4, p2_delta=2,
theta0 =5e-1, thetaL =1e-3, thetaU =1):
self.data = data
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146 self.ts = ts
# Divide signal into <step > segments
148 self.M = self.data.shape [0]
self.delta = 30 # Fit data in increments of 30 time steps
150 self.step = np.int(self.M/self.delta*1.0)
152 # self.nugget_ = None
# if nugget ==None: self.nugget = (np.var(data)/data)**2
154 # else: self.nugget = nugget
self.nugget = nugget
156
self.X_, self.y_,self.sigma_ = [],[],[]
158
self.bar_length = 20
160 self.step_range = range(1,self.delta)




168 self.G = None
170 # Function to fit Gaussian process in increments
def fit_data(self):
172 start_time = time.time()
for i in self.step_range:
174 step_i = i
176 count_data = np.copy(self.data[(step_i -1)*self.step:step_i*
self.step])
# count_data[count_data <0] = 0
178 n_count_data = len(count_data)
180 X, y = ts[(step_i -1)*self.step:step_i*self.step][:,None],
count_data
# if len(self.nugget) >1: self.nugget_ = self.nugget [(step_i
-1)*self.step:step_i*self.step]
182 # else: self.nugget_ = self.nugget
184 # Estimate probable signal mean for segment using
# Gaussian process
186 self.G = GaussianProcess(corr=’squared_exponential ’,
theta0=self.theta0 , thetaL=self.thetaL , thetaU=self.thetaU
,nugget=self.nugget)
188 self.G.fit(X, y)
190 # Calculate the predicted pressure and the mean squared
error
X_pred = np.linspace(X.min(), X.max())[:, None]








200 # Just a simple progress bar visualization
percent = float(i-self.step_range [0]) / (self.step_range
[-1]-self.step_range [0])
202 hashes = ’#’ * int(round(percent * self.bar_length))
spaces = ’ ’ * (self.bar_length - len(hashes))
204 runtime = int(time.time()-start_time)
sys.stdout.write("\rPercent: [{0}] {1}% completed in {2}
seconds".format(hashes + spaces , int(round(percent * 100)),
runtime))
206 sys.stdout.flush()
208 self.y_pctiles = np.percentile(np.ravel(self.y_) ,(25,75))
210 def contiguous_regions(self ,cond):
self.cond = cond
212 """Finds contiguous True regions of the boolean array "
condition". Returns
a 2D array where the first column is the start index of the
region and the
214 second column is the end index."""
# Find the indicies of changes in "condition"
216 d = np.diff(self.cond)
idx , = d.nonzero ()
218 # We need to start things after the change in "condition".
Therefore ,
# we ’ll shift the index by 1 to the right.
220 idx += 1
if self.cond [0]:
222 # If the start of condition is True prepend a 0
idx = np.r_[0, idx]
224 if self.cond [-1]:
# If the end of condition is True , append the length of the
array
226 idx = np.r_[idx , self.cond.size] # Edit
# Reshape the result into two columns
228 idx.shape = (-1,2)
return idx
230
# Return summary of findings
232 def summary(self):
y__ = np.ravel(self.y_)
234 X__ = np.ravel(self.X_)
self.condition = y__ > self.y_pctiles [-1]
236 # Print the start and stop indicies of each region where the
absolute
# values of x are below 1, and the min and max of each of
these regions
238 for start , stop in self.contiguous_regions(self.condition):
segment = y__[start:stop]
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240 seg_time = X__[stop]-X__[start]
if seg_time >= self.p3_delta:
242 print("--- Continuous segment length: %.2f min [%.2f : %.2
f] ---" % (X__[stop]-X__[start],X__[start], X__[stop]))
244 # Plot results
def plot_phases(self):
246 # figsize (12.5 , 4)
for i in range(len(self.step_range)):
248 step_i = i+self.step_range [0]
250 X__ ,y__ ,sigma__ = self.X_[i],self.y_[i],self.sigma_[i]
252 plt.plot(ts[(step_i -1)*self.step:step_i*self.step], self.
data[(step_i -1)*self.step:step_i*self.step], color="#348 ABD",
alpha =.25)
plt.plot(self.X_[i],self.y_[i],’g:’)
254 plt.plot(X__[y__ <self.y_pctiles [0]], y__[y__ <self.y_pctiles
[0]], ’k.’, label=u’PI ’)
plt.plot(X__[(self.y_pctiles [0]<=y__) * (y__ <self.y_pctiles
[1])], y__[(self.y_pctiles [0]<=y__) * (y__ <self.y_pctiles [1])
], ’b.’, label=u’PII ’)
256 plt.plot(X__[y__ >=self.y_pctiles [1]], y__[y__ >=self.
y_pctiles [1]], ’r.’, label=u’PIII ’)
plt.fill(np.concatenate ([X__ , X__ [:: -1]]),
258 np.concatenate ([y__ - 1.9600 * sigma__ ,
(y__ + 1.9600 * sigma__)[:: -1]]),
260 alpha =.3, fc=’k’, ec=’None ’, label =’95% confidence
interval ’)
# plt.legend(loc=’upper left ’)
262 def plot_regions(self):
y__ = np.ravel(self.y_)
264 X__ = np.ravel(self.X_)
self.condition = y__ > self.y_pctiles [-1]
266
plt.plot(self.ts ,self.data ,alpha =.5)
268 plt.xlim((self.ts[0],self.ts[-1]))
for start , stop in self.contiguous_regions(self.condition):
270 seg_time = X__[stop]-X__[start]
[ts_start ,ts_stop] = [np.abs(self.ts - X__[start ]).argmin (),
np.abs(self.ts - X__[stop]).argmin ()]
272 if seg_time >= self.p3_delta: plt.plot(self.ts[ts_start:
ts_stop],self.data[ts_start:ts_stop],’g’,alpha =1)
274 # Return summary of findings
def summary ():
276 cond1 = X_classified ==1
# Print the start and stop indicies of each region where the
absolute
278 # values of x are below 1, and the min and max of each of these
regions
for start , stop in contiguous_regions(cond1):
280 segment = X_classified[start:stop]
seg_time = ts[stop]-ts[start]
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282 if seg_time >= 1: print("--- Phase I: %.2f min [%.2f : %.2f]
---" % (ts[stop]-ts[start],ts[start], ts[stop]))
cond2 = X_classified ==2
284 # Print the start and stop indicies of each region where the
absolute
# values of x are below 1, and the min and max of each of these
regions
286 for start , stop in contiguous_regions(cond2):
segment = X_classified[start:stop]
288 seg_time = ts[stop]-ts[start]
if seg_time >= 1: print("--- Phase II: %.2f min [%.2f : %.2f]
---" % (ts[stop]-ts[start],ts[start], ts[stop]))
290 cond3 = X_classified ==3
# Print the start and stop indicies of each region where the
absolute
292 # values of x are below 1, and the min and max of each of these
regions
for start , stop in contiguous_regions(cond3):
294 segment = X_classified[start:stop]
seg_time = ts[stop]-ts[start]
296 if seg_time >= 1: print("--- Phase III: %.2f min [%.2f : %.2f]
---" % (ts[stop]-ts[start],ts[start], ts[stop]))
298 def contiguous_regions(cond):
"""Finds contiguous True regions of the boolean array "condition
". Returns
300 a 2D array where the first column is the start index of the
region and the
second column is the end index."""
302 # Find the indicies of changes in "condition"
d = np.diff(cond)
304 idx , = d.nonzero ()
# We need to start things after the change in "condition".
Therefore ,
306 # we ’ll shift the index by 1 to the right.
idx += 1
308 if cond [0]:
# If the start of condition is True prepend a 0
310 idx = np.r_[0, idx]
if cond [-1]:
312 # If the end of condition is True , append the length of the
array
idx = np.r_[idx , cond.size] # Edit




Use the test data from MMS (loaded above)
320 ’’’
322
# Signal from first channel
324 indeces = [0]
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X = np.ndarray ((len(indeces) ,),dtype=np.object)
326 for ind in range(len(indeces)):
X[ind] = GP_analysis(mydata_corr [:,indeces[ind]],ts=ts)
328
start_time = time.time()
330 for i in range(len(indeces)):
print("\n--- Channel %d ---" % indeces[i])
332 X[i]. fit_data ()
print("--- Parallelized execution completed: %s seconds ---" %
float(time.time() - float(start_time)))
334







342 fig = plt.figure(dpi =120)









352 X__ = np.ravel(X[0].X_)
sigma__ = np.ravel(X[0]. sigma_)
354 condition = y__ > X[0]. y_pctiles [-1]
356 figsize (7.5 ,3)
fig = plt.figure(dpi =120)
358 plt.plot(ts ,X[0].data ,alpha =.25, label=’Signal ’)
plt.xlim(ts[0],ts[-1])
360 plt.plot(X__[y__ <X[0]. y_pctiles [0]], y__[y__ <X[0]. y_pctiles [0]], ’
k.’, label=u’Low ’)
plt.plot(X__[(X[0]. y_pctiles [0]<=y__) * (y__ <X[0]. y_pctiles [1])],
y__[(X[0]. y_pctiles [0]<=y__) * (y__ <X[0]. y_pctiles [1])], ’b.’,
label=u’Medium ’)
362 plt.plot(X__[y__ >=X[0]. y_pctiles [1]], y__[y__ >=X[0]. y_pctiles [1]],
’r.’, label=u’High ’)
plt.fill(np.concatenate ([X__ , X__ [:: -1]]),
364 np.concatenate ([y__ - 1.9600 * sigma__ ,
(y__ + 1.9600 * sigma__)[:: -1]]),
366 alpha=.3, fc=’k’, ec=’None ’, label =’95% CI ’)
plt.title(’Predicting Average Pressures ’)
368 plt.ylabel(’Pressure (mmHg)’)
plt.xlabel(’Time (min)’)
370 plt.legend(bbox_to_anchor =(1.05 , 1), loc=2, borderaxespad =0.)





376 X__ = np.ravel(X[0].X_)
X_labeled = np.empty_like(X__)
378 X_labeled[y__ <X[0]. y_pctiles [0]] = 1
X_labeled [(X[0]. y_pctiles [0]<=y__) * (y__ <X[0]. y_pctiles [1])] = 2
380 X_labeled[y__ >=X[0]. y_pctiles [1]] = 3




plt.plot(ts ,mydata_corr [:,0],’:k’,alpha =.5)
386 plt.xlim((ts[0],ts[-1]))
388 condition = y_filt > 2 # y__ > X[0]. y_pctiles [-1]
ind = 1
390 tmp_reg = contiguous_regions(condition)
for start , stop in contiguous_regions(condition):
392 seg_time = X__[stop]-X__[start]









400 if (X__[tmp_reg[ind ][0]] - X__[stop]<= 10):
[ts_start ,ts_stop] = [np.abs(ts - X__[stop]).argmin (),np.abs
(ts - X__[tmp_reg[ind ][1]]).argmin ()]
402 X_class[ts_start:ts_stop] = 3
plt.plot(ts[ts_start:ts_stop],mydata_corr[ts_start:ts_stop
,0],’r’,alpha =1)
404 ind += 1
condition = (y_filt <= 2) * (y_filt > 1)
406 # (y__ <= X[0]. y_pctiles [-1])*(y__ > X[0]. y_pctiles [0])
ind = 1
408 tmp_reg = contiguous_regions(condition)
for start , stop in contiguous_regions(condition):
410 if stop <len(X__):
seg_time = X__[stop]-X__[start]
412 [ts_start ,ts_stop] = [np.abs(ts - X__[start ]).argmin (),np.abs(
ts - X__[stop]).argmin ()]
X_class[ts_start:ts_stop] = 2
414 if seg_time >= 2:
# plt.plot(ts[ts_start:ts_stop],mydata_corr[ts_start:ts_stop
,0],’b’,alpha =1)
416 if ind <len(tmp_reg):
if (X__[tmp_reg[ind ][0]] - X__[stop]<= 5):
418 [ts_start ,ts_stop] = [np.abs(ts - X__[stop]).argmin (),np






422 condition = (y_filt == 1)
424 ind = 1
tmp_reg = contiguous_regions(condition)
426 for start , stop in contiguous_regions(condition):
if stop <len(X__):
428 seg_time = X__[stop]-X__[start]
[ts_start ,ts_stop] = [np.abs(ts - X__[start ]).argmin (),np.abs(
ts - X__[stop]).argmin ()]
430 X_class[ts_start:ts_stop] = 1
if seg_time >= 1:
432 if ind <len(tmp_reg):
if (X__[tmp_reg[ind ][0]] - X__[stop]<= 30):
434 [ts_start ,ts_stop] = [np.abs(ts - X__[stop]).argmin (),np







440 Make sure the transitions are appropriate , else it is a false
positive detection
442 1 -> 2: -1
2 -> 3: -1
444 3 -> 1: 2
446 1 -> 3: -2
2 -> 1: 1
448 3 -> 2: 1
450 ’’’
452 X_classified = np.copy(X_class)
for i in range(len(X_class) -1):







f, (ax2 ,ax0 ,ax1) = plt.subplots(nrows=3,ncols=1,dpi=120, sharex=
True ,sharey=False)
460 ax2.plot(ts ,mydata_corr [:,0],’:k’,alpha=.5, label=u’Signal ’)
ax2.set_xlim ((ts[0],ts[-1]))
462 ax2.set_ylim ((-5,250))
ax2.plot(ts[X_classified ==1], mydata_corr[X_classified ==1,0], ’.g
’, label=u’PI ’)
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464 ax2.plot(ts[X_classified ==2], mydata_corr[X_classified ==2,0], ’.b
’, label=u’PII ’)
ax2.plot(ts[X_classified ==3], mydata_corr[X_classified ==3,0], ’.r
’, label=u’PIII ’)
466 ax2.set_title(’Phase Classification ’)
ax2.set_ylabel(’Pressure (mmHg)’)
468 ax2.legend(loc=’upper center ’, bbox_to_anchor =(0.5 , 1.05),
ncol=4, fancybox=True , shadow=True)
470 ax2.text(10, 190, ’58.60 min ’, style=’normal ’,
bbox={’facecolor ’:’blue ’, ’alpha ’:0.25 , ’pad ’:10})
472 ax2.text(60, 190, ’24.80 min ’, style=’normal ’,
bbox={’facecolor ’:’red ’, ’alpha ’:0.25 , ’pad ’:10})
474 ax2.text (110, 190, ’71.33 min ’, style=’normal ’,
bbox={’facecolor ’:’green ’, ’alpha ’:0.25 , ’pad ’:10})
476 ax2.text (165, 190, ’55.42 min ’, style=’normal ’,
bbox={’facecolor ’:’blue ’, ’alpha ’:0.25 , ’pad ’:10})
478 ax2.text (210, 190, ’27.54 min ’, style=’normal ’,
bbox={’facecolor ’:’red ’, ’alpha ’:0.25 , ’pad ’:10})
480
ax0.plot(ts ,.009*X_classified/np.max(X_classified))
482 ax0.set_ylim (0 ,.01)
ax0.set_ylabel(’Phase ’)
484 majorticks = np.array ([1,2,3], dtype=’float ’)/3*.009
ax0.set_yticks(majorticks)
486 ax0.set_yticklabels ([’I’,’II ’,’III ’])
ax0.set_xlim ((ts[0],ts[-1]))
488 sns.rugplot(np.array(data), c=c1 , ax=ax0)
490 # Set up the plots
c1, c2 = sns.color_palette("husl", 3)[:2]
492 # Plot the summed basis functions
summed_kde = np.sum(kernels , axis =0)
494 # ax1.plot(xx, summed_kde , c=c1)
sns.kdeplot(np.array(data), bw=bandwidth , linewidth=1, shade=True ,
color=c1, label=r’Peak Density ’, ax=ax1)








A Machine Vision Approach to Visualize and
Analyze Intracellular Crystalloid Objects in
Transmission Electron Microscope Images
B.1 Introduction
With the increasing use of electron microscopy, more studies rely on the use of
computational tools to not only to detect and quantify morphological features, but
also the ability to do so in an objective and efficient manner for large volumes of data.
Structural comparisons were carried out, for example, between different microfibrils
composed of collagen tetramers and banded aggregates11. For the analysis of repeti-
tive texture features, fast Fourier transform (FFT) analysis was used to study protein
aggregates composed of laterally-assembled microbfibrils which were themselves com-
posed of collagen VI, an extracellular matrix component that forms structural links
with cells. In a more chemical realm, the topology of monolayer graphene was an-
alyzed for surface defects or rippling effects that were revealed by FFT procedures,
helping to visualize changes in bond lengths6. Similarly, an FFT-based analysis of
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nanoparticle super-lattices and temperature-induced restructuring revealed hexago-
nal and distorted hexagonal structures in the range of 4-8 nm, suggesting ordered
self-assembly of these structures based on center-to-center distances15.
Lattice-like morphological features have also been identified in electron microscope
images of intracellular structures. For example, endoplasmic reticulum differentiated
into stacked arrays17; sinusoidally-packed compressed bodies3; membranous whorls
10; crystalloid ER7; and stacked cytoplasmic membranes surrounding yeast nuclei
20. Recently, studies have suggested cubic membranes that represent curved, three-
dimensionally periodic structures based on mathematically-defined surfaces as models
for such phenomena12,13. To study TEM micrographs in the context of theoretical
3D structures, a direct template correlative (DTC) matching method has been em-
ployed based on matching images with projections of three fundamental families of
cubic membranes based on recognizing pattern and symmetry1,8,12. These templates
rely, however, on a three dimensional structural hypothesis of the components they
represent.
Here, we developed a more empirical, image analysis approach employing fast
Fourier transforms to extract repetitive textured features in TEM images of spec-
imens, whose molecular organization may not be fully known, such as crystalloid
features that have been observed in certain drug-treated cells. Morphologically, we
considered the smallest repeating feature of a textured pattern present in a crystalloid
object as being analogous to the unit cell of a crystal without exactly corresponding
to the physical repeating unit of a crystal. Therefore, as has been done with other
crystals and crystalline-like objects, we hypothesized that crystalloid objects present
in cells of living organisms may display symmetry and properties similar to long-range
orientation and translational order of true crystals, which could thus be analyzed by
FFT to identify the simplest morphological repetitive feature (“unit cell”) as well as
its orientation, spacings, and its relation to higher-order morphological features such
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as the variation of the unit cell and its alignment in relation to the overall shape of
the crystalloid.
B.2 Methods
B.2.1 Development of algorithm
The algorithm was developed to select points of interest in the Fourier domain
that appear brightly in the amplitude spectrum–here the logarithmic absolute value
of the Fourier coefficients. Taking advantage of the symmetry of Fourier transforms,
only the first and second quadrants were considered. The pixel intensity histogram
of the amplitude spectrum displayed bi-modality for images containing lattice-like
features. A band-pass filter was applied to keep only relevant frequencies in the
5 to 25 nm/cycle range. This effectively shifted the mean of the first distribution
to the origin. A regression in MATLAB was used to fit the bimodal distribution,
determining the two means and variances. Pixels that were two at least standard
deviations above the mean were then retained as peaks from the Fourier domain.
To validate the selected peaks and test against noise due to orientation, the images
were rotated at two randomly-generated angles where-upon the same analysis was
conducted, and only the preserved points were kept. The reconstructed image based
on the detected points was compared to the original image.
B.2.2 Optimization image sets
An initial set a set of images was used based on proposed computer-generated two-
dimensional projections of hypothetical three-dimensional structures representing pe-
riodic supramolecular structures2,18. This set, along with intensity- and noise-altered
versions of each image, was used to help fine-tune the algorithm in the detection of
lattice-like features. A test set based on 48 patterns was used to help fine-tune the
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fitting and ensure that the algorithm could detect lattice-like features. The test im-
ages were modified by adjusting the contrast and adding noise. Further testing was
done on the images which these projections were suggested to match2,18.
B.2.3 Quantitative analysis of lattice-like features
For carrying out intra-image comparisons, images were divided into non-overlapping
square regions for analysis of local features to compare with long-range repetitive tex-
tures and symmetries. The size of these squares, 480 x 480 pixels, was determined
based on the Nyquist-Shannon sampling theorem which, for the spatial domain, re-
quires using more than twice the highest desired frequency to fully capture the repet-
itive feature and resolution while avoiding anti-aliasing16 as well as the suggestion
that the image frame need be several times larger than the characteristic frequencies
to ensure the FFT captures them with adequate resolution9. Treating the FFT as a
linear regression for each non-overlapping segment of the image, the sum of squares
of the regression (reconstructed image versus original image) of the region had to be
at least one percent of the total sum of squares (variance in the original image) of the
region. The detected peaks in each region were then used to reconstruct and classify
the patterns based on the dimensions of the unit cells composing them–the smallest
repeating pattern that can account for the entire detected structure.
B.2.4 Application to a test set of images from treated animals
To test our visualization and analysis algorithm, we analyzed electron microscope
images obtained from animals fed with clofazimine, a drug that induces crystalloid
features to form inside macrophages5. These drug induced crystalloid objects pos-
sessed repetitive texture features when observed by TEM14,19. Briefly, mice were fed
with drug with powder chow (3 mg/ml clofazimine in sesame oil, mixed at 0.01%
oil to chow). Blood was collected from euthanized mice and fixed by perfusing 0.1M
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Sorensen’s buffer and Karnovsky’s fixative (3% paraformaldehyde, 2.5% glutaralde-
hyde) infused to left ventricle and egressed to vena cava (2.5 ml/min). Tissues were
minced smaller than 1 mm in each dimension followed by TEM sample preparation
and imaging4. Control mice were fed with 0.01% oil to chow, and wash out mice were
fed drug- and oil-free chow. Representative images were acquired using a Philips
CM-100 electron microscope at magnifications from 4600X to 130000X.
B.3 Results
B.3.1 Development of machine vision algorithm
To help visualize the lattice-like features, we explored the use of FFTs. To iden-
tify peaks in the spatial domain corresponding to repetitive lines or bands in the raw
images, we developed an algorithm to identify local maxima. This algorithm was op-
timized using sets of images adapted from2,18 (Figure B.1). This included altering the
sets of images to account for detected peaks in the presence of background noise; op-
timizing the algorithm; quantitatively analyzing the resultant peaks; and testing the
algorithm on images with both the presence and absence of drug-cell aggregates; and
overlaying the reconstruction of repetitive patterns onto the images for highlighting
the lattice-like features and confirming their existence by visual inspection.
By visual inspection, the reconstructed spatial patterns of features detected with
the algorithm were directly comparable to the spatial patterns of features in the
raw images. In the training set of images (Figure B.1), the reconstructed structural
features clearly overlapped with the actual features present in the images. For fine-
tuning the peak detection algorithm, noise was added to a repeating structure (Figure
B.1A; adapted from2, Figure 1B), contrast was lowered between the image features
and background (Figure B.1B; adapted from2, Figure 1B), and as a further test, an
EM image of an organized smooth endoplasmic reticulum (Figure B.1C; adapted from
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18, Figure 7D) was used. The resolutions were set such that the repeating patterns
shown corresponded to features in the 5-25 nm range.
Each image was first converted to a corresponding discrete Fourier transform
(Figure B.1D-F). Applying the algorithm, peaks in the 5-25 nm per cycle range were
selected (Figure B.1G-I). By visual inspection, reconstructions based on the detected
peaks appeared true to the original images. The noisy image had five clusters of
contributive points that sufficed to recreate the pattern (Figure B.1J). The FFT of the
low-contrast image proved more difficult to visually distinguish the peaks, however,
with the selected points the recreated pattern appeared to match the original image
(Figure B.1K). The EM image contained not only noise and varying contrast but
also distortions in the repeating patterns due to being a biological sample. However,
the detected peaks revealed a regular repeating structure throughout the image that
indeed corresponded to one of the two-dimensional projections used in the DTC
scheme2.
B.3.2 Visualizing regions with repetitive texture features in electron mi-
croscope images
After the parameters were adjusted, images of cells with objects containing tex-
tured patterns with hints of lattice-like features were visualized and compared (Figure
B.4). Displaying the results of repetitive feature detection algorithm directly on these
EM images, the green highlighted regions corresponded to segments of the FFT image
where peaks were detected. From these peaks, images were reconstructed using the
inverse Fourier trans-form algorithm, to visualize the correspondence between the de-
tected repetitive patterns and the texture of the segments. In this manner, we looked
for macrophage-like cells in clofazimine-treated mice containing stained polyhedral
objects with texture patterns (Figure B.4A-C). The red squares correspond to the
magnified segments of the images. These segments displayed certain regular textures
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that appeared diagonally parallel but the repetitive details not readily perceptible
by the eye (Figure B.4A), hexagonally-arranged repeating unit cells (Figure B.4E),
and a meshwork pattern that was not easily discernible (Figure B.4F). The FFTs
were next considered for each segment. The parallel pattern in Figure B.4A had five
peaks arranged as a rectangle surrounding the origin of the FFT and set to an angle
corresponding to the direction of the texture (Figure B.4G). The repeating pattern
from Figure B.4B had six peaks in the frequency domain arranged in a hexagonal
pattern. The meshwork from Figure B.4F had four peaks also creating a rectangle
but set closer to the origin of the FFT (Figure B.4I). To facilitate visualization of
the repetitive patterns in the selected regions, the image segments were reconstructed
based on the peaks selected by the algorithm using the inverse Fourier transform
function. The diagonally parallel striations were maintained (Figure B.4J). The re-
peating structures appeared to correspond to the original image (Figure B.4K). The
meshed pattern was created from intersecting parallel lines in the original image that
corresponded to each pair of peaks in the FFT image; one set in the north-west to
south-east direction and the other in the south-west to north-east direction of the
image (Figure B.4L).
B.3.3 Machine vision-assisted morphometric analysis
Next, we proceeded to study the morphological features of crystalloid objects
observed in the cells of clofazimine-treated mice. For analysis, we identified clusters of
selected regions containing lattice-like features as identified by the algorithm (Figure
B.5A). Zooming into one of these regions (Figure B.5B), revealed what seemed like
a lattice-like textured pattern. Magnification of a different, adjacent region (Figure
B.5C) similarly revealed a repetitive texture pattern. After applying the Fourier
transform to these two segments (Figure B.5D and E, respectively) a pattern of
peaks was clearly observed in the FFT images. With the most prominent selected
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peaks in the spatial frequency domain, images were reconstructed corresponding to
the patterns seen in the images. The re-construction for the first region revealed the
underlying lattice-like features (Figure B.5F). The colored diagonals corresponded to
the two major axes of symmetry. The intersection of repeating diagonals in along
both of these axes yielded a unit cell that repeated throughout the image. A similar
arrangement was also evident in the second region (Figure B.5G). To confirm the
detected patterns, a reconstructed image based solely on selected frequencies was
compared to the original segment being analyzed (Figure B.6A). Overlaying a semi-
transparent copy of the reconstruction over the original image was used to highlight
the corresponding lattice-like features in the original image with the unit cell shown
in the center (Figure B.6B). The lattice arrangement, the shortest two directions in
which the unit cell repeated, as well as the angle separating the vectors shown as
purple arrows in Figure B.6C.
The internal arrangement of the unit cells was then compared for the entire image
(Figure B.6). The extracted unit cells for each of the non-overlapping quadrants were
used as metrics to define the regions analyzed by the vector lengths and angle of
separation (Figure B.6A). Variations in the unit cells in Figure B.6A reflect slight
variations in the detected peaks of the frequency do-mains which defined the unit
cell shapes and sizes, which in turn affects the morphological definition of the unit
cell boundaries. The distribution of the regions’ properties, along with the two larger
segments analyzed in Figure B.6, were plotted as a homogenous cluster, with the
first edge measuring 2±1.99±0.07 nm, the second edge 11.14±0.15 nm, and the angle
separating them 87.80±0.41 degrees (Figure B.6B). This indicated the presence of
long-range order across the entire crystalloid object.
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B.4 Discussion
Here, we developed a machine vision-based algorithm that can be fine-tuned for
the detection, visualization and analysis of repetitive texture features in electron mi-
croscope images. A tailored version of this algorithm was implemented for detecting
and enhancing repetitive structures at the nanometer scale on the order of 5 to 25 nm.
Such repetitive, nanometer-scale crystal-like features were difficult to unambiguously
detect with the naked eye, especially given images with low contrast and noisy back-
ground. Applied to electron microscope images of macrophages of mice fed with a
clofazimine-supplemented diet for a period of several months, the algorithm revealed
structural details about the internal organization of drug induced, crystalloid objects
evident in macrophages. Consistent with previous reports, these crystalloid objects
possessed a bounding membrane and were polyhedral in shape, yet their internal or-
ganization seemed almost featureless, aside from global textures, when viewed by the
naked eye. By fine-tuning the machine vision algorithm with a training set of images,
pattern detection and visualization of lattice-like features was readily per-formed. By
applying the algorithm to non-overlapping square regions of images, we were able
to further optimize the algorithm so it only detected regions containing the puta-
tive, nanometer-scaled periodic features. After optimization, the algorithm mostly
detected nanometer scale lattice-like features in the regions that were associated with
specific objects of interest. The algorithm did not detect as many regions from the
same image outside the polyhedral membrane. The algorithm also did not detect
regions of images of control, untreated animals that lacked lattice-like features.
Applying this optimized algorithm to larger domains of the drug-induced polyhe-
dral structures present in macrophages of clofazimine-treated animals, we were able to
obtain detailed in-formation about the spatial arrangement, symmetry and spacings
of periodic features present in those domains. Within a single polyhedral structure,
different domains could be compared, to establish the long range similarities or dif-
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ferences across the interior of the object. Furthermore, applying the same algorithm
to different polyhedral structures found in the same image, we were able to estab-
lish the similarities and differences in the interior organization of different structures.
Strikingly, within an individual polyhedral structure, the machine vision algorithm
revealed the presence of an asymmetric, repetitive unit, with internal features in the
order of 5 nm in size, and a unit cell size of 10 to 20 nm (Figure B.6). Without
computational assistance, this level of detail was not so apparent by visual inspection
(Figure B.6). Different domains within the membrane-bound polyhedral object pos-
sessed similar features in the same orientation, indicating a long-range order (Figure
B.6. In the particular example analyzed in this study (Figure B.6), the mean perime-
ter of the parallelogram circumscribing pairs of red and blue segments was 47.60±1.80
nm with calculated interior angles of 84.61±5.12 and 95.39∓5.12 and degrees. The
observed variations in morphological unit cell across a single crystalloid object were
small, and could have been due to (i) lack of complete homogeneity in the repetitive
texture of the samples being imaged, (ii) distortive noise perturbing the position of
detected peaks in the Fourier domains, and (iii) ambiguity in the selection and filling
of the boundaries of the region that defines the unit cell as the smallest repeating
segments that describes the texture pattern across the entire image. ). Interestingly,
the overall shape of the outer membrane bound perimeter of the entire structure was
parallel to the lattice vectors of the unit cell, suggesting that the observed unit cell
arrangement may be structurally linked to the overall shape of the crystalloid.
Nevertheless, to interpret the observed patterns, it is important to note that one
of the difficulties of standard electron microscopy is that it only allows one to view
a thin cross sectional plane across the structure of interest. Therefore, the plane at
which the structure is cut, and the thickness of the section may influence the appear-
ance of the internal organization of the structure. In the future, more sophisticated
electron microscopy tomography techniques that allow for visualizing the organization
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of three-dimensional structures may prove useful for gaining further in-sights into the
morphology of drug induced membrane aggregates.
B.5 Conclusion
We have successfully developed and demonstrated the usefulness of a machine
vision approach for detecting, extracting and enhancing low-contrast and distorted
repetitive morphological features in transmission electron microscope images, without
a priori knowledge about their molecular organization. Beyond detection and visual-
ization of lattice-like features, the algorithm could be further developed and applied
towards quantitative analysis of the shape, angles, spacings of the unit cell, and spa-
tial analysis of variation in unit cell features and orientation across the entire object
and with respect to the object perimeter and surrounding morphological features, in
an objective, quantitative and reproducible manner.
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B.7 Figures
Figure B.1: (A-B) Images adapted from2 and (C)18. (D-F) The FFTs of the template
images (G-H) Detected peaks in the Fourier domain (J-H) Reconstructions based on
the detected peaks.
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Figure B.2: (A) Normalized Fourier domain histograms of Figure B.1C and (B) Figure
B.4F.
Figure B.3: (A) Image from Figure B.1B. (B) A circularly cropped. (C-D) B rotated
15◦ and 95◦, respectively. (E-F) The detected peaks from the FFTs of images A-D.
(I) The peaks that are maintained under rotation. (J) Reconstructions based on the
maintained peaks
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Figure B.4: Detected regions of interest in images. (A), (B), and (C) The highlighted
boxes show regions where peaks were detected in images of intestinal villi of treated
mice. The red regions in each image are magnified in (D), (E), and (F). Detected
points are shown in (G), (H), and (I). The detected points were used to reconstruct
the images in (J), (K), and (L), in which regular patterns are seen.
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Figure B.5: (A) Contiguous regions were selected from figure B.4C, magnified in (B)
and (C); the Fourier transforms are shown in (D) and (E), along with correspond-
ing reconstructions showing hexagonal patterns highlighted in blue in (F) and (G),
respectively.
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Figure B.6: (A) Selected region in a crystalloid object. (B) Inverse Fourier transform
of the peaks in the FFT, superimposed on the same selected region as in A. (C)
Repetitive pattern in the crystalloid object, with the unit cell indicated by purple
arrows. (D) Quadrants in a hexagonal crystalloid were peaks were detected in the
FFT. Superimposed are the enlarged unit cells of each quadrant. (E) Plot of the two
shortest directions and the angle of separation. The colors of the circles correspond
to the colored quadrants in D. The average measure for edge 1 was 21.99±0.07 nm,
edge 2 11.14±0.15 nm, and the angle separating them 87.80±0.41 degrees.
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B.8 MATLAB Code
function [pve heatmap points] = fft_analysis(img ,fact ,res ,scale)
2 % Run entire analysis on an image. Given the input image ,
threshold factor
% (how many standard deviations above mean should be considered),
4 % resolution , and scale bar , the PVE , corresponding heatmap , and
detected
% points are output. The PVE is just used to map where on the
figure
6 % detected patterns are found. The input image is assumed to be
2400 x2400





scale_r = scale (:,1);
12 scale_c = scale (:,2);
14 % Step size , or the dimension (one side) of non -overlapping square
region
% to be analyzed.
16 cutoff = 0.01; step = 480;
18 % If a resolution is given as input use it else default
if res , temp_filt = fft_filt(step/2,0,res);
20 else temp_filt = fft_filt(step /2); end
22 % Scan the image in the required step size without displaying the
results.
[pve , heatmap , points] = fft_scan(img (1:2400 ,1:2400) ,step ,2,res ,0)
;
24




30 % Show image with the regions of detected patterns highlighted
temp_img_selected = 0.4.*img(:,:,1);
32 for i = 1: length(scale_r)
temp_img_selected (2200 -1+ scale_r(i) ,2075-1+ scale_c(i)) = 255;
end;
34 imshow(temp_img_selected (1:2400 ,1:2400));
hold on;
36 g = imshow(img (1:2400 ,1:2400));
set(g,’AlphaData ’,(heatmap >cutoff))
38
% Wherever a pattern is discovered (PVE >cutoff) draw a square
40 [m n] = find(pve >cutoff);
for i=1: length(m)
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42 hold on; rectangle(’Position ’,[(m(i) -1)*step+1 (n(i)
-1)*step+1 step -1 step -1],’EdgeColor ’,’g’,’LineWidth ’,2);
end;
44
% Select one of the pattern -containing squares as an example
46 [r c] = find(pve(3:end ,3:end)>cutoff ,1,’first ’) ; c = (c-1+3); r
= (r-1+3);
temp_img = img((r*step) -(step -1):r*step ,(c*step) -(step -1):c*step);
48 hold on; rectangle(’Position ’,[(c*step)-(step -1) ,(r*step)-(step -1)
,step ,step],’FaceColor ’,’r’);
mysubplot (4,1,2);
50 imshow(temp_img ,[]); % Display the segment
mysubplot (4,1,3);
52 temp_pts = fft_points3(fftshift(fft2(temp_img)),fact ,1); xlim ([2*
step/5 3*step /5]); ylim ([2*step/5 3*step /5]); % Show the FFT
and detected peaks for that region
reduced_3 = fft_reconstruct(fftshift(fft2(temp_img)) ,(temp_pts));
54 mysubplot (4,1,4);
imshow ((ifft2(ifftshift(reduced_3))) ,[]); % Reconstruct and
display image based on detected peaks
56
%% Analyze detected region
58 % figure (2); clf;
% points = struct(’pts ’,[0 0],’theta ’,0,’radius ’,0);
60 %
% [M N] = size(pve);
62 %
% angle_count_map = ones(M,N).* -1;
64 % angle_mean_map = ones(M,N).* -1;
% angle_skew_map = ones(M,N).* -1;
66 % angle_kurtosis_map = ones(M,N).* -1;
%
68 % rad_var_map = ones(M,N).* -1;
% rad_mean_map = ones(M,N).* -1;
70 % rad_skew_map = ones(M,N).* -1;
% rad_kurtosis = ones(M,N).* -1;
72 %
% % Show image with highlighted regions corresponding to areas
where patterns
74 % % were detected
% temp_img_selected = 0.4.*img(:,:,1);
76 % for i = 1: length(scale_r)
% temp_img_selected (2200 -1+ scale_r(i) ,2075-1+ scale_c(i)) =
255; end;
78 % imshow(temp_img_selected (1:2400 ,1:2400));
% hold on;
80 % g = imshow(img (1:2400 ,1:2400));
% set(g,’AlphaData ’,(heatmap >cutoff))
82 %
% % Determine angle and radius for each detected region
84 % theta = 0:.5:180; radians = .5:.5: step /2;
% ind = 0;
86 % [m n] = find(pve >= cutoff);
% for i=1: length(m)
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88 % ind = ind+1;
% hold on; rectangle(’Position ’,[(m(i) -1)*step+1 (n(i)
-1)*step+1 step -1 step -1],’EdgeColor ’,’g’,’LineWidth ’,2);
90 %
% k = (n(i) -1)*step +1;
92 % j = (m(i) -1)*step +1;
%
94 % temp_segment = img((n(i) -1)*step +1:(n(i) -1)*step +1+
step -1,(m(i) -1)*step +1:(m(i) -1)*step +1+step -1);
% temp_fft = fftshift(fft2(double(temp_segment)));
96 % points(ind).pts = fft_points3(temp_fft ,fact ,0);
% if(points(ind).pts)
98 % clear m_t m_r bin_t bin_r
% [points(ind).theta , points(ind).radius] =
fft_angle(temp_fft ,points(ind).pts);
100 %
% points(ind).theta(points(ind).theta <0) = points(
ind).theta(points(ind).theta <0) +180;
102 % points(ind).theta(points(ind).theta ==0) = 180;
% [m_t ,bin_t] = histc(points(ind).theta ,theta);
104 % [m_r ,bin_r] = histc(points(ind).radius ,radians);
% num_bins = length(bin_t);
106 % % Draw vectors proportional to angle and radius
for each
% % set of points.
108 % for kk = 1: length(bin_t)
% arrow_rad = (radians(bin_r(kk))/max(radians(
bin_r (:))))*(step /2);
110 % u = arrow_rad*cosd(theta(bin_t(kk))); v =
arrow_rad*sind(theta(bin_t(kk)));
% hold on; quiver(j+step/2,k+step/2,u,v,’Color
’,[1 1 1],’LineWidth ’,3); hold off;
112 % hold on; quiver(j+step/2,k+step/2,-u,-v,’
Color ’,[1 1 1],’LineWidth ’,3); hold off;
%
114 % end
% % Statistics of radii and angles
116 % rad_var_map(n(i),m(i)) = var(radians(bin_r));
% rad_mean_map(n(i),m(i)) = mean(radians(bin_r));
118 % rad_skew_map(n(i),m(i)) = skewness(radians(bin_r
));
% rad_kurtosis(n(i),m(i)) = kurtosis(radians(bin_r
));
120 %
% angle_count_map(n(i),m(i)) = length(theta(bin_t)
);
122 % angle_mean_map(n(i),m(i)) = median(theta(bin_t))
;
% angle_skew_map(n(i),m(i)) = skewness(theta(bin_t
));





%128 % % Resize into matrix
% j = 0; k = 1; l = 1;
130 % [m n] = find(pve >= cutoff);
% for i=1: length(m)
132 % j=j+1;
% if(points(j).pts)
134 % temp_size = length(points(j).theta (:,1));
% temp_ang(k:k+temp_size -1,1) = points(j).theta;
136 % k = k+temp_size;
% temp_size = length(points(j).radius (:,1));
138 % temp_rad(l:l+temp_size -1,1) = points(j).radius;





144 % %% Display the average radius and histogram of angle
distsributions
% figure (3); clf;
146 % max_val = round(max(rad_mean_map (:)));
% cmap = mysubplot (2,1,1);
148 % imagesc(rad_mean_map); % title(’Mean Radius ’); %#
Create a colored plot of the matrix values
% % caxis ([0 max_val ]); h_cb2 = colorbar ();
150 % textStrings = num2str(rad_mean_map (:) ,’%0.2f’); %# Create
strings from the matrix values
% textStrings = strtrim(cellstr(textStrings)); %# Remove any
space padding
152 % textStrings = strrep(textStrings ,’-1.00’,’’);
% [x,y] = meshgrid (1: length(rad_mean_map)); %# Create x and y
coordinates for the strings
154 % hStrings = text(x(:),y(:),textStrings (:),... %# Plot the
strings
% ’HorizontalAlignment ’,’center ’);
156 % midValue = mean(get(cmap ,’CLim ’)); %# Get the middle value of
the color range
% textColors = repmat(rad_mean_map (:) > midValue ,1,3); %# Choose
white or black for the
158 % %# text color of
the strings so
% %# they can be
easily seen over
160 % %# the background
color
% set(hStrings ,{’Color ’},num2cell(textColors ,2)); %# Change the
text colors
162 % set(cmap ,’XTickLabel ’,{},... %# Clear axes
% ’YTickLabel ’,{},...
164 % ’TickLength ’,[0 0]);
%




% fplot = mysubplot (2,1,2);
170 % numbins = 100; n = length(temp_ang);
% binwidth = range(temp_ang)/numbins;
172 % edg = 0: binwidth :180;
% [count ,bin] = histc(temp_ang ,edg);
174 % % h = bar(edg ,count ,’histc ’);
% [temp_count ,temp_bin] = histc(temp_ang ,0:1:180);
176 % h = bar (0:1:180 , temp_count ./max(temp_count));
% set(h, ’facecolor ’, [0.2 0.2 1]); % change the color of the
bins
178 % set(h, ’edgecolor ’, [0.2 0.2 1]);
% p = count;
180 % hold on;
% % plot(edg ,p./max(p),’Color ’,[1 .5 .5],’LineWidth ’,4);
182 % xlim ([0 180]); % plot(p,edg) is the smooth curve representing
the probability density function you are looking for.
% % set(fplot ,’FontSize ’,55);
184 % xlabel(’Angle ’);%,’fontsize ’,55,’fontweight ’,’b’);
% ylabel(’Frequency ’);%,’fontsize ’,55,’fontweight ’,’b’);
186
188 % set(findobj(gcf ,’Type ’,’text ’),’FontSize ’,55,’fontweight ’,’b’);
./AppendixB/src/fft analysis.m
1 function [theta , radius] = fft_angle(fourier ,points ,res)
% Take a Fourier transform and the detected points of interest ,
compute
3 % angles and radii for each set of symmetric points and return as
vectors
% theta and radius. The resolution of the corresponding image can
be input
5 % to scale accordingly.
7 global Fx Fy;
9 % Check for number of input arguments. If resolution is not given ,
assume
% standard (292, corresponding to 130 ,000X magnification image).
11 if nargin < 3, res = 292; end;
13 [M N] = size(fourier);
15 % Sampling frequeny (pixels per nm)
fsy = res /100; fsx = res /100;
17
% nm per pixel
19 dx = 1/fsx; dy = 1/fsy;
21 % pixels
x = dx*(0:N) ’; % nm
23 y = dy*(0:M) ’;
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25 % cycles per nm
dFx = fsx/(N); dFy = fsy/(M);
27 Fx = (-fsx /2: dFx:fsx/2-dFx)’;
Fy = (-fsy /2: dFy:fsy/2-dFy)’;
29
[M N] = size(fourier);
31
num_pts = length(points)/2;
33 radius = zeros(num_pts ,1); theta = zeros(num_pts ,1);
35 % Iterate through the input points and calculate the radius and
angle at
% which they fall with respect to the center (analogous to origin
if we
37 % assume Cartesian coordinates centered over the image).
for i = 1: num_pts
39 y = points(i,1); x = points(i,2);
yy = M/2-y;
41 if (x>=N/2), xx = x-N/2; theta(i) = atan2d(yy ,xx);
else xx = N/2-x; theta(i) = atan2d(yy ,xx); theta(i) = 180- theta
(i);
43 end;
radius(i) = 1/((Fx(x)^2+Fy(y)^2) ^.5);
45 end
./AppendixB/src/fft angle.m
1 function [filt] = fft_filt(dim ,show ,resolution)
% Create a Butterworth band pass filter of size dim given an input
3 % resolution corresponding to the image which is being analyzed.
5 if nargin < 2, show = 0; resolution = 292;
elseif nargin < 3, resolution = 292; end;
7
ind = (10*dim /400);
9 d0 = (13*dim /400);
d1 = (60*dim /400);
11




15 d0 = d0/resolution*292;
d1 = d1/resolution*292;
17
filt1 = ones(2*dim ,2*dim);
19 filt2 = ones(2*dim ,2*dim);
% Use Butterworth band pass filter.
21 for i=1:2*dim
for j = 1:2*dim
23 % Radial distance from center
dist = ((i-(dim +1))^2 + (j-(dim +1))^2) ^.5;
25
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% high pass filter
27 filt1(i,j)= 1/(1 + (dist/d0)^(2*ind));
filt1(i,j)= 1.0 - filt1(i,j);
29
% low -pass filter
31 filt2(i,j)= 1/(1 + (dist/d1)^(2*ind));
end
33 end
35 % Combine the two filters and normalize
filt = filt1.*filt2;
37 filt = filt./max(filt (:));
39 % Display filter if required by user
if show , subplot (1,3,1); imshow(filt1); subplot (1,3,2);
41 imshow(filt2); subplot (1,3,3); imshow(filt), end;
./AppendixB/src/fft filt.m
function [ points ] = fft_points3( fourier , fact , show ,
resolution)
2 % fft_points3
% takes as input the FFT of an image along with the
4 % multiplication factor determining how many standard deviations
above mean
% to look for peaks , a show toggle to display the results , and a
resolution
6 % scaling factor (default resolution is assumed to be 130000X,
this is the
% number of pixels per nm based on the scale bar in the TEM image)
.
8
global temp_filt scrsz Fx Fy;
10 points = [0 0];
sym_points = [0 0];
12
% Check input arguments and fill incomplete ones.
14 if nargin < 4 || resolution == 0, resolution = 292;
elseif nargin < 3, show = 0; resolution = 292;
16 elseif nargin < 2, show = 0; fact = 1; resolution = 292;
end
18
% Ensure conversion to double and create the filter.
20 [M N] = size(fourier); fourier = double(fourier);
temp_filt = fft_filt(M/2,0, resolution);
22
% Sampling frequeny (pixels per nm)
24 fsy = resolution /100; fsx = resolution /100;
26 % nm per pixel




30 x = dx*(0:N) ’; % nm
y = dy*(0:M) ’;
32
% cycles per nm
34 dFx = fsx/(N); dFy = fsy/(M);
Fx = (-fsx /2: dFx:fsx/2-dFx)’;
36 Fy = (-fsy /2: dFy:fsy/2-dFy)’;
38 % Take the log of the absolute value , this is the power spectrum.
transform = log(1+abs(fourier));
40 % Normalize
original_fft = transform ./max(transform (:));
42 temp_fft = transform;
temp_fft = temp_fft ./max(temp_fft (:));
44 % Apply Butterworth filter
temp_fft = temp_fft.*temp_filt;
46
% Take non -zero elements (assume anything smaller than order of
10^-3 is
48 % zero
temp = temp_fft(find(temp_fft >5e-3));
50 numbins = 120; n = length(temp);
binwidth = range(temp)/numbins;
52 edg = 0: binwidth :1;
[count ,bin] = histc(temp ,edg); p = count;
54 [temp_count ,temp_bin] = histc(temp ,0:.001:1);
56 % fit bimodal distributions to our defined function using an
extreme value
% possibility density function (with most values distributed near
0) and a
58 % normal possibility density function.
clear x y;
60 f = @(y,x)y(1)*evpdf(x,y(2),exp(y(3)))+(1-y(1))*normpdf(x,y(4),exp
(y(5)));
% Set options
62 temp_opts = statset(’MaxIter ’,700, ’MaxFunEvals ’,1000,’ FunValCheck
’,’off ’);
% Assume starting values , contribution of each pdf is a half here.
The
64 % log variances are used in the input vector.
% [fraction contribution , mu1 , sigma1 , mu2 , sigma2]
66 t0 = [0.5 0.01 -7 .6 -5.3];
% Use non -linear least squares regression to fit the defined
function above
68 % The iteration ensures the function is fit within 800 trials and
that we
% are not getting extraneous solutions (bounded variance).
70 temp_pdf = nlinfit(edg ’,p./max(p(:)),f,t0,temp_opts);
iter = 1;
72 while(temp_pdf (5) < -6.4 || temp_pdf (5) > -1 && iter < 800)
if temp_pdf (5) <-6.4, t0(5) = t0(5) +.01; end;
74 if temp_pdf (5) >-1, t0(5) = t0(5) -.01; end;
temp_pdf = nlinfit(edg ’,p./max(p(:)),f,t0,temp_opts);
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76 iter = iter +1;
end
78
% Iterate through the probability distribution function and find
the point
80 % that satisfy our condition of being a factor of the variance
fact*sigma
% greater than the mean (generally a factor of 2).
82 if(temp_pdf (4)>temp_pdf (2) && temp_pdf (1) <=1 && temp_pdf (1) >0 &&
temp_pdf (2) >0)
[r c] = find(temp_fft >=( temp_pdf (4)+fact*exp(temp_pdf (5))));
84 temp_mat = zeros(M,N);
for m=1: length(r), temp_mat(r(m),c(m)) = original_fft(r(m),c(m
)); end;
86
% Fill in the matrix for the corresponding symmetry.
88 [r c] = find(temp_mat (1:M/2,1:N) >1e-1);
points = [r c];




% Display the FFT and detected peaks if user has requested
94 if show
imshow(original_fft); hold on; plot(round(N+1)/2,round(M+1)
/2,’bo ’);
96 if ([ points ])
plot(points (:,2),points (:,1) ,’r.’,’MarkerSize ’,10); hold





% Return the pairs of detected peaks
102 points = [points; sym_points ];
./AppendixB/src/fft points3.m
function [img_PVE ,img_points] = fft_pve(image ,fact ,viz ,res)
2 % Input variable is M by N image and a box win that is a scalar
factor
% of the image. The peaks in the Fourier domain are isolated and
used to
4 % reconstruct a new image showing the base pattern. Thus the
Proportion
% of Variancec Explained , or PVE , is the ratio variance in the
6 % reconstructed versus original image.
8 % Check input arguments and set defaults if not given by user.
if nargin < 4, res = 0; end;
10 if nargin < 3, viz = 0; elseif nargin < 2, viz = 0; fact = 1; end
12 [M N] = size(image);
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14 % Variance of original image
img_var = var(double(image (:)));
16
% Take 2D FFT of image
18 img_fft = fftshift(fft2(double(image)));
20 % Scale according to input resolution if given
if(res), img_points = fft_points3(img_fft ,fact ,viz , res);
22 else img_points = fft_points3(img_fft ,fact ,viz); end;
24 % If points are detected , ensure they survive rotation and
calculate the
% PVE (proportion of variance explained)
26 if(img_points)
% Random rotations to ensure peaks are not aberrations due to
28 % orientation
temp_reduced = fft_rotate(image ,fact ,length(image),res ,0);
30
[r c] = find(temp_reduced);
32 temp_reduced_points = [r c];
img_points = img_points(ismember(img_points ,
temp_reduced_points ,’rows ’) ,:);
34
% Reconstruct image from FFT with only detected peaks
36 img_rec = ifft2(ifftshift(fft_reconstruct(img_fft ,img_points))
);
38 % Compute variance in the reconstructed image
img_rec_var = var(double(img_rec (:)));
40
% PVE - ratio of variance in reconstructed image vs original
image
42 img_PVE = img_rec_var/img_var;
else
44 img_PVE = 0;
end
./AppendixB/src/fft pve.m
1 function reduced_fft = fft_reconstruct(fourier ,fftpoints)
% Input variable is M by N image transfrom (FFT) and the highest
peaks
3 % (thresholded by fft_points3 () function)
% An ouptut minimal FFT is returned that contains only the
central peak
5 % (which is the image intensity) and the detected peaks.
K = size(fftpoints ,1);
7
[M N] = size(fourier);
9 reduced_fft = zeros(M,N);
11 if fftpoints
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for k = 1:K




17 % Normalize the peaks
reduced_fft(round ((M+1) /2),round ((N+1) /2)) = max(fourier (:));
./AppendixB/src/fft reconstruct.m
function [reduced_fft] = fft_rotate(img , thresh , dim , resolution ,
show)
2 % fft_rotate takes as input an image , the threshold scale (
multiplier of
% variance), dimension of non -overlapping square to be used ,
picture
4 % resolution , and an optional display toggle.
% The image is run through the detection algorithm but also using
random
6 % rotation of cropped , circular region of the image to test which
peaks are
% preserved under this transformation. This helps reduec erroneous
peaks
8 % detected due simply to the orientation of the original image.
10 % Check input arguments and set defaults
if nargin < 5, resolution = 0; show =0; end;
12
% Generate random angles for rotation.
14 for k = 1:2, angles(k) = (k-1)*90+ randi (90,1); end;
16 % Create circular crop filter.
[rr cc] = meshgrid (1:dim);
18 rad = ceil(length(img)/2+(1 -mod(length(img)/2,2)));
C = sqrt((rr-rad).^2+(cc-rad).^2) <=rad;
20
clear theta2 theta3 theta5 theta6
22 clear radius2 radius3 radius5 radius6
24 temp_pts2 = 0;
temp_pts3 = 0;
26 temp_pts5 = 0;
28 % Crop image into circular region and detect peaks. This is
attempted
% iteratively while decreasing the threshold each time as
30 % rotational/cropping distortion might obscure the peaks.
while(~ exist(’theta2 ’) | isempty(temp_pts2) | mean(temp_pts2)==0)
32 % Set the threshold minimum boundary
thresh = max([thresh ,1.9])*.85;
34 % Crop image into circular region
temp_img2 = double(img).*C;
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36 % Detect points
temp_pts2 = fft_points3(fftshift(fft2(temp_img2)),thresh ,show ,
resolution);
38 % Determine cartesian orgin (center of image is {0 ,0})
origin = [rad rad];
40 length(temp_pts2)
% Calculate radial distance from origin
42 for i = 1: length(temp_pts2)
y = temp_pts2(i,1); x = temp_pts2(i,2);
44 yy = rad -y;
if (x>=rad), xx = x-rad; theta2(i) = atan2d(yy ,xx);
46 else xx = rad -x; theta2(i) = atan2d(yy ,xx); theta2(i) =
180- theta2(i); end
radius2(i) = ((xx)^2+(yy)^2) ^.5;
48 end
% Determine Cartesian coordinates of detected peaks based on
polar
50 % coordinates determined above.
phi2 = zeros(1,length(theta2));
52 temp_pts2fin = overlay_rot(radius2 ,theta2 ,phi2 ,origin);
% Reconstruct image using the set of detected peaks
54 reduced_2fin = fft_reconstruct(fftshift(fft2(temp_img2)),
temp_pts2fin);
thresh = thresh - .1;
56 end
58 % Random rotation #1 of cropped region. Same process as above
aside from
% rotation.
60 while(~ exist(’theta3 ’) | isempty(temp_pts3) | mean(temp_pts3)==0)
thresh = max([thresh ,1.9])*.85;
62 temp_img3 = imrotate(img ,angles (1) ,’bilinear ’,’crop ’);
temp_img3 = double(temp_img3).*C;
64 temp_pts3 = fft_points3(fftshift(fft2(temp_img3)),thresh ,show ,
resolution);
for i = 1: length(temp_pts3)
66 y = temp_pts3(i,1); x = temp_pts3(i,2);
yy = rad -y;
68 if (x>=rad), xx = x-rad; theta3(i) = atan2d(yy ,xx);
else xx = rad -x; theta3(i) = atan2d(yy ,xx); theta3(i) = 180-
theta3(i); end
70 radius3(i) = ((xx)^2+(yy)^2) ^.5;
end
72 phi3 = repmat(angles (1) ,1,length(theta3));
temp_pts3fin = overlay_rot(radius3 ,theta3 ,phi3 ,origin);
74 reduced_3fin = fft_reconstruct(fftshift(fft2(temp_img3)),
temp_pts3fin);
thresh = thresh - .1;
76 end
78 % Random rotation #2 of cropped region. Same process as above
aside from
% rotation.
80 while(~ exist(’theta5 ’) | isempty(temp_pts5) | mean(temp_pts5)==0)
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thresh = max([thresh ,1.9])*.85;
82 temp_img5 = imrotate(img ,angles (2) ,’bilinear ’,’crop ’);
temp_img5 = double(temp_img5).*C;
84 temp_pts5 = fft_points3(fftshift(fft2(temp_img5)),thresh ,show ,
resolution);
for i = 1: length(temp_pts5)
86 y = temp_pts5(i,1); x = temp_pts5(i,2);
yy = rad -y;
88 if (x>=rad), xx = x-rad; theta5(i) = atan2d(yy ,xx);
else xx = rad -x; theta5(i) = atan2d(yy ,xx); theta5(i) = 180-
theta5(i); end
90 radius5(i) = ((xx)^2+(yy)^2) ^.5;
end
92 phi5 = repmat(angles (2) ,1,length(theta5));
temp_pts5fin = overlay_rot(radius5 ,theta5 ,phi5 ,origin);
94 reduced_5fin = fft_reconstruct(fftshift(fft2(temp_img5)),
temp_pts5fin);
thresh = thresh - .1;
96 end
98 % Determine the union of all detected peaks after rotations and
keep only
% those preserved.
100 reduced_fft = reduced_2fin.*reduced_3fin.*reduced_5fin;
102 if show
figure (1);
104 subplot (221); fftshow(reduced_2fin)
subplot (222); fftshow(reduced_3fin)





1 function [pve ,pve_heatmap ,points] = fft_scan(image ,step ,fact ,res ,
viz ,angle)
% Input variable is M by N image and a box win that is an scalar
factor
3 % of the image. The image is scanned sequentially with the box
and
% returns FFT transforms. The input image is iterateively
scanned with a
5 % non -overallping region of diminsions step*step. fact is the
scaling
% factor determining how many standard deviations above the mean
to use
7 % as a cutoff. res scale the resolution. viz is the toggle to
display
% output graphs. angle is a switch for turning on/off the
fft_angle call
9 % to calculate the polar coordinate of detected peaks.
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11 % Check if image size is divisible by step
[M N] = size(image);
13 if(mod(M*N,step))




% Set default inputs if not passed by user
19 if nargin < 6, angle =0; elseif nargin < 5, viz = 1; angle = 0;
elseif nargin < 3, viz = 0; angle =0; res = 0;
21 elseif nargin < 3, viz = 0; angle =0; res = 0; fact = 1;
end
23
if angle , points = struct(’pts ’,{},’theta ’,{}); end
25
xx = step;
27 yy = step;
29 pve = zeros(M/step*N/step ,1);
pve_heatmap = zeros(size(image));
31 if viz , figure (101),imshow(image ,[1 255]); end
n = 1;
33
% Iterate through the PVE matrix and create a heatmap of equal
size to the
35 % image.
for j = 1:yy:N
37 for i = 1:xx:M
temp_segment = image(j:j+yy -1,i:i+xx -1);
39 %
[pve(n),img_points] = fft_pve(temp_segment ,fact ,0,res);




45 points(n).pts = img_points;
% Record angles and radii
47 [points(n).theta , points(n).radius] = ...
fft_angle(temp_fft ,img_points);
49 % If the PVE is 0 (i.e. no pattern detected) return 0
else points(n).pts = 0;
51 points(n).theta = 0;
points(n).radius = 0;
53 end
elseif ~angle , points(n) = size(img_points ,1);
55 end
% Record the PVE for that segment
57 pve_heatmap(j:j+yy -1,i:i+xx -1) = pve(n);
% Iterate ocounter
59 n = n+1;
% If user wants to visualize , display the corresponding
region
61 % being scanned
175
if viz , figure (101); hold on;





% Reshape from an M*N/(step ^2) x 1 vector to an M/step x N/step
matrix
69 pve = reshape(pve ,M/step ,N/step);
./AppendixB/src/fft scan.m
function fftshow(f,type)
2 % Usage: FFTSHOW(F,TYPE)
%
4 % Displays the fft matrix F using imshow , where TYPE must be one
of
% ’abs ’ or ’log ’. If TYPE=’abs ’, then then abs(f) is displayed; if
6 % TYPE=’log ’ then log(1+abs(f)) is displayed. If TYPE is omitted ,
then
% ’log ’ is chosen as a default.
8 %
% Example:
10 % c=imread(’cameraman.tif ’);
% cf=fftshift(fft2(c));
12 % fftshow(cf,’abs ’)
%

















[1] Z. A. Almsherqi, C. S. McLachlan, P. Mossop, K. Knoops, and Y. Deng. Direct template matching reveals a host
subcellular membrane gyroid cubic structure that is associated with SARS virus. Redox Report, 10:167–171, 2005.
[2] Z. A. Almsherqi, S. D. Kohlwein, and Y. Deng. Cubic membranes: a legend beyond the Flatland of cell membrane
organization. Journal of Cell Biology, 173:839–844, 2006.
[3] R. G. W. Anderson, L. Orci, M. S. Brown, L. M. Garciasegura, and J. L. Goldstein. Ultrastructural Analysis of
Crystalloid Endo-plasmic-Reticulum in Ut-1 Cells and Its Disappearance in Response to Cholesterol. Journal of Cell
Science, 63:1–20, 1983.
[4] J. Baik and G. R. Rosania. Molecular Imaging of Intracellular Drug-Membrane Aggregate Formation. Molecular
Pharmaceutics, 8:1742–1749, 2011.
[5] J. Baik and G. R. Rosania. Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular
organization. PLoS One, 7, 2012.
[6] U. Bangert, M. H. Gass, A. L. Bleloch, R. R. Nair, and A. K. Geim. Manifestation of ripples in free-standing graphene
in lattice im-ages obtained in an aberration-corrected scanning transmission electron microscope. Physica Status
Solidi a-Applications and Materials Science, 206:1117–112, 2009.
[7] Chin, Luskey D. J., K. L., R. G. W. Anderson, J. R. Faust, J. L. Goldstein, and M. S. Brown. Appearance of
Crystalloid Endoplas-mic-Reticulum in Compactin-Resistant Chinese-Hamster Cells with a 500-Fold Increase in 3-
Hydroxy-3-Methylglutaryl-Coenzyme-a Reductase. Proceedings of the National Academy of Sciences of the United
States of America-Biological Sciences, 79:1185–1189, 1982.
[8] Y. R. Deng and M. Mieczkowski. Three-dimensional periodic cubic membrane structure in the mitochondria of amoebae
Chaos car-olinensis. Protoplasma, 203:16–25, 1988.
[9] T. Fujita and M. W. Chen. Characteristic length scale of bicontinuous nanoporous structure by fast Fourier transform.
Japanese Journal of Applied Physics, 47:1161–1163, 2008.
[10] F. C. Gong, T. H. Giddings, J. B. Meehl, L. A. Staehelin, and D. W. Galbraith. Z-membranes: Artificial organelles
for overex-pressing recombinant integral membrane proteins. Proceedings of the National Academy of Sciences of
the United States of America, 93:2219–2223, 1996.
[11] C. Knupp, C. Pinali, P. M. Munro, H. E. Gruber, M. J. Sherratt, C. Baldock, and J. M. Squire. Structural correlation
between collagen VI microfibrils and collagen VI banded aggregates. Journal of structural biology, 154:312–326, 2006.
[12] Tomas Landh. From entangled membranes to eclectic morphologies: cubic membranes as subcellular space organizers.
FEBS Lett., 369:13–17, 1995.
[13] V. Lucic, F. Forster, and W Baumeister. Structural studies by electron tomography: from cells to molecules. Annu.
Rev. Bio-chem., 74:833–865, 2005.
[14] A. V. Pais, S. Pereira, I. Garg, J. Stephen, M. Antony, and Y. K. Inchara. Intra-abdominal, crystal-storing histiocytosis
due to clofazimine in a patient with lepromatous leprosy and concurrent carcinoma of the colon. Leprosy Review, 75:
171–176, 2004.
[15] G. Q. Ren and Y. C. Xing. Temperature-induced restructuring of self-assembled PtPd nanoparticle superlattices.
Nanotechnology, 20:46, 2006.
[16] C. E. Shannon. A Mathematical Theory of Communication. Bell System Technical Journal, 27:623–656, 1948.
[17] S. Smith and G. Blobel. Colocalization of Vertebrate-Lamin-B and Lamin-B-Receptor (Lbr) in Nuclear Envelopes and
in Lbr-Induced Membrane Stacks of the Yeast Saccharomyces-Cerevisiae. Proceedings of the National Academy of
Sciences of the United States of America, 94:10124–10128, 1991.
[18] E. L. Snapp, R. S. Hegde, M. Francolini, F. Lombardo, S. Colombo, E. Pedrazzini, N. Borgese, and J. Lippincott-
Schwartz. Formation of stacked ER cisternae by low affinity protein interactions. Journal of Cell Biology, 163:
257–269, 2003.
177
[19] S. Sukpanichnant, N. S. Hargrove, U. Kachintorn, S. Manatsathit, T. Chanchairujira, N. Siritanaratkul, T. Akar-
aviputh, and K. Thakerngpol. Clofazimine-induced crystal-storing histiocytosis producing chronic abdominal pain in
a leprosy patient. The American journal of surgical pathology, 24:129–135, 2009.
[20] R. Wright, M. Basson, L. D’Ari, and J Rine. Increased amounts of HMG-CoA reductase induce ”karmellae”: a
proliferation of stacked membrane pairs surrounding the yeast nucleus. J. Cell Biol., 107:101–114, 1998.
178
